Azathioprine use in inflammatory bowel disease by Campbell, Simon Scott.
THE UNIVERSITYof EDINBURGH
Title Azathioprine use in inflammatory bowel disease
Author Campbell, Simon Scott.
Qualification MD
Year 2003
Thesis scanned from best copy available: may
contain faint or blurred text, and/or cropped or
missing pages.
Digitisation notes:
• Page number 39 is missing in the original thesis.




Dr Simon Scott Campbell




I hereby declare that the work in this thesis is original and undertaken by myselfwhile
working as a research fellow at The Gastrointestinal Unit, Western General Hospital,
Edinburgh 1998-2001.1 confirm that the thesis has not been submitted in candidature
for any other degree, diploma or professional qualification
Dr Simon Campbell MB ChB MRCP (UK)
2
Acknowledgements
This thesis would not have been possible without the support ofmy family and work
colleagues. My work colleagues enthusiasm and expertise have been an inspiration to
me during this period.
In particular I would like to thank my mentor Professor Subrata Ghosh, who has
guided me throughout this work. Kathy Kingstone has been an invaluable colleague in
helping to set up and running the radiochemical assay work - her endless patience has
been hugely appreciated. Finally, I would like to thank Gordon Brydon and Norman




ARDS - Adult respiratory distress syndrome
ASD - Atrial septal defect
AZA - Azathioprine
CCF-IOIBD - Crohn's and Colitis Foundation of America / International organization
of inflammatory bowel disease
CD - Crohn's disease
CRP - C-reactive protein
CyA - Cyclosporin
DMSO - Dimethylsulphoxide
DNA - Deoxyribonucleic acid
EDTA - Ethylenediaminetetraacetic acid
F- Female
GETAID - Groupe d'Etude Therapeutique des Affections Inflammatories Digestives
GCSF - Granulocyte colony stimulating factor
HBI - Harvey Bradshaw Index
HPLC - High performance liquid chromatography
HPRT - Hypoxanthine guanine phosphoribosyl transferase
IBD - Inflammatory bowel disease
IV - Intravenous
M- Male
MCV - Mean corpuscular volume
MWT - Mann-Whitney Test
NHL - Non-Hodgkin's Lymphoma
4
NVD -Normal vaginal delivery
PCP - Pneumocystis Carnii pneumonia
PBS - Phosphate buffer solution
PRPP - 5-phosphoribosyl 1-pyrophosphate
RBC - Red blood cell
SAH - S-adenosyl homocysteine
SAM - S-adenosyl methionine
tIMP- Inosine monophosphate
TPMT - Thiopurine-methyl-transferase
UC - Ulcerative colitis
WCC - White cell count




6-MMR's - 6-methylmercaptopurine ribonucleotides
6-TG - 6-thioguanine
Publications arising from this thesis
Papers
Campbell S, Kingstone K, Ghosh S
Relevance of thiopurine methyltransferase activity in inflammatory bowel
disease patients maintained on low-dose azathioprine
Alimentary Pharmacology and Therapeutics 2002;16: 389-398
Campbell S., Ghosh S.
Effective maintenance of IBD remission by azathioprine does not require
concurrent 5-ASA
European Journal Gastroenterology & Hepatology 2001 Nov ;13: 1297-301
Campbell S., Ghosh S.
Is neutropenia required for effective maintenance of remission during
azathioprine therapy in inflammatory bowel disease
European Journal ofGastroenterology & Hepatology 2001 Sep; 13: 1073-6
Campbell S., Ghosh S.
Azathioprine use in Inflammatory bowel disease - Are we using it
appropriately?
Inflammatory bowel disease monitor 2001 3(1); 2-9
6
Abstracts
Campbell S, Ghosh S
Combination immunomodulatory therapy with cyclosporin, azathioprine and
corticosteroids in severe ulcerative colitis: The Edinburgh experience of outcome
Gut supplement II 2002: 50: A72 (262)
Joy D, Macpherson R, Campbell S, Kingstone K, Ghosh S
Relationship of thiopurine methyltransferase (TPMT) activity to mean
corpuscular volume (MCV) in inflammatory bowel disease (IBD) patients
maintained on azathioprine
Gut supplement II 2002:50: A79 (289)
Campbell S, Ghosh S
Relevance of thiopurine methyltransferase activity in inflammatory bowel
disease patients maintained on low dose azathioprine
Gut supplement II 2002: 50: A14 (051)
Campbell S., Ghosh S




Campbell S., Ghosh S.
'Maintenance of remission in IBD by Azathioprine - Is neutropenia necessary
Gastroenterology supplement II 2000: 118(4); A785 (4194)
Campbell S., Ghosh S.
'Safety ofAzathioprine use in Pregnancy'
Gut supplement (II) 2000:46;A13(T52)
Campbell S., Ghosh S.
'Is 5-ASA therapy required in IBD patients maintained on azathioprine ?'
Gastroenterology supplement II 2000:118(4);A785(4193)
8
Papers submitted
Campbell S, Ghosh S
Cyclosporin rescue therapy in combination with azathioprine and corticosteroids
in severe ulcerative colitis
Digestive and Liver Diseases (submitted)
Campbell S, Ghosh S
Effect of azathioprine on pregnancy outcome in IBD patients maintained on
azathioprine
Digestive and Liver diseases (submitted)
Oral Presentations
Azathioprine dose and concurrent 5-ASA treatment - Do they effect relapse
rates in IBD patients ?
Academic Surgical meeting, Lister Institute, Edinburgh 1999
Relevance of thiopurine methyltransferase activity in inflammatory bowel
disease patients maintained on low dose azathioprine




Azathioprine (AZA) is an effective therapy for steroid dependent/resistant
inflammatory bowel disease (IBD). Its optimal use is hampered by several areas of
uncertainty. It is unclear whether neutropenia as an end-point ofAZA therapy may be
desirable. There are no data that confirm whether concurrent 5-acetyl salicylic acid
(5-ASA) with AZA is beneficial in maintaining remission in IBD patients. In-vitro
studies suggest that 5-ASA inhibits thiopurine methyltransferase (TPMT) and
therefore increases AZA toxicity. Anecdotal reports ofAZA use by women during
pregnancy report low birth weight and skeletal abnormalities in their offspring. In
male patients on AZA, chromosomal abnormalities and lower fertility have been
reported. Low TPMT activity levels predispose to bone marrow suppression in
patients treated with AZA. Furthermore, the level of TPMT activity has been shown
to correlate with disease relapse rates in other medical conditions treated with AZA -
but this has not as yet been reported in IBD patients. The role ofAZA in maintaining
remission in UC patients who have responded to intravenous cyclosporin (CyA) has
not been specifically addressed.
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Methods:
A retrospective database was created using data from 220 IBD patients who were
taking or had taken AZA. Other data that were collected included dosage, concurrent
medications, disease type and distribution, relapse rates, pregnancy and offspring
details, surgery. Red cell TPMT activity was ascertained by radiochemical assay.
Relapse rates per year of follow-up and time to first relapse were used to assess 4
main hypotheses :-
1) There is no difference in remission maintenance in IBD patients treated with
AZA who achieve a neutropenic nadir neutrophil count compared with those
who do not.
2) There is no difference in remission maintenance in IBD patients on concurrent
5-ASA + AZA therapy versus IBD patients on AZA therapy alone.
3) The total white cell count (WCC) and neutrophil count at 4 months do not
correlate with IBD patients' respective nadir WCC and neutrophil count
during AZA therapy.
4) There is no difference in remission maintenance in IBD patients treated with
AZA when comparing those with low TPMT activity (<20 nmol/hour/ml)
versus those with normal TPMT activity (>20 nmol/hour/ml).
The outcomes ofpregnancies in IBD patients taking AZA and the outcomes of
pregnancies of partners ofmale IBD patients taking AZA were reported upon. Finally
the experience of long-term outcome of acute severe UC patients initially treated with
IV CyA and then maintained on oral AZA was described.
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Results:
Mean relapse rates per year of follow up for the non-neutropenic (>2.5xl 09) group
compared with the neutropenic group (< 2.5 x 109) were not significantly different.
Analysis was performed on UC and CD sub-groups and relapse rates were not
significantly different. For 5-ASA, analyses were performed in UC, CD and IBD
patient groups. There were no statistically significant differences between AZA alone
and AZA+5-ASA groups. Patients who became neutropenic had a significantly lower
mean TPMT activity than the mean TPMT activity ofpatients who developed other
side effects. Patients on low-dose AZA had a significantly lower number of relapses
patients if they also had a low TPMT level. In patients who responded to IV CyA,
AZA therapy was beneficial in maintaining remission. Analysis of 25 pregnancies
where one or other parent was on AZA at the time of conception did not show any
unusual occurrence of birth defects in the newborn.
Conclusions:
Patients who developed a neutropenic nadir neutrophil count did not achieve
increased disease remission compared with those who did not. Patients on concurrent
5-ASA with AZA do not appear to be afforded any benefit in terms of remission
maintenance, but there were no excesses of clinically significant side effects with
concurrent 5-ASA and AZA therapy. IBD patients treated with low dose AZA relapse
less frequently if they have low TPMT activity levels. Offspring from IBD patients
treated with AZA did not appear to have any obvious excess of birth defects, but the
numbers ofpatients analysed were too small to make firm conclusions with regard to
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the absolute safety ofAZA during pregnancy. Although the numbers ofCyA treated
with concurrent AZA were small, the long-term outcomes of these patients support a
view that concomitant use ofCyA and is (relatively) safe and efficacious.
13
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Chapter 1 Azathioprine use in inflammatory bowel disease
1.1 Introduction
Azathioprine (AZA) therapy is an invaluable immunosuppressant used in the
treatment for inflammatory bowel disease (IBD) as a second line drug. Optimal use of
azathioprine and 6-mercaptopurine (6-MP) continues to be refined with our growing
experience with its use. However, there are several areas of uncertainty in the use of
AZA in IBD and this thesis aims to address some of these issues mainly from
retrospective analysis of a large cohort of well characterised patients in Edinburgh.
AZA and 6-MP are purine analogues that interfere with nucleic acid metabolism and
cell proliferation and thus have immunosuppressive properties. 6-MP was first
synthesized in 1951 and initially used to treat leukaemia. Its pro-drug form AZA was
produced in 1957, and used predominantly for preventing rejection in renal
allografts(Murray et al. 1963). The first documented use of antimetabolite analogues
in the treatment of IBD was in 1962 when a patient with chronic ulcerative colitis
(UC) was successfully brought into remission with 6-MP(Bean 1962). Later, in 1969,
AZA was used in a case where active Crohn's disease (CD) was successfully brought
into remission(Brooke et al. 1969). Since then AZA and to a lesser extent 6-MP (the
latter is used more widely in the US) are now regarded as the treatment of choice for
IBD patients who are steroid refractory or dependent.
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Since its first use in IBD, there have been numerous studies into the efficacy of the
drug in both controlled and uncontrolled trials looking at remission induction and
maintenance. Despite several conflicting reports, large meta-analysis have now
confirmed both the safety and efficacy of the drug in maintaining remission, and
answered several questions concerning dosage, and time to onset of action. Despite
this the use ofAZA remains less frequent than ideal - a recent Swedish study revealed
that AZA accounts for as little as 2.2% of the annual drug prescriptions for CD
patients and 0.5% for UC patients(Blomqvist et al 2001). In addition to this there is
considerable heterogenicity between countries in their prescribing patterns of
immunosuppressants(Meuwissen et al. 2000). For example, AZA is prescribed more
often in Europe than North America, but the reverse is true for 6-MP.
At present, several questions remain unanswered with regard to the optimal use of
AZA and 6-MP.
1.2 The purpose of the thesis
The purpose of this thesis was to address some of, as yet unanswered questions,
concerning the use ofAZA/6-MP therapy in the treatment of IBD. Specifically, five
areas and key questions were chosen to be addressed by analysis of our patient
database. The retrospective nature of the analysis would provide data that may be
subject to biases and the conclusions therefore may require to be substantiated by
prospective controlled studies, though the latter may not be possible for some of the
questions.
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1.2.1 Neutropenia: Is induction ofmodest neutropenia necessary for optimal
maintenance of remission with AZA ?
It has long been recognized that immunosuppression of organ transplant patients with
purine analogues sometimes caused potentially serious bone marrow
suppression(Block, 1968; McGrath et al. 1975). This has meant that diligent blood
count monitoring was required, and subsequently drug withdrawal was sometimes
necessary when there was evidence of bone marrow suppression, in particular
neutropenia. More recently this side effect ofAZA/6-MP has now been looked at in a
different light. In the treatment of IBD, there has been growing interest in the
potential role of'therapeutic neutropenia' as being a possible desirable end-point to
such therapy. At present, AZA/6-MP dose is not routinely adjusted according to
neutrophil count, unless dangerous levels of neutropenia occur. However, there have
now been anecdotal reports ofprolonged remission in IBD patients after life-
threatening neutropenia caused by AZA/6-MP(Burke et al. 1989). There have also
been reports of lower white cell counts and lower neutrophil counts in IBD patients
who achieve remission earlier and achieve remission maintenance for longer(Colonna
and Korelitz 1994; Korelitz et al. 1997). To investigate this question a retrospective
study was performed on our IBD patients treated with AZA/6-MP and analysed by
remission rates per year of follow-up, time to first relapse, and nadir neutrophil counts
to elucidate whether neutropenia was of potential value in the treatment of IBD
patients.
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1.2.2 Concurrent 5-Aminosalicvlate therav\(5-ASA): Is the use ofconcurrent 5-
ASA therapy necessary for optimum maintenance ofremission with AZA ?
The use of 5-aminosalicylates (5-ASA) in IBD patients predates the use ofmore
powerful immunosuppressants such as AZA/6-MP. The efficacy of 5-ASA
monotherapy in remission maintenance is accepted in the treatment ofUC(Green et al.
1998), but probably has a more limited role in the maintenance treatment of
CD(Sutherland et al. 1997). There is also some evidence that some 5-ASAs may have
a therapeutic role in inducing remission in IBD patients(Biddle and Miner, Jr., 1990;
Sutherland et al. 2000). Furthermore, there may be more long-term benefits of 5-ASA
therapy, such as a reducing the overall risk of developing colonic
carcinoma(MacGregor et al. 2000; Moghadasian et al. 1996).
In current clinical practise, concurrent use of purine analogues and 5-ASAs remains
controversial and has not been systematically investigated. In-vitro work has
suggested that benzoic acid derivatives such as 4 and 5-aminosalicylates inhibit the
enzyme TPMT(Lowry et al. 1999; Szumlanski and Weinshilboum, 1995). This has
led to concerns that patients taking concurrent 5-ASA medications with AZA/6-MP
may be at increased risk ofAZA/6-MP toxicity. Furthermore, it is unknown whether
5-ASA therapy in conjunction with AZA/6-MP has any beneficial effects on
remission maintenance in IBD patients.
To answer some of these questions, this study looked at our IBD patients taking
AZA/6-MP and analysed relapse rates and time to first relapse in these patients,
stratifying them according to their 5-ASA status. In addition, documented side effects
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while on AZA/6-MP therapy were analysed to evaluate the influence of concurrent 5-
ASA therapy on these effects. However, the study did not specifically address the
issue of development of colon cancer while on maintenance therapy, as_there was no
such patient on our database.
1.2.3 Pregnancy issues with azathioprine: Is the use ofAZA at the time of
conception safe regarding pregnancy outcome ?
Animal studies with AZA/6-MP have raised considerable concerns over the
teratogenicity and clastogenicity of purine analogues. There have been numerous
anecdotal reports of infections in neonates, skeletal and karyotypic abnormalities,
increased spontaneous abortions and reduced birth weights from mothers who have
been taking AZA/6-MP (Alstead et al. 1990; Evans et al. 1975; Williamson and
Karp, 1981). Most of this experience has been from organ transplant patients who are
often taking other concurrent immunosuppressives. Unfortunately, there has only been
one report that has presented small series of outcomes of IBD patients taking AZA/6-
MP(Alstead et al. 1990), and as such provided little information as to the clinical
safety of AZA/6-MP with regards to potential offspring of patients taking AZA/6-MP.
Finally, the effects ofpurine analogue therapy on the progeny of fathers who are
taking such medication have received even less interest. A concern over fertility and
possible clastogenicity in male patients remains (Eslami et al. 1976; Papoff et al.
1977; Salant et al. 1976). To address this, female IBD patients taking AZA/6-MP
who had become pregnant were investigated and their experiences were reported. In
addition, a postal survey was performed on male IBD patients taking AZA/6-MP to
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give further information upon their progeny.
1.2.4 Thiopurine Methvltransferase activity (TPMT): How does TPMT activity
levels in patients takins AZA relate to efficacy ofmaintenance therapy with
AZA?
TPMT has received a lot of interest in recent years. Not only has it been recognized
that low TPMT activity in patients leads to increase risk of developing neutropenia
while taking AZA/6-MP, but there has been considerable interest in the genotypic and
phenotypic variation of this enzyme and its activity (Corominas et al. 2000; Ishioka et
al. 1999; Sebbag et al. 2000; Stolk et al. 1998). While it is recognized that patients
with low TPMT activity should be given lower doses ofAZA/6-MP or even avoid
such treatment altogether, there has been concerns that patients with high TPMT
activity may be more resistant to the immunosuppressants effects ofAZA/6-MP
therapy. Ofparticular interest is the fact that the majority of IBD patients in the UK
get relatively modest doses ofAZA/6-MP (often less than 2mg/kg). There have been
many anecdotal reports in several centres of IBD patients being maintained in
remission on even lower doses of AZA/6-MP. In this study the hypothesis that this
apparent efficacy of low dose AZA/6-MP could be due to lower TPMT activity in
these individual patients was tested. Initially a radiochemical assay to reliably
measure TPMT activity was set up. After analysis results were pooled together,
relapse rates were examined in these patients and stratified as to the dosage (<2mg/kg
or >2mg/kg) and as to their measured TPMT activity (<20u/hr/ml or >20u/hr/ml).
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1.2.5 Cyclosporin (CxA) therapy in acute severe ulcerative colitis - the need for
AZA: What is our sinsle centre experience with the use ofCyA and AZA as
dual immunosuppressive therapy regarding efficacy and side effects ?
Along the theme of immunosuppressants in the treatment of IBD, CyA therapy has re-
emerged as an important agent for rescue therapy in acute severe UC. Initial reports
were disappointing with 1 year relapse rates being particularly high(Kornbluth et al.
1994), advocating only a limited role of this intravenous therapy in light of the narrow
therapeutic index CyA and its side-effect profile. However, more recently, there has
been encouragement from the concomitant use ofAZA in these patients. This has
provided more encouraging remission maintenance(D'Haens et al. 2001). In this
thesis the Edinburgh experience of outcome with this small group ofUC patients was
analysed and reported. This included dose regimens, AZA usage, surgery
requirements, and side effects to add further important information for the role of
CyA and AZA therapy. The limitations of such an observational study in a small
series of patients is recognized but the reported experience with the use ofCyA and
AZA in the setting ofUC remains quite limited.
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Chapter 2 Literature Review
2.1 Pharmacology
AZA (6-(l-Methyl-4-nitroimidazol-5-ylthio)) is an imidazole derivative of 6-MP. It
has the molecular formula C9H7N7O2S and has a relative molecular mass of 277. The
chemical structure ofAZA and 6-MP are shown in Figure 2.1.
2.1.1 Pharmacodynamic properties - In-vivo AZA is rapidly converted to 6-MP
and a methylnitroimidazole moiety by a non-enzymatic pathway dependent on
glutathione and other sulphydryl containing proteins - see Figure 2.2. Subsequently 6-
MP is left available to the circulation. AZA is about 55% 6-MP by weight, and since
over three-quarters ofAZA is converted to 6-MP, lmg ofAZA is equivalent to 0.5mg
6-MP(Lennard, 1992).
Bioavailability of these drugs are low (less than 50%) due to the extensive catabolism
by xanthine oxidase found in enterocytes and hepatocytes (but not haemopoietic
tissue) (Lennard, 1998). 6-MP rapidly crosses the cell membranes and is converted
intracellularly into a number of purine thioanalogues. There are 3 pathways;
converted by xanthine oxidase into inactive thiouric acid (and renally excreted),
converted by TPMT to inactive 6-methyl mercaptopurine (6MMP) or anabolized by
hypoxanthine phosphoribosyl transferase (HPRT) to its active metabolites 6-
thioguanine nucleotides (6TG) and 6-methylmercaptopurine ribonucleotides (6-
MMPRs) (Elion 1969; Elion 1989). Up to 40% of 6TG is subsequently renally
excreted (Elion 1989). This is summarized in figure 2.3. These enzymatic pathways
are distinct and competitive and thus a lack of enzymatic activity at one point will
result in an excess product being produced from a competing pathway.
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Figure 2.1 - Chemical structure of Azathioprine and 6-mercaptopurine
AZATHIOPRINE
Table 2.1. Range of toxicity caused by Azathioprine (Present et al 1989)
Toxic reaction % Occurrence
Infection 40%*
Bone Marrow Suppression 15%*
Hepatitis (mild derangement of liver
function tests, intrahepatic cholestasis,
irreversible liver injury)
3%*




Other allergic type reactions (nausea,
abdominal pain, fever, skin rashes)
12%*
* There is a considerable overlap between different forms of toxicity that occur in
individual patients
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Figure 2.3. 6-Mercaptopurine metabolism.
6-MP (6-mercaptopurine), 6-MMP (6-methylmercaptopurine), HPRT (hypoxanthine
phosphoribosyltransferase), 6-TGN (6-thioguanine nucleotides), SAM (S-adenosyl
methionine), SAH (S-adenosvl homocysteine). PRPP (5-phosphoribosvl 1-
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The precise activity of the imidazole derivative has not been clearly defined. In-vitro
evidence suggests that these imidazole derivatives possess independent
immunomodulatory activity by alkylating thiol groups on T-cell surface membranes
blocking antigen recognition(Crawford et al, 1996). In addition, pro-inflammatory
cytokines are suppressed by high dose AZA but not 6-MP (Louis et al, 2000). Some
have proposed that it is the imidazole derivative that may be responsible for some of
the side effects related to AZA use (McGovern et al 2002).
The precise mechanisms of action ofAZA remain to be elucidated, but suggested
mechanisms are as follows: -
1) The release of 6-MP that acts as a purine antimetabolite.
2) The possible blockade of-SH groups by alkylation.
3) The inhibition ofmany pathways in nucleic acid biosynthesis, hence preventing
proliferation of cells involved in the determination and amplification of the
immune response.
4) Damage to deoxyribonucleic acid (DNA) through incorporation of purine thio-
analogues and hence inhibiting de novo purine synthesis (Tidd and Paterson,
1974).
It is thought to be due to some of these mechanisms that the therapeutic effect of
AZA/6-MP may take up to 3 months to become evident. These mechanisms act upon
rapidly dividing cells including T and B-lymphocytes as well as gut endothelium and
bone marrow elements.
2.1.2 Pharmacokinetics - Following oral administration, AZA is well absorbed
from the gastrointestinal tract. Up to 30% ofAZA is bound to plasma proteins and
hence distribution occurs rapidly throughout the body. Following oral administration
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of labelled 35S-AZA, maximum plasma radioactivity occurs at 1-2 hours and then
decays with a half-life of 4-6 hours. The latter reflects elimination from the plasma of
AZA, rather than the half-life ofAZA itself. Extensive and rapid metabolism ofAZA
means that only a fraction of the radioactivity measured in the plasma is comprised of
unmetabolized drug. Other studies measuring AZA and 6-MP directly in the plasma
following intravenous administration estimate the half-life ofAZA and 6-MP to be 6-
28 minutes and 38-114 minutes respectively (Dollery, 1991).
Excretion ofAZA is principally in the form of thiouric acid, while the imidazole
derivative component can be detected as a minor excretory product. Only a small
amount of the dose of the administered AZA is excreted unmetabolized.
2.1.3 Azathioprine toxicity - The main limiting factor in AZA use are the
occurrence of side effects. Between 10-15% ofpatients who are started on AZA will
have some form of toxic reaction (Present et al. 1989). The nature of these toxic
effects and the proportion ofpatients (out of all developing toxic effects) developing
specific toxic effects is shown in table 2.1. Broadly speaking there are 2 categories of
toxic reactions; namely allergic-type (e.g. pancreatitis, fever, rash, non-specific
abdominal pain, nausea, rash and hepatitis) and non-allergic type (e.g. leucopenia,
thrombocytopenia, infections, malignancies and some cases of hepatitis). The latter
group usually occurs after months or years and appears to be dose dependent, while




TPMT is a cytosolic enzyme. TPMT levels are determined by a well-documented co-
dominant genetic polymorphism in Caucasian and Africo-American
populations(McLeod et al. 1994; Weinshilboum and Sladek, 1980). Approximately
90% of the population has normal expression of TPMT (TPMTH/TPMTH), 10% have
intermediate activity due to heterozygosity at the TPMT locus (TPMTH/TPMTL),
while between 0.3 to 1% have TPMT deficiency (TPMTL/TPMTL), inherited as an
autosomal recessive trait (Weinshilboum and Sladek, 1980). In the latter patients there
is excessive shunting of by-products down other enzymatic pathways, leading to
excesses in 6-TG's, which exert cytotoxic and immunosuppressive effects leading to
bone marrow toxicity. Other adverse side effects such as pancreatitis and hepatitis are
thought to be idiosyncratic reactions, unrelated to TPMT activity(Kader et al. 2000).
There has been considerable interest in TPMT levels and the occurrence ofAZA/6-
MP toxicity. This was first investigated in children with acute lymphoblastic
leukaemia treated with AZA, where it has been recognized that TPMT levels
corresponded to reduced risk of relapse, but a higher risk of neutropenia(Lennard et
al. 1990; Lilleyman and Lennard, 1994). In addition, TPMT genotyping has been
shown to correlate well with TPMT enzymatic activity(Yates et al. 1997)and follows
a trimodal population distribution as shown in figure 2.4. TPMT activity can be
measured in red blood cells by a variety of methods including reverse phase high-
performance liquid chromatography (HPLC)(Lennard and Singleton, 1994) and by
radio-incorporation assay(Weinshilboum et al. 1978; Deininger et al. 1994). To date,
there have been few studies looking at TPMT activity in IBD patients and associated
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toxicity. TPMT genotyping (shown to reflect enzymatic activity) has been shown to
correlate well with myelotoxicity, but otherwise does not predict hepatotoxicity or
occurrence ofpancreatitis.
It should be borne in mind that while TPMT measurements (genotypic and activity)
clearly appear to have a useful role in identifying 'at risk' patients susceptible to
myelotoxicity, other environmental factors can play a role in the development of drug
toxicity such as parvovirus B19 infection (Higashida et al. 1997). Higashida et al
implicated the susceptibility to infection with viruses such as parvovirus B19 in AZA
immunosuppressed patients that may be an important factor in some patients who
develop severe myelosuppression. In the case of parvovirus B19 infection, the usual
resultant haematological problem is pure red cell aplasia(Higashida et al. 1997).. This
means that blood count monitoring remains essential, since severe myelosuppression
can occur despite normal TPMT levels. A genotype analysis of TPMT has confirmed
that myelosuppression in patients on AZA is often not related to homozygous TPMT
deficiency (Colombel et al 2000).
2.2.2 HPRT
HPRT deficiency was recognized in patients with raised urate levels and predisposed
to gout. In its severest form, the deficiency presents in childhood with associated
neurological defects and is known as Lesch-Nyhan Syndrome. The gene that codes for
HPRT is X-linked and there are several described mutations along this gene that
causes a variable degree of deficiency in HPRT levels. Such is its rarity that
deficiency of HPRT is probably of little clinical relevance with respect to AZA
therapy in IBD patients. Such patients would be resistant to the immunosuppressive
36
effects ofAZA therapy(Kelley et al. 1967).
Xanthine Oxidase (XO)
It is well recognized that allopurinol (which inhibits XO) interacts with AZA and can
precipitate toxicity. XO catalyses the conversion of 6-MP to thiouric acid (inactive)
and hence genetically low levels ofXO leaves more 6-MP available for conversion
into 6TG's. Xanthine oxidase deficiency is an autosomal recessive disorder, occurring
in about 2% of the population, and is often picked up incidentally by the presence of
hypouricaemia(Serre-Debeauvais et al. 1995). Like TPMT deficiency this condition
is associated with haematotoxicity but has received only modest interest when
compared to TPMT associated toxicity.
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Figure 2.4 Trimodal frequency distribution of red cell TPMT activity with
genotypes (TPMTH/TPMTH - homozygous normal TPMT; TPMTH/TPMTL -
heterozygous intermediate TPMT; TPMTL/TPMTL- homozygous low















estimated overall common odds ratio was 3.09 (95% CI, 2.45 to 3.91) in
favour ofAZA or 6-MP therapy and is summarized in table 2.2.
Fraser et al (Fraser et al 2002) published their retrospective 30-year experience
from Oxford. They examined 192 CD patients who had received AZA for a
minimum of 6 months. Complete remission (no need for concurrent steroid
therapy) was achieved in 64%. The study did not comment of the ability of
steroid dose reduction with AZA, and interestingly found that colonic disease
was associated with a higher remission rate. Follow up in this study was for a
mean of 6.9 years. Thirty nine percent of the study group discontinued AZA
after 2 years ofAZA achieved remission and were included in the final
analysis.
Maintenance therapy: Two studies have looked exclusively at treatment with
AZA in quiescent disease(0'Donoghue et al. 1978; Rosenberg et al. 1975),
while there have been several others that have included maintenance therapy
as part of a multiarm study(Candy et al. 1995; Summers et al. 1979;
Willoughby et al. 1971). Again, all of these exhibited varying degrees of
benefit (odds ratios 1.20-4.48), and meta-analysis by Pearson et al estimated a
common odds ratio of 2.27 (95% CI, 1.76 to 2.93) in favour ofAZA therapy
(Pearson et al. 1995), this is summarized in table 2.3. Fraser et al (Fraser et al
2002) analysed a total of 324 IBD patients (122 CD, 202 UC) in whom
remission was achieved and maintained after 6 months of therapy. At
12,24,36,48 and 60 months, the proportion remaining in remission (CD and
UC combined) was 0.95, 0.90, 0.69, 0.63 and 0.62 respectively. There was no
difference between CD and UC groups in the rate of remission.
Table 2.2. Odds ratio of response in randomized controlled studies of
azathioprine and 6-mercaptopurine for active Crohn's disease (Pearson et al.
1995)
Study Odds Ratio (95% CI)
Rhodes et al(Rhodes et al. 1971) 1.00 (no confidence interval, no
responders)
Klein et al(Klein et al. 1974) 1.00 (0.22-4.54)
Candy (Part 1) et al(Candy et al. 1995) 1.55 (0.52-4.59)
National Cooperative Crohn's Disease
Study (Part I, Phase l)(Summers et al.
1979)
1.57(0.75-3.29)
Ewe et al(Ewe et al. 1993) 4.57 (1.36-15.27)
Present et al(Present et al. 1980) 10.45 (4.14-26.38)
Willoughby (Group 1) et al(Willoughby et
al. 1971)
23.17(2.57-99.9)
Common Odds Ratio 3.09 (2.45-3.91)
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Table 2.3 Odds ratio of response in randomised controlled studies of
azathioprine for quiescent Crohn's disease (Pearson et al. 1995)
Study Odds ratio (95% CI)
National Cooperative Crohn's Disease
Study, Part I, phase 2 (Summers et al.
1979)
1.73 (0.37-8.05)
National Cooperative Crohn's Disease
Study, Part II(Summers et al. 1979)
1.20 (0.60-2.41)
O'Donohogue et al(0'Donoghue et al.
1978)
2.95 (0.97-9.00)
Rosenberg et al(Rosenberg et al. 1975) 3.16 (0.57-17.62)
Willoughby et al Group 2(Willoughby et
al. 1971)
4.48 (0.41-49.43)
Candy et al Part 2(Candy et al. 1995) 7.12 (2.11-23.99)
Common Odds Ratio 2.27 (1.76-2.93)
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2.3.2 Ulcerative Colitis
(i) Active disease: The use of both AZA and 6-MP in active colitis is limited
due to the protracted time to maximal onset ofAZA effect (approximately 3-4
months). There is no evidence that AZA plus steroids versus steroids alone
increases remission rates, but there is evidence of a steroid sparing effect
within this time frame(Adler and Korelitz, 1990; Kirk and Lennard-Jones
1982). In the study by Fraser et al (Fraser et al 2002), a total of 232 UC
patients were given AZA following a relapse. Remission was achieved in
58% of these patients (87% in UC patients who completed a minimum of 6
months AZA). This latter figure was statistically significantly higher
(p=0.0001) than their CD patients described before.
(ii) Maintenance therapy: AZA therapy has been studied more extensively than
6-MP in UC. There is good evidence that AZA/6-MP allow steroid dose
reduction, a conclusion found in several studies to date (AZA dose 1.5-2.5
mg/kg)(Adler and Korelitz, 1990; Caprilli et al. 1975; Jewell and Truelove
1974; Kirk and Lennard-Jones 1982; Rosenberg 1975). It should be noted
that there is no clear evidence from studies to show that AZA or 6-MP are of
benefit in the chronic active UC patient who is steroid resistant. Jewell et al
studied such patients for 12 months and found no clear benefit(Jewell DP and
Truelove SC, 1974), although uncontrolled data from others has shown
beneficial effects(George et al. 1996). Further evidence can be drawn from
withdrawal studies which although unable to comment on the magnitude of the
effect ofAZA, have shown that AZA withdrawal during remission leads to
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increased relapse rates(Hawthorne et al. 1992, Fraser et al 2002). There are no
controlled randomized trials that have looked exclusively at 6-MP and
maintenance therapy in UC.
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2.4 Current Issues
Optimal antimetabolite therapy is a minefield in current practice. This is partly due to
poorly designed studies mentioned before, but more importantly a lack of specific
studies looking at unanswered issues. Since there has been more extensive research
into AZA and other medical conditions, conclusions have been drawn from them and
extrapolated into IBD therapy - but it should be noted that some conclusions might
not equally apply to IBD patients.
2.4.1 Intravenous azathioprine use: In the light of the delayed onset of action of
oral AZA, there has been growing interest in the use of intravenous AZA in the hope
of decreasing the time of therapeutic onset and increase the therapeutic capability of
AZA in acute UC. TPMT activity status is a pre-requisite to using AZA intravenously
to stop potentially fatal side effects.
The first published experience in IBD was by Sandborn et al in 1995(Sandborn et al.
1995), where CD patients were loaded with 1800 mg ofAZA over 36 hours. They
concluded that there was a reduced time to response in these patients. Subsequently
Casson et al presented three patients with acute fulminant colitis (1UC, 1
indeterminate colitis, 1CD) who were treated with low dose intravenous AZA
(3mg/kg/day) for 5-7 days(Casson et al. 1999). All three patients achieved remission
on this treatment. Subsequently there have been two more publications. Firstly by
Sandborn et al in 1999, who took a placebo controlled trial of intravenous loading
dose ofAZA (40mg/kg/36hours) in 51 patients versus 45 placebo 'control' patients in
steroid resistant CD patients(Sandborn et al. 1999). They concluded that there was
no decrease in time to response in these patients, despite achieving higher 6-TG
concentrations at 0.2 weeks and 1 week. Thereafter, 6-TG concentrations in the 2
groups were the same, hinting that oral AZA therapy achieves similar 6-TG levels to
intravenous AZA. Finally, Mahedevan et al looked at acute UC in 9
patients(Mahadevan et al. 2000). Three groups of 3 were treated with
20mg/kg/36hours, 40mg/kg/36hours or 40mg/kg as three separate 8-hour infusions
over 3 days. Fifty-six percent of these patients avoided colectomy, and response was
seen within 4 weeks, with therapeutic 6-TG concentrations being achieved by 12
weeks. They concluded that intravenous AZA appeared to be safe and of clinical
benefit in steroid refractory UC patients.
2.4.2 Azathioprine dose: Current practice involves the use of a low dose of AZA/6-
MP for the first 6-8 weeks with subsequent dose adjustment to approximately 2mg/kg
or even higher if tolerated by the patient. There is evidence that doses of between 1.5-
2.5 mg/kg are effective in IBD, borne out in single studies and meta-analysis(Adler
and Korelitz, 1990; Kirk and Lennard-Jones 1982; Rosenberg 1975). In Fraser et al's
analysis (Fraser et al 2002) the mean dose ofAZA was 1.65 mg/kg in those who
achieved remission versus a mean of 1.64 mg/kg in those who did not achieve
remission. They concluded that higher AZA dose was not predictive of the ability to
achieve remission. Doses below 1.5 mg/kg probably have little clinical efficacy; with
strong evidence that a dose of 1mg/kg is ineffective in CD. There are no studies that
have directly compared different doses of either AZA or 6-MP to look at relapse rates
or degree of steroid sparing effect. In addition there have been no trials looking at
doses ofmore than 3mg/kg.
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2.4.3 Concurrent 5-ASA use: The concomitant use of 5-ASA with AZA may have
potential advantage in reducing the long-term colorectal malignancy risk associated
with IBD. On the other hand there is rising concern over the possible interaction of 5-
ASA compounds and their breakdown products and TPMT - the enzyme used in the
handling of both AZA and 6-MP(Woodson et al. 1983). In-vitro studies have
suggested that 4-ASA, 5-ASA and sulphasalazine all inhibit TPMT activity to
differing degrees (Lewis et al. 1997; Lowry et al. 1999; Szumlanski and
Weinshilboum, 1995). While the efficacy of long-term remission maintenance of
concurrent 5-ASA use with AZA versus AZA alone remains unstudied to date, the
long term clinical impact on colorectal malignancy risk remains unanswered. Until
there are studies to address this issue, it would seem sensible to add in AZA/6-MP
therapy with concurrent 5-ASA treatment where indicated being aware of a potential
drug interaction. Further prospective studies are now required.
2.4.4 Neutropenia: It is a matter of debate whether neutropenia is a prerequisite for
optimal AZA therapy. In current clinical practice, AZA dose is not titrated against
neutropenia, unless dangerous levels of neutropenia are seen.
There has been interest in the role of AZA/6-MP induced leucopenia in accomplishing
disease remission (Colonna and Korelitz 1994). The large retrospective study by
Fraser et al (Fraser et al 2002) found a lower nadir WCC and lower nadir neutrophil
count was predictive of achieving remission in IBD patients, and also suggested that a
lower nadir WCC helped keep these patients in remission for longer. In addition there
have been anecdotal reports ofprolonged remission in patients who have sustained
pancytopenia during AZA therapy(Burke et al. 1989). More recently, it has been the
significance ofwhite cell differential in leucopenia patients which has received
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interest (Korelitz et al. 1997). It has been proposed that it is the preferential
suppression of neutrophils during leucopenia that effects remission induction with
AZA/6-MP. The lack of studies concerning this area of treatment strategy means that
neutrophil count should not currently be used as an end point to dose titration ofAZA
or 6-MP.
2.4.5 Mean Corpuscular Volume: It has long been recognized that AZA/6-MP
causes blood count abnormalities such as leucopenia, thrombocytopenia and raised
MCV. The latter parameter is not a sign of toxicity. The mechanism by which MCV
increases is thought to be related to interference of cell proliferation in blood
precursors committed to erythropoiesis, with subsequent adaptive changes leading to
megaloblastic erythropoiesis (Williams et al. 1978). The rise in MCV following
administration of AZA/6-MP is not necessarily inevitable, nor does the level that the
MCV rise correlates with drug dosage (Nicholls and Davidson, 1979).
Mean corpuscular volume changes have been studied extensively in renal transplant
patients, but only one study has been published in IBD patients. Fraser et al (Fraser et
al 2002) found that a higher mean MCV was a predictor of achieving remission in
IBD patients (mean 93.3 in remission achieved versus 88.8 in remission not achieved,
p=0.0001).
Studies looking at MCV changes (8MCV) during therapy have been shown to be a
reasonable indirect estimation of 6-TG levels, but advocated a prospective study
before this parameter is utilized in clinical practice (Decaux et al. 1999). 6TG levels
measured directly have been shown to correlate well with actual bioavailability of oral
AZA/6-MP and hence ability to retain disease remission during therapy.
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2.4.6 6-TG monitoring: There has been increasing interest in the use monitoring 6-
MP metabolite levels as a more accurate method of assuring drug response, and
compliance. Erythrocyte 6TG levels represent an indirect measure of bone marrow
uptake and hence degree of immunosuppression. Red cell 6-TG levels can be
measured by a modification of a reversed phase HPLC (high performance liquid
chromatography) method initially used to measure TPMT levels(Lennard and
Singleton, 1994). 6-TG levels have been shown to exhibit a significant inverse
correlation with the HBI (Harvey-Bradshaw Index) in CD(Cuffari et al. 1996). Thus
measurements of 6-TG levels are useful in assessing both drug compliance,
responsiveness to treatment while preventing under and over-dosing.
2.4.7 Pregnancy and fertility issues: Clinicians are not under any form of
compulsion to report the outcome of administration of drugs during pregnancy to a
central monitoring authority. Therefore, data concerning both pregnancy and fertility
in patients taking AZA are confined to those voluntarily reports submitted for
publication and those reported to the pharmaceutical company. Initial published
literature was in renal transplant patients, following which, smaller and less detailed
reports have been published in other medical conditions such as rheumatoid arthritis,
SLE, renal transplantation, autoimmune hepatitis and IBD(Alstead et al. 1990;
O'Donnell et al. 1985; Ramsey-Goldman et al. 1993; Steven et al. 1979). In the
latter disease group there is a clear paucity of published data, although the reported
risk of foetal abnormalities from such patients taking AZA is approximately 2%.
There is no doubt that AZA crosses the placenta and is expressed in breast milk in
mothers taking AZA. However, the plasma concentrations are small representing up
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to 14% of the orally administered dose, and thus it appears unlikely that such
metabolite concentrations will have a clinically significant effect on the
foetus(Rosenkrantz et al. 1967). Cytogenetic analysis has detected chromosomal
aberrations in offspring ofpatients with CD, but long term follow up has not revealed
further problems in these infants(Willoughby et al. 1971). Immunological
abnormalities have also been reported in the newborn's of these patients(Golby, 1970;
Williamson and Karp, 1981), constituting lymphopenia, thymic hypoplasia and bone
marrow hypoplasia, but all of these have subsequently resolved later in infancy.
Unfortunately, there is a lack of reports of detailed immunological assessments in
these patients. Table 2.4 summarizes the relative percentage occurrence of reported
foetal abnormalities in patients taking AZA.
Overall, good control of the patient's IBD is much more important for the well being
of the foetus and pregnancy. It should be remembered that patients with CD have
higher rates of spontaneous abortion and stillbirths, and that controlling disease
activity may reduce these risks (Alstead et al. 1990).
There are a lack ofpublications that have looked at male fertility in IBD patients
taking AZA. Spermatogenesis has been studied in renal transplant patients and shown
to be similar to healthy controls (Evans et al. 1975), other small reports in renal
transplant patients revealed decreased sperm counts but the counts remained within
the normal range (Handelsman et al. 1984). In a study reported after the
commencement of our own work, male fertility on AZA appeared to be normal in
IBD patients (Dejaco et al 2001), despite earlier concerns in the rheumatological
literature (Janssen et al 2000).
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2.4.8 Neoplasia Risk: It has been well recognized that the risk of various malignant
disorders is higher in transplant recipients receiving immunosuppressive therapy than
in the general population. In particular prospective studies have shown an excess of
non-Hodgkin lymphoma (NHL), squamous cell carcinoma and hepatoma (Hoover and
Fraumeni, Jr., 1973; Kinlen et al. 1979; Kinlen and Hoover, 1979). In addition,
rheumatoid arthritis patients receiving AZA have been shown to exhibit excessive
frequencies of these malignancies beyond that associated with rheumatoid
disease(Silman et al. 1988). Studies in IBD patients have been sparse. One IBD study
was by Connell et al in 1994 who looked at 755 IBD patients taking AZA (2mg/kg)
studied over a 29 year period (Connell et al. 1994). They concluded that while
colorectal carcinoma occurred in excess (something observed in IBD patients
anyway), there were no cases ofNHL, although the study's power was relatively low.
Another study by Present et al looked at 396 IBD patients, treated with 6-MP for a
mean period of 5.4 years. They described 12 cases ofmalignancy, 1 ofwhich was
NHL (Present et al. 1989). Finally, a large analysis of 782 IBD patients by Farrell et
al concluded that although there was an increased risk of non-Hodgkin's lymphoma,
but the overall risk was low (Farrell et al. 2000). Clearly, as long as patients are
informed of the potential and seemingly small risks ofAZA therapy, it seems sensible
that AZA should be used considering the morbidity associated with other long-term
medical therapies and risks from surgery. Table 2.5 summarizes published relative
risks of developing malignancy in patients receiving AZA.
2.4.9 Duration of therapy: One of the most frequently asked questions by patients
taking AZA is how long does treatment last. There have now been several long-term
studies looking at both AZA and 6-MP use in both CD and UC. Probably the most
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quoted paper is that from Bouhnik et al that first addressed this question(Bouhnik et
al. 1996). They looked at 157 patients over a 6-year period. Relapse rates were
examined in patients on AZA/6-MP compared with those whose AZA/6-MP therapy
was discontinued. They concluded that beyond 4 years of therapy, relapse rates were
the same for both groups. It should be noted that at this time point, the two groups
were small and hence may not have had the power to detect a significant difference in
relapse rates. A smaller study involving 105 UC patients came to a different
conclusion (George et al. 1996). Duration of follow up was approximately 5 years,
but relapse in the withdrawal group was very small (n=15) making conclusions
somewhat difficult to interpret. More recently, Kim et al looked at 6-MP therapy in
120 CD patients with a follow up period of over 8 years (Kim et al. 1999). Again
study design was similar, but final conclusions from this study found statistical
significance between 6-MP and withdrawal group. Their conclusions advocated the
indefinite use of 6-MP therapy once remission was achieved, although admitted that
until there is a placebo-controlled withdrawal trial, optimal duration of therapy is
unlikely to be known. Fraser et al (Fraser et al 2002) also examined IBD patient
relapse after cessation ofAZA therapy. Duration ofAZA before cessation was not
predictive of the duration of remission, and concluded that from their data there was
no evidence to support the concept of no benefit after 4 years as proposed by Bouhnik
et al. Indeed at 5 years into AZA therapy some 62% of patients remained in remission.
A recent randomised controlled trial by the GETAID group ofAZA withdrawal after
at least 42 months of therapy in CD patients in good remission showed that AZA
withdrawal was associated with a higher frequency of relapses. (Lemann et al 2002).
Clearly there appears to be good evidence for use up to 4-5 years, and if the drug is
well tolerated longer therapy may well be indicated. In the authors experience it is
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often the patient that will request discontinuation of therapy after prolonged remission
and therefore it is important that patients are aware that evidence suggests higher
relapse rates once therapy is withdrawn even after several years.
2.4.10 Azathioprine or 6-Mercaytoyurine therapy? Although the side effect profiles
of both AZA and 6-MP are very similar, there is evidence of different bioavailabilities
of these two drugs, and between branded AZA and generic AZA (Cuffari et al. 2000).
This has further implications with regard to optimizing drug treatment with 6-TG
monitoring. In addition, there are small series of patients who have been re-challenged
with 6-MP after being intolerant to AZA. In a group of 11 patients, 54% (6) were able
to tolerate 6-MP, hinting that 6-MP may have benefits over AZA for initial therapy
(Bowen and Selby 2000). McGovern et al (McGovern et al 2002) has also suggested
that it may the imidazole moiety that is released during AZA breakdown that may be
responsible for the intolerance ofAZA and the tolerance of 6-MP.
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2.5 Conclusion
In summary, antimetabolite therapy has proven itself an extremely valuable and
efficacious drug that now forms an invaluable option to the gastroenterologist in
helping treat steroid refractory/dependent IBD. Although there may well be a great
number of small and poorly designed studies, experience with time has given us
increasing understanding in helping to develop ever more optimal immunosuppressive
therapy in IBD patients. Its long-term safety is now generally well accepted with
appropriate monitoring and with more studies, further information will help us refine
antimetabolite use in the future.
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Table 2.4 Percentage occurrence of foetal abnormalities reported in the
literature (Alstead et al. 1990; O'Donnell et al. 1985; Ramsey-Goldman et al. 1993;
Steven et al. 1979; Golbv 1970)







Neural tube defects 4
Other abnormalities 15
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Table 2.5 Relative risk ofmalignancy associated with AZA therapy (including
non-IBD patients treated with AZAXFraser et al 2002; Farrell et al 2000, Connell et
al 1994; Gaya et al 1995; Kinlen et al 1985; Lewis et al 2001)







*No significant difference found when compared against disease matched controls
** Relative risk increased with duration ofAZA therapy
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Chapter. 3. Is neutropenia in inflammatory bowel
disease patients treated with azathioprine desirable?
3.1 Introduction
AZA use in IBD has been now widely accepted as an invaluable second line
immunosuppressive agent in the treatment of steroid refractory or steroid dependent
disease (Marion and Present 1997; Pearson et al. 1995). The optimal therapy
regimen for AZA use continues to be defined as experience with its use in IBD grows.
AZA is usually introduced at a low dose and titrated up to an arbitrary dose of
approximately 2mg/kg, although higher doses are generally used in the United States.
The mean time to onset of effect ofAZA is about 3 months, and it is generally
accepted that a dose of between 2-2.5 mg/kg is efficacious. AZA is broken down to 6-
MP and then on to active 6-thioguanine molecules by the enzyme thiopurine-methyl-
transferase (TPMT). TPMT is genetically determined, and inherited in a co-dominant
fashion (Dubinsky et al. 2000). Genetically low levels of TPMT have shown to
correlate well with the occurrence of some AZA induced side-effects, in particular,
the development of neutropenia (Colombel et al. 2000).
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Both macrocytosis and lymphopenia are well recognized haematological effects of
AZA therapy and their relevance to achieving or maintaining remission remains
uncertain (Colonna and Korelitz 1994; Decaux et al. 1999; Colonna and Korelitz
1994; Decaux et al. 1999). The dangers of leukopenia and, perhaps more importantly
neutropenia have long been recognized, necessitating regular blood count monitoring
ofpatients taking AZA.
More recently, there has been interest in the potential therapeutic value of'safe' levels
ofneutropenia and leukopenia in achieving and maintaining remission (Colonna and
Korelitz 1994; Korelitz et al. 1997). Anecdotal reports have suggested that these may
be now desirable end points to AZA therapy (Burke et al. 1989). However this
remains unanswered and in current clinical practice, AZA dose is not titrated against
neutropenia, unless dangerous levels of neutropenia are seen.
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3.2 Patients & Methods
The hypothesis was that there is no difference in remission maintenance in IBD
patients treated with AZA who achieve a neutropenic neutrophil count compared to
those who do not.
A database was constructed containing information on IBD patients maintained on
AZA (n=203; UC=94; CD=109; median age 39 years, range 15-82 years, 88 male:l 15
female). For the purpose of this study, patients were excluded if they were not
maintained on AZA for a minimum of 6 months or if there treatment was stopped due
to non-haematological side effects, or if their disease remained active despite AZA
therapy. This left a total of 173 IBD patients (UC=77;CD=96, median age 39 years,
range 16-81 years; 76 male, 97 female) who had been maintained in remission on
AZA. Median duration of follow up was 4.0 years (range 0.6-21 years). Other
information that was collected included the lowest neutrophil count ever recorded
during therapy, the lowest neutrophil count within the first 4 months of therapy,
anatomical disease distribution, AZA dose, patients weight at induction of therapy and
smoking status. Relapse was defined as necessity for surgery, or clinical recurrence
(as assessed by an experienced clinician based on clinical features of diarrhoea,
abdominal pain, general well being, weight loss and inflammatory parameters -
haemoglobin, ESR, CRP, white cell count and platelets). Requirement for surgery for
purely mechanical obstruction, without abnormal inflammatory parameters was not
considered a relapse of active disease. Endoscopic findings complemented clinical
features and blood parameters, but were not used solely to determine relapse. Relapse
rates per year of follow up were compared with the lowest degree of neutropenia
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achieved during AZA therapy. A neutrophil count of <2.5x 109 was used to define
neutropenic patients. All cases were examined by one investigator (SC).
There were 44 patients who had been neutropenic (mean neutrophil count 1.9; SD
0.34) while taking AZA, with 129 patients not achieving any neutropenia (mean
neutrophil count 3.7; SD 0.9). Doses ofAZA were similar in both groups of patients
(neutropenic 1.8mg/kg, SD 0.41; UC 1.9 mg/kg, SD 0.42; CD 1.75 mg/kg, SD 0.43;
non-neutropenic 1.9mg/kg, SD 0.47; UC 1.85 mg/kg, SD 0.48; CD 1.95 mg/kg, SD
0.45). Also comparable were mean duration of follow up, duration of therapy, disease
anatomy, concurrent use of steroids and use of 5-ASA drugs. These results are
summarized in table 3.1.
3.2.1 Statistical analysis - Statistical analysis was by non-parametric Mann-
Whitney test for comparing the two groups. Relapse rates were calculated using
Kaplan Meier survival curves and compared using log rank test analysis.
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Table 3.1: Group characteristics (disease distribution, AZA dose, duration of






































5.0 41 17:27 1.8 1.9
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3.3 Results
A total of 173 IBD patients were stable on AZA for a minimum of 6 months. Median
duration of therapy was 4.0 years (range 0.6-21 years). Forty-four patients (25 %)
became neutropenic (lowest neutrophil achieved during therapy of <2.5x 109) while
taking AZA ofwhich 4 patients had stopped treatment due to severe life threatening
neutropenia (2 CD, 2 UC), and were included in the final analysis. The two Crohn's
patients suffered from severe sepsis. One was from a urinary tract infection (lowest
neutrophil count 0.5x 109) and resolved with intravenous antibiotics. The other patient
developed neutropenic sepsis necessitating the use of Granulocyte Colony Stimulating
Factor (GCSF, Filgrastim, Roche, Welwyn Garden City) (lowest neutrophil count
0.2x 109), intensive care admission for 10 days and haemodialysis, but made a full
recovery. One of the UC patients developed severe pancytopenia and subsequent
Adult Respiratory Distress Syndrome (ARDS - lowest neutrophil count 0.8x 109),
necessitating intensive care treatment for 5 days, but made a full recovery. The other
UC patient developed no complications (lowest neutrophil count 0.8x 109) and their
blood count returned to normal within a week of stopping AZA.
For all IBD patients (M=66, F=107), mean relapse rates in the neutropenic group
(mean AZA dose 1.80 mg/kg, SD 0.41, M=17, F=27) were 0.28/year follow up
(SD=0.43) compared with 0.19/year follow up (SDK).37) for the non-neutropenic
group (mean AZA dose 1.90 mg/kg, SD 0.47, M=49, F=80); this was not statistically
significant (p=0.37 Mann-Whitney test). Figure 3.1 shows cumulative survival curves
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for IBD patients with no statistical difference between neutropenic and non-
neutropenic groups by log rank analysis (%2=1.49, p=NS).
For the UC patients (M=22:F=56), the neutropenia group (mean AZA dose 1.90
mg/kg, SD 0.42, M=11: F=17) had a mean relapse rate of 0.30/year follow up
(SD=0.48) compared with 0.18/year follow up for the non-neutropenic group (mean
AZA dose 1.85 mg/kg, SD 0.48, M=11 :F=39; p=0.63 MWT). For CD patients
(M=44:F=51), the neutropenic patients (mean AZA dose 1.75 mg/kg, SD 0.43,
M=6:F-10) had a mean relapse rate of 0.20/ year follow up (SD=0.32) compared with
0.23 /year (SD=0.44) follow up in the non-neutropenic group (mean AZA dose 1.95
mg/kg, SD 0.45, M=38:F=41, p=0.41 MWT). Figure 3.2 shows cumulative remission
percentage in UC and Figure 3.3 CD using Kaplan-Meier survival curves. There is no
statistical difference between neutropenic and non-neutropenic groups (y2=0.76 for
UC, x2=0.33 for CD, p=NS). These results are summarized in table 3.2.
In addition, univariate and multivariate analysis were performed in smoking and non¬
smoking groups. These were not statistically significant in any group.
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From this cohort of 173 patients remission maintenance is not statistically different in
neutropenic versus non-neutropenic patients. If anything, the survival curves suggest
that time to first relapse is shorter for patients who achieved neutropenia (neutrophil
counts <2.5x 109). Further analyses were performed using <2x 109 as the cut-off for
the neutropenic groups (data not shown) and again no significant difference in relapse
rates were found. In addition we analysed the lowest neutrophil counts within the first
4 months of therapy (data not shown). This correlated well with the nadir neutrophil
count (Pearson correlation coefficient r= 0.7, P<0.005); again supporting that
neutropenia is not purely a sporadic phenomenon. In view of the fact that neutropenia
is not a sporadic phenomenon, we have not used the mean of neutrophil counts, but
the lowest neutrophil count in our study. The lowest neutrophil count reflected in
general the pattern of neutrophil counts closely.
AZA immunosuppression is probably mediated through its effects on lymphocytes,
although there appears to be preferential suppression of neutrophils when leukopenia
occurs (Korelitz et al. 1997). It has been suggested that AZA's anti-inflammatory
action may be mediated through its effects on neutrophils, and it has been shown that
neutrophil migration into the lamina propria occurs during clinical relapse in IBD
(Teahon and Bjarnason 1993). However, the complex mechanism by which AZA
affects many cell lines means that it is difficult to implicate these lines in the
pathogenesis of IBD. Indeed. An anecdotal report has described prolonged remission
of in excess of 4 years following AZA induced pancytopenia (Burke et al. 1989).
This report compares well with our own experience, where 3 of the 4 patients that
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developed severe neutropenia have remained in remission up to 21 months following
that episode. More interestingly, the 3 patients achieving remission all developed
sepsis necessitating hospital admission for treatment.
Probably the best documented study looking at the role of leukopenia was by Colonna
et al (Colonna and Korelitz 1994), whom studied 98 CD patients retrospectively.
They concluded that patients achieving leukopenia were more successful in reducing
their CCFA-IOIBD (Crohn's and colitis Foundation ofAmerica/International
organization of inflammatory bowel disease) index and in maintaining or inducing
clinical remission. In addition these patients were more able to reduce their
corticosteroid dose. Flowever, this study had a relatively short period of follow-up of
about 18 months, and did not look specifically at neutropenia.
Our study involves a large number of patients over a long period of follow up of up to
21 years. Despite this being a retrospective analysis, and hence subject to type II
errors, this study has an 80% power to detect a 30% difference between the two
groups. Thus it could be argued that a smaller difference between the two groups may
not have clear implications considering the potential risks of neutropenia. Since
neutropenia can occur at any time during therapy and hence relatively unpredictable, a
randomised study may prove difficult and possibly hazardous to perform. However
the retrospective and observational nature of our study needs to be considered in
interpreting results which could be biased by patient selection and only a randomised
study with AZA metabolite and careful neutrophil monitoring can conclusively
answer the question.
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In conclusion, these data do not support the hypothesis that patients who achieve a
nadir neutrophil count of< 2.5 x 109 while taking AZA maintain disease remission for
longer. A prospective, randomized trial ofAZA induced neutropenia is required to
ascertain whether neutropenia is a desirable end-point in IBD patients.
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Chapter 4. 5-Aminosalicvlate drug use in conjunction
with Azathioprine therapy in inflammatory bowel disease
patients
4.1 Introduction
AZA therapy is an extremely valuable second line therapy in IBD patients who are
refractory to or dependent on steroid therapy. Optimal drug therapy in patients on
AZA still remains unanswered, with a considerable percentage of patients remaining
on a 5- aminosalicylate (5-ASA) derivative as well as AZA. Some may also require
low dose corticosteroid therapy.
The concomitant use of 5-ASA with AZA may have potential advantage in reducing
the long-term colorectal malignancy risk associated with IBD. On the other hand there
is rising concern over the possible interaction of 5-ASA compounds and their
breakdown products and TPMT - the enzyme used in the handling of both AZA and
6-MP. In-vitro studies have suggested that 4-ASA, 5-ASA and sulphasalazine all
inhibit TPMT activity to differing degrees, but as yet there has been no studies
looking at the clinical impact and side effect profiles in patients who take AZA and
concurrent 5-ASA drugs.
It is not known whether concomitant 5-ASA therapy is required in patients maintained
in remission with azathioprine. It is possible that 5-ASA therapy may be of additional
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benefit in maintaining remission in UC but 5-ASA is unlikely to have such a role in
CD. In a retrospective study, we compared relapse rates and AZA discontinuation
rates in both UC and CD patients_maintained in remission on AZA alone with that in
patients' maintained on AZA and a 5-ASA drug.
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4.2 Patients & Methods
The hypothesis was there is no difference in remission maintenance in IBD patients
on concurrent 5ASA+AZA therapy versus IBD patients on AZA therapy alone.
From our database of IBD patients maintained on AZA (n=203;UC=94;CD=109;
median age 39 years, range 15-82 years, 88 Male.T 15 Female), we retrospectively
examined relapse rates per year of follow up (i.e. total number of relapses divided by
duration of follow up). All case notes were examined by one investigator (SC).
Relapse was defined as a requirement for surgery or documented symptoms consistent
with a relapse necessitating rescue medication such as corticosteroid therapy. Thirty-
four patients (16%) had stopped AZA due to side effects (dangerous blood dyscrasias,
pancreatitis, nausea, abdominal pain, skin rashes or myalgia). Seventeen patients
developed side effects late into AZA therapy before discontinuation while the
remaining other 17 patients encountered side effects within the first 6 months of
treatment and were never stabilized on AZA - this latter group were excluded from
further analysis. This left a total of 186 patients (median age=39 years, range 15-82
years, 75 Male: 111 Female) who were stable on therapy for a minimum of 6 months
and in remission. Median duration of follow up was 3.8 years (range 0.6-15.5 years).
Information was also examined on the 34 patients who had to discontinue AZA due to
adverse side effects, and assessed whether the patients were on a 5-ASA at the time of
discontinuation.
One hundred and three (55%) out of 186 patients were taking AZA for a minimum of
6 months were also on concomitant 5-ASA drug (mean AZA dose for
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UC=1.75mg/kg, range 0.8-3.5mg/kg; CD=1.70mg/kg, range 0.8-2.7 mg/kg), while 83
patients were taking AZA alone (mean AZA dose for UC=1.85mg/kg, range 1.0-2.7
mg/kg; CD=1.8mg/kg, range 0.6-3.0 mg/kg). Median 5-ASA doses were 2.4g
mesalazine/day (range 0.8-3.2g/day n=71) (Asacol and Pentasa), 1.5g
sulphasalazine/day (range l-4g/day, n=30), while 2 patients were taking 7.5g
balsalazide/day and 2 patients 1.75g olsalazine/day. The mean dose ofAZA (AZA),
duration of therapy, frequency of use of low dose corticosteroid_in the two groups,
mean neutrophil counts and disease anatomy were comparable. These characteristics
are summarized in table 4.1.
4.2.1 Statistical analysis - Statistical analysis was by Students't' test for
comparing continuous variables between the two groups, AZA alone and AZA + 5-
ASA in UC and CD separately. Categorical data were compared using the chi-squared
test with Yates' correction. Kaplan Meier Survival Curves were constructed using
time to first relapse, and compared between the two groups using log rank test.
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4.3 Results
186 IBD patients were stable on AZA for a minimum of 6 months. The mean duration
of therapy was 3.8 years (SD=3.0). One hundred and three patients (55%) were taking
concurrent 5-ASA drugs.
Analyses were performed for both UC and CD patient groups separately. In the UC
group (n=82), patients taking AZA + 5-ASA (n=55) had a mean relapse rate of
0.21/year follow up (SD=0.31) compared with the AZA alone (n=27) group with a
mean relapse rate of 0.19/year of follow up (SD=0.28) (p=0.69; Student 't'-test). In
the CD group (n=104), AZA + 5-ASA patients (n=48) relapse rates were 0.27/yr
follow up (SD=1.0) compared with the AZA alone group (n=56) relapse rate 0.30/yr
follow up (SD=0.8), (p=0.97; Student 't'-test). Figure 4.1 shows remission percentage
based upon time to first relapse for UC patients, Figure 4.2 shows the same analysis in
CD patients. There was no statistical difference between those on AZA alone and on
AZA + 5-ASA in either disease by log rank test (x2=0.06 for UC and 0.01 for CD
respectively, p=NS). These results are summarized in table 4.2
5-ASA therapy (n=15) was no more frequent in those patients who had to discontinue
AZA therapy (n=34) due to side effects (Number discontinued in AZA alone group
versus number discontinued in AZA +5-ASA group: x2=0.4, p=NS). In addition,
comparing the 17 patients who discontinued AZA before stabilization (i.e. before 6
months) against those whom discontinued after 6 months_(n=17) showed no
significant differences in side effect types or mean dose ofAZA. This is summarized
in table 4.3.
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Finally, there were no cases ofmalignancy in this group, although one patient with
CD developed Waldenstroms macroglobulinaemia after 7 years AZA and mesalazine
therapy, and two patients with UC developed low-grade dysplasia, one after 5.8 years
of treatment with AZA and sulphasalazine and the other 3 years of treatment with
AZA and mesalazine.
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Figure 4.1 Remission percentages based upon time to first relapse for
ulcerative colitis patients
Months of AZA Rx
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Figure 4.2 Remission percentage based upon time to first relapse
for Crohn's disease patients
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Relapse rates per year of follow up were not statistically different between the AZA +
5ASA groups and the AZA alone group (in UC or CD groups) and our cumulative
remission curves compare well with other studies which have looked at remission
maintenance with 5-ASA and AZA ( Messori et al, 1994; Pearson et al. 1995;
d'Albasio et al, 1997; Jean-Pierre Gendre et al, 1993; M.C.M.Rijk et al. 1992; Yoram
Bouhnik et al, 1996). It would therefore appear that 5-ASA compounds afford no
additional clinical benefit on relapse rates in patients suffering from either UC or CD.
This study used data from a large database of IBD patients who were well matched for
disease type and distribution, and there were comparable numbers of patients taking
5-ASA compounds to those who were not (table 1). However, this is a retrospective
analysis of 2 groups of patients that may be selectively biased. It could be suggested
that patients taking AZA alone were patients with more aggressive disease who were
treated early on with AZA rather than using 5-ASA's. However, patients who were
taking 5-ASA in addition to AZA did not have a more aggressive disease course from
the standpoint ofprevious relapses and anatomical extent of disease. It was not
possible to elucidate the impact of 5-ASA compounds on long-term malignancy risks
in these patients because of the retrospective nature of the study. Although there are
recent studies advocating the protective role of 5-ASA drugs in the development of
colorectal malignancy(Davis et al. 1992; Ekbom, 1995; Moody etal. 1996;
Andrianopoulos et al. 1989; Eaden et al. 2000), it still remains uncertain whether
this is a direct effect of 5-ASA drugs or merely as a result of prolonged disease
remission. Interestingly there have been reports of the potential role of folate
supplementation in patients' taking sulphasalazine (a competitive inhibitor of folate
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absorption) to reduce the incidence of dysplasia and cancer in chronic UC(BA
Lashner et al. 1989). The role of 5-ASA's, especially sulphasalazine, in the
prevention of colorectal malignancy is controversial and currently firm evidence is
lacking. It is worthy to note that one case of dysplasia reported here was in a patient
taking sulphasalazine, there was no obvious excess occurrence ofmalignancy in our
group of patients taking sulphasalazine.
There has been growing interest over the last few years of the possible interaction
between 5-ASA compounds and the enzyme TPMT. It has been reported that TPMT
is potently inhibited by derivatives of benzoic acid (Woodson et al. 1983). Indeed
there is convincing evidence that it is the 3-,4-, and 5-ASA components, that inhibit
TPMT rather than other carrier molecules that are involved in the drug interaction (
Szumlanski and Weinshilbourn 1995). In-vitro analysis has highlighted significant
interactions with TPMT and balsalazide (Lowry et al. 1999), olsalazine(PW Lowry et
al. 1999) and sulphasalazine (Lewis et al, 1997), and it is likely that mesalazine has a
similar effect despite lack of data. In our study, the majority of patients were taking
mesalazine, with smaller numbers taking sulphasalazine, balsalazide and olsalazine
and it would appear that there is no evidence of any clinical risk from this potential
drug interaction. Clearly, caution should be exercised whenever 5ASA drugs are
being used in conjunction with AZA or 6-MP, especially ifmore potent inhibitors
such as olsalazine and balsalazide are being used. The importance ofTPMT inhibition
by these drugs will be especially important in the minority of patients (up to 10%)
who have genetically low levels of TPMT.
In summary, it is now important to follow up this study with a prospective double
blinded and placebo controlled study to further validate these results.
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Such a study will need to be multi-centre to answer adequately the question posed,
and can be designed either to withdraw 5-ASA from patients maintained in remission
on AZA+5-ASA in a ramdomised manner, or to commence AZA with or without 5-
ASA at the initiation of immunosuppressive therapy.
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Chapter 5. Azathioprine use in pregnancy in
inflammatory bowel disease patients
5.1 Introduction
AZA is regarded as an important second line therapy in patients with steroid
refractory or dependent IBD.
AZA has been reported to be safe during pregnancy in organ transplant patients and
rheumatology patients, but there is clear paucity of similar data in IBD patients.
Indeed, in animal models including rabbits, mice and rats AZA has been shown to be
teratogenic, albeit at much higher doses mg/kg than is used in clinical practise in IBD
patients. The reported occurrence of foetal abnormalities from patients taking AZA is
somewhat varied. Prematurity for example has been reported in up to 22% of
pregnancies while other complications such as cardiac, skeletal and haematological
abnormalities occur between 9-17% ofpregnancies (Alstead et al. 1990; O'Donnell et
al. 1985; Ramsey-Goldman et al. 1993; Steven et al. 1979; Golby 1970).
Though most gastroenterologists consider the use ofAZA to be relatively safe in
pregnancy, variation in practice exists as to whether AZA therapy should be continued
throughout pregnancy or omitted before conception. In this section we report on our
experience of pregnancy outcome in patients who had conceived while on AZA
therapy.
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5.2 Materials and methods
A database ofAZA using IBD patients (n=223; UC=104; CD=119) was searched and
identified 11 patients suffering from IBD (8 CD, 3 UC) who had conceived while
taking AZA. One patient had become pregnant twice, giving a total of 12 pregnancies.
Antenatal and postnatal details as well as duration of drug therapy were obtained from
the case records and from their respective general practitioners.
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5.3 Results
There were 12 pregnancies from 11 women - mean age at conception was 29 years
(range 26-33 years), eight had CD, and three UC. There were 10 live births from 12
pregnancies. One patient underwent a voluntary termination because of social reasons,
and one patient underwent an emergency operation for an ectopic pregnancy. In
neither case were the foetuses abnormal. At the time of pregnancy mean duration of
AZA therapy was 3.5 years (range 0.6-6.4 years) and mean disease duration was 8
years (range 2-20 years). Only 2 patients had undergone surgery for their IBD before
conception - both having a right hemicolectomy and ileal resection for ileocolonic
CD (Table 5.1).
All but one was taking concurrent 5-ASA compounds - either mesalazine or
sulphasalazine, while 3 other patients were, in addition, on low dose prednisolone
(<10mg od) (Table 5.1). In 8 of the 12 pregnancies, AZA was taken for the duration
of gestation, mean AZA dose 1.9mg/kg (range 1.5-2.3 mg/kg). Out of the remaining 4
pregnancies, one had emergency surgery for an ectopic pregnancy at 6 weeks
gestation and had previously had abdominal surgery; another stopped AZA at 5 weeks
gestation, because ofAZA induced headaches. One patient stopped her AZA at 6
weeks after concerns over breast-feeding and the fourth patient underwent a voluntary
termination for social reasons. There were no medical antenatal complications (Table
5.2).
Only one pregnancy did not go to term, delivered at 37 weeks. One patient delivered
by caesarian section and this was performed electively at 39 weeks; the remaining
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patients had normal vaginal deliveries. Mean birth weight was 3450 grams (range
3140-4100 grams), with 6 boys and 4 girls.
Excessive or serious infections in infancy, suggesting immunodeficiency, were not
reported in any of the children. However, Postnatal complications were noted in 2
births - namely one baby with hypertrophic pyloric stenosis, requiring emergency
surgery within the first week of life, and the other with an asymptomatic atrial septal
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AZA is a synthetic antimetabolic drug and its effects have been well documented in
pregnant animals, namely, mice rabbits and rats. At high doses of around 20mg/kg, it
impairs tissue, organ and placental differentiation in rats, although congenital
abnormalities have not been reported(Cote et al. 1974; Gross et al. 1977). In rabbits
and mice, teratogenicity has been shown (predominantly skeletal abnormalities,
haemopoietic and thymic depression) even ifAZA was given up to the midpoint of
gestation(Tuchmann-Dupleiss and Mercier-Parot 1966).
There is no doubt that AZA crosses the placenta and expressed in breast milk in
mothers taking AZA. However, the concentrations in placental tissue are small
representing up to 14% of the orally administered dose, and thus it appears unlikely
that such metabolite concentrations will have a clinically significant effect on the
foetus (Rosenkrantz et al. 1967).
In humans, AZA's effect on pregnancy and offspring has been predominantly looked
at in organ transplant patients - usually taking AZA and prednisolone. Here,
cytogenetic analysis has detected chromosomal aberrations in offspring, but long term
follow up has not revealed further problems in these infants (Willoughby et al. 1971).
There is no current evidence of fertility problems in patients taking AZA (Thiersch
1962). Immunological abnormalities have also been reported in the newborn's of these
patients(Golby, 1970; Williamson and Karp, 1981), constituting lymphopenia, thymic
hypoplasia and bone marrow hypoplasia, but all of these have subsequently resolved
later in infancy. Unfortunately, there is a lack of reports of detailed immunological
assessment in these patients.
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There have also been isolated anecdotal reports of skeletal abnormalities such as type
1 preaxial Polydactyly in children, whose mothers have been taking AZA (Schwartz
1966). However such abnormalities often have a polygenic aetiology and it is difficult
to attribute such isolated abnormalities directly to AZA use - especially when
equivalent doses used in humans (2-4 mg/kg) do not appear to show teratogenic
effects in animal models. Indeed the differences in clinical effects between animal
models and humans may well be attributed to different enzymic handling ofAZA and
6MP.
In this study, there were no premature births recorded, although there were 2 infants
that suffered congenital abnormalities. However there were no skeletal deformities
recorded in any of the infants, and it is plausible that these infants had sporadic
abnormalities, rather than these being directly as a result ofAZA. The lack ofpower
of this study combined with the occurrence of 2 congenital abnormalities suggests we
should be a little less certain about the absolute safety ofAZA in pregnancy in IBD.
Previous studies in groups of IBD patients taking AZA have also recorded healthy
offspring, although there have been cases ofviral infections - Hepatitis B and
Cytomegalovirus in the mother and subsequently the offspring (Saarikoski and
Seppala, 1972; Willoughby et al. 1971). In summary, AZA therapy appears to be
associated with successful outcome of pregnancy in the majority of patients, though
much larger numbers of reports need to be collated to have robust data on its use in
pregnancy. Our own data relates to use of the drug in therapeutic doses of around
2mg/kg, but it must be remembered that higher doses are often used in the US. Our
current practice with IBD patients who conceive while taking AZA, is to continue
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therapy, on the basis that good control of the patients IBD is much more important for
the well being of the foetus and pregnancy. It should be remembered that patients with
CD have higher rates of spontaneous abortion and stillbirths, and that controlling
disease activity may reduce these risks (Alstead et al. 1990). AZA is generally not
started during pregnancy, as there are potential risks from AZA related adverse drug
reactions, which occur in up to 10% ofpatients starting therapy. All patients get an
AZA information sheet from our pharmacy, explaining risks and benefits ofAZA
therapy, and patients are reassured that with increasing numbers of reports, it appears




Effects ofAzathioprine on progeny ofmale
6.1 Introduction
Clinicians are not under any form of compulsion to report outcome of administration
of drugs during pregnancy to a central monitoring authority. Therefore, information
regarding pregnancy outcome is reliant upon voluntary reporting - and therefore
subject to an obvious bias and tendency to report unfavourable outcomes, rather than
routine findings after such treatment. Hence there is a relatively small amount of
information regarding pregnancy outcomes in patients taking AZA. The majority of
reports have been in transplant patients where the origins ofAZA usage began.
Furthermore, even less attention has focussed upon the progeny of fathers who have
received similar AZA therapy. Again, the majority of current information is available
on renal transplant patients, but numbers remain small. There is only one study to date
that has examined progeny ofmale IBD patients taking 6-MP. This has urged caution
in fathers taking 6-MP within 3 months of conception due to an increase in pregnancy
related complications (Rajapakse et al 2000).
Studies in rats have also suggested that spermatogenesis is effected by AZA and 6-MP
(Karl et al 1991), calling for further evaluation of fertility in male patients receiving
AZA or 6-MP. Although male fertility has been reported to be reduced in the
rheumatological literature (Janssen et al 2000), more recent work studying male
fertility in IBD patients on AZA has been reported to be normal (Dejaco et al 2001).
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The aim of this study was to examine the clinical outcomes ofprogeny of fathers who
received AZA therapy for their IBD.
6.2 Patients and Methods
Male IBD patients taking AZA or 6-MP were identified from an IBD database.
Patients were excluded if they were aged below the age of 18 years or above the age
of 65 years. A total of 81 male patients (47 UC, 34 CD, median age 37 years, range
21-65 years) were surveyed.
Patients were contacted by post and asked to fill in (anonymously) a questionnaire
regarding AZA usage, partners' conception, and offspring health. Other information
obtained included concomitant medications, age at partners conception, disease
distribution duration and duration ofAZA therapy.
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6.3 Results
A total of 81 letters were sent to 81 male IBD patients. Forty-nine (60%) patients
replied. There were a total of 13 documented pregnancies from 10 fathers (6CD:4UC,
median age at partners conception 33 years, range 24-55 years) and 10 mothers
(median age at conception 28 years, range 22-40 years). All male patients were taking
AZA at the time of their partners' conception. None of the patients' partners were
taking immunosuppressive agents.
Median dose ofAZA was 1.9mg/kg (range 1.2-2.3 mg/kg); median duration ofAZA
therapy at partners' conception was 3.5 years (range 1.0-6.1 years). Seven out of the
10 fathers were taking a 5-ASA drug (mesalazine, median dose 800mg tds, range 400-
800 mg tds). None were taking sulphasalazine. There were only 2 patients taking low-
dose steroid therapy (prednisolone lOmg/day). Two patients were taking AZA alone.
Three of the fathers had 2 progeny while they were taking AZA. There were no
premature births or birth defects in this cohort. One father's progeny had autism, but
his partner suffered from epilepsy was taking carbamazepine during the pregnancy
and was also suffering from hypothyroidism (with thyroxine replacement). Another
father's progeny developed a cerebral tumour (astrocytoma) at the age of 10 years old.
All of the other progeny were clinically well, with no reported problems with fertility
and conception. Except the one mother who suffered from epilepsy, all the other
mothers were well and not taking any medications during the pregnancy. Table 6.1
summarises these result.
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There were a total of 13 pregnancies and thirteen live births, with 10 fathers currently
taking AZA at the time of their partner's conception. All the fathers were taking AZA
for a minimum of 1 year.
There have been very few studies that have looked at teratogenesis and clastogenesis
resulting from paternal use ofAZA. There have been several small papers describing
experiences pregnancies in the partners ofmale renal transplant patients - more than
90% of births were overtly normal, with spontaneous abortion, neural tube defects and
trisomy 21 making up the remainder of birth complications (Eslami et al. 1976;
Papoff et al. 1977;Whetham et al. 1983). To date there has been only one study
that has described outcome of pregnancy when fathers are treated with 6MP for IBD
(Rajapakse et al 2000). They describe a single centre retrospective experience over a
period of 27 years. They compared the outcome of pregnancies fathered by IBD men
taking 6MP (subdivided into group la (n=13), fathers who conceived within 3 months
of 6MP use and group lb (n=37), those who conceived at least 3 months after 6MP
was stopped) versus IBD men not taking 6MP. The only complications they reported
were in group la. The 4 complications included 2 spontaneous abortions and 2
congenital abnormalities (acrania and a missing thumb). This study was criticised
because of its retrospective nature and the small numbers of patients in the 6MP
group.
In this cohort, there were only 2 progeny who later developed complications - 1 with
autism, and the other progeny who developed a cerebral astrocytoma at the age of 10
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years. While it could be argued that these may have been associated with the fathers
AZA therapy, these 2 conditions are relatively common childhood conditions and
probably would have occurred even if the father was not taking AZA. The aetiology
of autism is unknown, although there are reports of associations with maternal
hypothyroidism (Gillberg et al. 1992), and increasing evidence that environmental
factors upon the mother during pregnancy may increase the risk of their children
developing autism (London and Etzel 2000). There has also been speculation that
there may be a predominance of autism in children who have 'new variant
inflammatory bowel disease' (Wakefield AJ et al 1998). This latter report remains
controversial with a more recent epidemiological study reporting conflicting evidence
(Taylor B et al 1999). Malignant cerebral tumours are the second most common
childhood cancers (after leukaemia's) and their incidence in the UK is rising,
accounting for around 300 cases per year (McKinney et al. 1998). Astrocytoma's
account for nearly 30% of newly diagnosed cases, making them the most common
form of childhood cerebral tumour (Stiller et al 2000).
Detailed evaluations of fertility issues were not possible in this study, but there were
no reports of infertility or problems with partners conceiving. Animal models have
suggested that spermatogenesis is impaired - but this has been when higher doses of
3-5mg/kg AZA are used (Karl et al. 1991). Studies of spermatogenesis in humans
have had conflicting results. A study of 34 renal transplant patients had spermograms
which were not significantly different from healthy controls (Evans et al. 1975).
Other smaller studies have reported significantly lower sperm quality in renal
transplant recipients (Salant et al. 1976). Finally, studies in patients with rheumatoid
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arthritis (Currey et al. 1974) and systemic lupus erythematosa (Masramon etal.
1980) revealed normal sperm counts in all of their cohorts.
This is a small cohort ofmale IBD patients who were taking AZA, and therefore it
would be difficult to make substantial conclusions from this experience alone. Indeed,
like the study by Rajapakse et al (Rajapakse et al 2000), this study can also be
criticised because of its retrospective nature. This further highlights the difficulty in
obtaining conclusive data from this type of patient group from a single centre. As
stated earlier with pregnancy in IBD patients, a central database collecting
information from multiple centres would help to give more conclusive information.
However, these patients were well established upon their AZA therapy for several
years and in addition were taking substantial doses of the drug (median dose
1.8mg/kg).
In summary, there does not appear to be any obvious serious implications for the
progeny of IBD patients taking AZA. Before male patients are started upon AZA risks
should always be explained to the patient, as well as the potential risks to any progeny
they may sire - albeit seemingly low. More data is required and caution similar to
maternal use ofAZA should be exercised and individualised decisions taken. Though
most men and women with UC and CD can expect a healthy child (Ludvigsson JF et
al 2002), US studies have urged caution in fathers using 6-MP within 3 months of
conception due to increase in pregnancy related complications (Rajapakse et al 2000,
Korelitz et al 2001).
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Chapter 7. Cyclosporin rescue therapy used in
combination with azathioprine and corticosteroids in severe
ulcerative colitis
7.1 Introduction
CyA is a fungal metabolite and is a powerful immunosuppressant. Its action is
lymphocyte specific, inhibiting interleukin-2 and therefore the function of T helper
cells. Thereafter, recruitment of cytotoxic T cell populations are inhibited as well as
the release of other lymphokines (Baker and Jewell 1989).
Patients with a severe attack ofUC, characterised by severe rectal bleeding, diarrhoea
and fever (Edwards and Truelove 1963) will inevitably require hospitalisation and the
administration of intravenous steroid therapy. Response to this intravenous treatment
is in excess of 60% (Jarnerot et al. 1985), leaving the remainder of patients with the
options of curative surgery (i.e. panproctocolectomy) or the administration of
intravenous rescue therapy with CyA. Intravenous CyA is far from widely accepted
by the medical community, and to date there have been only two randomised
controlled trials into the use ofCyA in severe relapses ofUC (D'Haens et al. 2001;
Lichtiger et al 1994). Lichtiger et al (Lichtiger et al 1994) studied a total of 20 patients
who were randomised to receive IV CyA (4mg/kg/day) or placebo, in addition to
continued glucocorticoids for up to 14 days. Nine out of eleven patients receiving
CyA improved after 7 days compared with 0 of 9 for the placebo arm. They
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concluded that CyA was an effective treatment in the acute setting, but did not assess
long-term follow-up on these patients. None of these patients receive AZA. D'Haens
et al studied monotherapy with intravenous CyA versus intravenous glucocorticoids in
severe attacks ofUC. A total of 30 patients were studied (15 patients received CyA
and 15 received glucocorticoid). Eight of the 15 patients who received intravenous
methylprednisolone (40mg/day) responded after 8 days versus 9 of 14 who received
CyA (4mg/kg/day). At 1 year, 7 of these CyA patients maintained their remission
versus only 3 of 8 treated with methylprednisolone. It is of note that all the patients
who received CyA continued on oral AZA, while only 37% of the methlyprednisolone
treated patients subsequently went on to receive AZA. Actis et al (Actis et al 2001)
examined the safety and efficacy of azathioprine in the maintenance of cyclosporin-
induced remission ofUC as compared to remission attained by intravenous steroids.
They found that discontinuation ofAZA was similar in both groups advocating the
safety of overlapping AZA, CyA and a reducing dose of oral steroid therapy. Their
CyA group was particularly heterogeneous - some patients receiving AZA after their
first relapse following CyA therapy and others receiving AZA at the time of initial
CyA therapy, making the role ofAZA in these patients unclear.
There are several uncontrolled trials that have shown promising initial response rates
of 82% at day 7 and 69% response by 6 months (Kornbluth et al. 1994; Lichtiger et
al. 1994). However there is not enough data to firmly conclude that CyA therapy is
definitely beneficial in patients with severe UC.
Unfortunately there been contradictory studies, reporting much higher relapse rates
recorded at 12 months and beyond (Baert and Hanauer 1994). In addition to this,
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there are concerns over the number of potential toxicity from CyA therapy (Carbonnel
et al. 1996). Successful treatment with CyA avoids the immediate necessity of a
surgical procedure, but the relapse rate and colectomy rate subsequently may be high.
To reduce this high relapse rate, the addition of oral AZA after remission has been
achieved with CyA has been tried.(Cohen et al. 1999; Fernandez-Banares et al.
1996), but there are serious concerns about side effects including opportunistic
infection such as Pneumocystis carnii pneumonia.
The paucity of data currently available on patients receiving rescue CyA therapy in
combination with AZA and corticosteroids compounds our indecisive use of this
treatment regimen within the acute setting. The aim of this study was to report our
experience of the use of intravenous CyA in acute UC in combination with AZA and
steroids and to contribute further information as to its optimal use.
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7.2 Patients and Methods
The hypothesis was that there is no difference in long term outcome in severe UC
patients who received intravenous CyA who subsequently received AZA therapy
compared to those patients who did not.
Between January 1994 and January 2001, 17 patients had received intravenous CyA
for acute attacks of UC at the Western General Hospital, Edinburgh. The aim of this
was to gather information regarding CyA use in UC patients. The decision to
administer CyA was taken after detailed discussion with the patient about potential
risks and benefits. In addition it was only patients expressing the strong desire to
avoid surgery that were counselled in this fashion. Follow-up treatment with AZA and
the potential alternative of proctocolectomy were also discussed. These discussions
always involved a consultant caring for the patient (SG).
Information obtained was age, disease duration and anatomy, concurrent use ofAZA,
time to surgery, side effects from CyA, use of Pneumocystis Carnii (PCP)
prophylaxis, CyA dosage and duration and previously published predictors of
outcome(Travis et al. 1996) (CRP at 3 days, stool frequency at 3 days). This left 17
patients who had received intravenous CyA for acute UC. One patient had moved area
and their case notes could not be located, leaving 16 patients who were evaluable (7
female, 9 male, mean age 33 years, mean disease duration 6.6 years, mean follow up
3.1 years).
All patients were refractory to treatment with a standardized intravenous steroid
regimen of 60mg methylprednisolone given over 24 hours as a continuous infusion
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(for a minimum of 5 days). The majority ofpatients receiving oral CyA received
Neoral® micro emulsion preparation tablets, only 2 patients received oil based
preparations. Only patients who responded initially to intravenous CyA were
commenced on AZA, and all patients were given 5-ASA therapy (mesalazine 800mg
tds). Our discharge practice for these patients involved oral triple immunosuppressive
therapy (oral CyA, azathioprine, oral steroids). Patients were started on oral
prednisolone at a dose of 40mg tapering by 5 mg every week (unless the patient
relapsed and steroid doses were kept at a stable enough dose to achieve remission).
At the same time oral CyA was commenced (and dose adjusted to serum levels) and
maintained for a minimum of 4 weeks (median 6 weeks, range 4-15 weeks). AZA
therapy was titrated to as close to 2mg/kg as was allowed by blood count and liver
function test monitoring or patient side effects. Oral steroids were tapered first
followed by CyA. AZA therapy was continued thereafter with a 5-ASA drug.
Throughout the duration ofCyA therapy, PCP prophylaxis was given in the form of
Septrin 960mg on alternate days.
7.2.1 Statistical analysis - Statistical analysis was by Mann-Whitney test (for
non parametric data) and time to first relapse data was analysed by Kaplan-Meier
survival curves and log rank testing. Statistical significance was taken for p <0.05. All
statistical analyses were performed using Minitab release 13.20 software.
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7.3 Results
This study includes 16 patients (7 female:9 male, median age 35 years, range 22-43
years) who were treated for acute severe UC with intravenous CyA. All met Truelove
and Witts criteria for severe acute UC. The median disease duration was 5.4 years
(range 0.9-25 years). All patients were refractory to IV methylprednisolone
60mg/24hr and subsequently treated with CyA at a dose of 4mg/kg. Trough CyA
levels were checked 72 hours into IV CyA, and weekly for oral CyA patients. Our
laboratory reference range is 120-300 nmol/1. Nine patients had this subsequently
reduced according to CyA levels (median CyA dose 267mg, range 200-400mg). The
median duration of intravenous CyA therapy was 7 days (range 3-16 days), with
subsequent oral CyA (median dose 350mg, range 150-400mg) being continued in 9
patients (median duration 6weeks, range 0.3-15 weeks). Median follow-up duration
after initial CyA therapy was 2.6 years (range 0.5-7 years). Two of the 9 patients
received oil-based CyA preparations, while the remaining 7 patients received
microemulsion preparation (Neoral®). These 9 patients were simultaneously started
on oral AZA (median dose 1.8 mg/kg, range 1.2-2.1 mg/kg) in conjunction with oral
CyA oral steroids and mesalazine. Although an AZA dose of 2mg/kg body weight
was the primary goal, dose adjustment was necessary in some patients due to side
effects (e.g. nausea, slight abnormalities in LFT's, and neutropenia). The remaining 7
patients underwent surgery (6 had panproctocolectomy and ileostomy, while one
patient had a panproctocolectomy and ileo-anal pouch formation) before oral CyA and
oral AZA therapy was instituted. Five patients were admitted with their first attack
requiring CyA rescue therapy. All patients had a flare-up of their known UC - 14
patients had pan colitis, and 2 had left sided colitis. The median lead-in-time for
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patients (duration of symptoms before admission) was 18 days (range 7-60 days).
These characteristics are summarized in table 7.1.
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Table 7.1 - Patient characteristics
Variable Median value (range)
Male: Female 9:7
Age 35 years (22-43)
Disease Duration 5.4 years (0.9-25)
Number admitted with 1st attack 5
CRP @ 3 days 4.4(1.5-18)
Stool frequency @ 3 days 8 (3-9)
Disease distribution L- 1
(L-lefit side, P-pan colitis, D- distal) P - 14
D - 1
Duration of IV CyA 7 days (3-16)
Duration of oral CyA 6 weeks (4-15)
Duration ofhospital stay 27 days (9-34)
Number taking PCP prophylaxis 16
Lead-in-time 18 days (7-60)
Patients requiring surgery 7 (44%)
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Figure 7.1 shows a Kaplan Meier survival plot for time to first relapse for all patients
and patients who had received a combination ofCyA and AZA. All patients in long-
term remission were taking AZA. Fifty-six percent of patients retained their colon.
Comparisons were made between patients who presented with their 1st attack with
patients who had more than one attack of severe colitis (median number of attacks =
3, range 2-5) - this data is shown in figure 7.2. Log rank analysis was again not
statistically significant (x2=0.06, p=NS).
Comparisons were also made between patients who had <7 days of intravenous
steroid (n=10, median duration 6 days; range 5-7 days) versus patients having >7 days
intravenous steroids (n=7, median duration 12 days; range 8-16 days) prior to
commencement ofCyA therapy. Figure 7.3. Illustrates the survival curves for this
data. Log rank analysis was not statistically significant (y2=0.0005, p=NS).
Comparative Kaplan-Meier survival curve analysis for time to first relapse (not
shown) were performed with other subgroups, including stool frequency at 3 days (<8
stools per day versus >8 stools per day) and CRP at 3 days (CRP <4.5 versus CRP
>4.5) - neither reached statistical significance (x2=0.3, p=NS and x2=0.2, p=NS
respectively).
Finally, comparisons were made between patients who underwent surgery and
patients who had successful rescue therapy with AZA. Median age, lead-in-time, and
median CyA levels were not statistically significant between the two groups. Of
interest, was that predictive markers of the need for surgery (CRP and bowel
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Figure 7.1 - Survival curve for time to 1st relapse for all patients.
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Figure 7.3 - Survival curve comparison (time to first relapse) for
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frequency at 3 days). Bowel frequency at 3 days just failed to reach statistical
significance, with a median CRP of 5.2 in the surgical group (MWT, p=0.06). The
median CRP was higher in the surgical group, although this did not reach statistical
significance (MWT, p=0.7). Median duration of intravenous CyA was higher in the
non-surgical patient group when compared to the surgical group (7 days versus 4
days, MWT; p=0.05). These results are summarized in Table 7.2.
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7.4 Discussion
CyA rescue therapy has previously been shown to be extremely useful in inducing
remission and saving patients with UC from surgery; studies have reported early
response rates in between 60 to 80% (Lichtiger and Present 1990; van Gossum et al.
1996; Sandborn 1995). Our series also confirms this relatively high initial response
rate (11 patients, 69%). Interestingly our long-term success rate was more in
impressive than results from Baert et al (Baert and Hanauer 1994) and comparable to
that found by other studies (Sandborn 1995) (9 patients avoided surgery - 56% - with
a follow up of 3 years).
Side effects are a significant cause ofmorbidity in patients treated with CyA(Cohen
et al. 1999) and our experience was similar to that published previously. Figure 7.4
Illustrates CyA related side effects in our patient group. Hypomagnasaemia,
abdominal pain, tremor and myalgia being the most common, but more importantly
none of these side effects were deemed severe enough by the patient or physician to
merit discontinuation, something that may have been aided by strict and regular CyA
level monitoring and dose adjustment in this group. One patient developed mild
epigastric discomfort associated with a raised amylase. It was unclear whether this
particular side effect was due to CyA or concurrent AZA. This resolved
spontaneously and did not require dose adjustment of either immunosuppressants. In
addition, this study involves a relatively small number ofpatients and therefore may
be subject to type II errors. The small number of patients per year in this study as
compared to other studies (Cohen et al 1999, Actis 2000) does not reflect a strict pre¬
selection criteria but rather a much lower trend in the UK of cyclosporin use in
116
general. It should be noted that other groups have reported serious side effects with
similar immunosuppressive drug regimens and in one Belgium study, 3 deaths were
attributed to opportunistic infection (1 PCP, 2 aspergillus infection) and 1
anaphylactic reaction that the patient survived. This study cohort contained 86
patients and it is of note that the patients who developed infectious complications
were not given antibiotic prophylaxis (Arts et al 2001).
The use ofAZA alone has been shown to be effective in inducing and maintaining
remission in UC patient's outwith ofCyA use (Sandborn, 1998). In this study only 2
(22%) patients who were started on concurrent AZA later required surgery, with the
remaining 7 patients maintaining clinical remission to date (and also exhibited a
significant steroid sparing effect). In the opinion of the author, this further advocates
the concurrent use of oral AZA in the setting of remission induction by IV CyA. This
is in light of the high percentage of patients successfully rescued in this series that
remained in remission long-term and is much higher than the colectomy rate
previously published with CyA therapy without subsequent oral AZA (Gurudu et al.
1999). There was only one patient who had to discontinue AZA because of side
effects (nausea) and that patient underwent surgery.
From our survival curves it seems that if patients go into remission by 4 weeks into
therapy with CyA and AZA then the majority (56%) will maintain this remission long
term. In addition, this data would support the potential role of oral CyA as a good
bridging therapy to AZA, a role that steroid monotherapy has previously been used
for. Figure 7.5 summarizes the outcome of these patients. Table 7.3 summarizes the
follow-up time for the 9 patients who avoided surgery.
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Of note also are the predictive markers of requirement of surgery. Median bowel
frequency at day 3 was significantly higher in patients who finally underwent surgery.
Median CRP at day 3 was also higher in the surgery group (but did not reach
statistical significance), confirming results by Travis et al (Travis et al. 1996) that
these are valuable markers in predicting patients that will finally need to undergo
surgical intervention.
Oral CyA is rarely used as a second-line agent (like AZA) in treating steroid
refractory or resistance disease. This has been compounded by mixed reports
concerning the bioavailability of different oral CyA preparations in patients as well as
different absorption rates in different ethnic groups (Choc, 1997; Curtis et al. 1999;
Palma-Aguirre et al. 1997). In particular this led scepticism upon absorptive rates of
CyA in IBD patients and hence its relative effectiveness when used in such patients.
Latteri et al revealed that the pharmacokinetic profiles ofCyA microemulsion is
broadly similar in IBD and healthy volunteers (Latteri et al. 2001). The clinical
efficacy of oral CyA in this series confirms this, with the majority of patients (71%)
remaining in remission long-term and would support the potential role of oral CyA
maintenance therapy as an AZA substitute in patients who can not tolerate AZA.
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Figure 7.4 - Summary of Cyclosporin related side effects
amylase
Cyclosporine related Side Effect
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In summary, the use of CyA in acute severe UC is now a well-established alternative
to early surgery - the current standard practice (Kornbluth et al. 1994). It should be
remembered that patients quality of life has been shown to be higher in patients kept
in remission with CyA when compared to those patients who have undergone surgery
(Cohen et al. 1999). While the significant side-effect profile ofCyA should be always
be borne in mind, this study further strengthens both the role ofCyA as a 3rd line drug
therapy option that significantly reduces the need for surgery, while having a
relatively good safety profile when monitored carefully and of triple
immunosuppressive therapy with AZA in maintaining the remission achieved by IV
CyA. If oral CyA is used, this should be followed by AZA therapy to avoid the high
relapse rate, and such vigorous immunosuppression, while associated with potential
risks, can result in satisfactory long-term outcome. In addition, oral CyA should be
considered as an alternative to oral AZA in those patients who are unable to tolerate
it.
120
Figure 7.5 - Flow-chart summarizing outcomes of UC patients
treated with CvA
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Table 7.3 - Patients who avoided surgery and duration of follow-up












Chapter 8. White Cell Count at 4 months - a predictor
of future myelosuppression in patients taking Azathioprine
8.1 Introduction
AZA use as a 2nd line immunosuppressant is well established. Approximately 10% of
patients taking AZA have to discontinue it due to a variety of side effects, including
myelosuppression.
There has been growing interest in the role of the enzyme TPMT in the development
ofneutropenia. Although there have been conflicting reports, it is generally accepted
that low levels of TPMT are a risk factor for early bone marrow suppression in
patients taking AZA (Colombel et al. 2000; Kader et al. 2000; Naughton et al. 1999;
Sebbag et al. 2000; Stolk et al. 1998). There may be other factors that determine late-
onset neutropenia in these patients such as viral infections such as Parvovirus B19
(Higashida et al. 1997).
Currently, TPMT activity monitoring and TPMT genotyping is not in widespread use
in the UK. The use ofmore simple laboratory methods of predicting efficacy and
toxicity have been examined, such as mean corpuscular volume (Decaux et al. 1999)
and 6-thioguanine levels (Cuffari et al. 1996). We examined the nadir white cell
count (WCC) at 4 months into AZA therapy in a cohort of IBD patients to see if this
was a predictor of future myelosuppression in these patients.
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8.2 Patients and Methods
The hypothesis was that WCC and neutrophil counts at 4 months do not correlate with
IBD patients' respective nadir WCC and neutrophil count during AZA therapy.
We retrospectively examined our database of IBD patients who were currently taking
AZA. They were a total of 172 patients (96CD:76UC, 76M:96F; median age 39 years,
range 16-81 years) who were taking AZA for a minimum of 6 months and were stable
of treatment (median duration of therapy 4.0 years, range 0.7-21 years). Information
recorded was WCC at 4 months, neutrophil count at 4 months, nadir WCC and nadir
neutrophil count during AZA therapy. In addition, AZA dose (mg/kg) and IBD
disease (CD or UC) were recorded for these patients.
8.2.1 Statistical analysis - Regression analysis were performed on these data,
correlating WCC and neutrophil count at 4 months with respective nadir WCC and
neutrophil count during AZA therapy. Sub-group analysis for both CD and UC were
also performed.
Correlation was assessed by calculating the Pearson correlation coefficient, a p value




One hundred and seventy two IBD patients were evaluated (96CD:76UC, 75M:97F).
Mean AZA dose was 1.8mg/kg (SDK).36) for this group. In the CD group
(40M:56F), mean AZA dose was 1.75mg/kg (SDK).22), and the UC group, mean
AZA dose was 1.85 mg/kg (SDK).40).
Regression analyses were performed for each patient group, comparing neutrophil
count at 4 months against nadir neutrophil count and WCC at 4 months against nadir
WCC. Figure 8.1 shows linear regression plot for IBD patients for neutrophil count
and figure 8.2 WCC. Pearson coefficients were statistically significant for neutrophil
count (p<0.0001), r=0.70 and WCC (pO.OOOl), r=0.69. Figures 8.3 and 8.4 show the
same analysis for CD patients. There was significant correlation for neutrophil count
(r=0.60, pO.OOOl) and WCC (r=0.59, p<0.0001). Finally, figures 8.5 and 8.6 show
the same analysis for UC patients and they too were statistically significant
(neutrophil count, r=0.81, pO.OOOl; WCC, rK).80, pO.OOOl).
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8.4 Discussion
There were 172 IBD patients who were taking AZA for a minimum of 6 months and
were stable on AZA therapy. There was a statistically significant correlation between
WCC and neutrophil count at 4 months and the lowest respective WCC and neutrophil
count ever obtained during AZA therapy.
TPMT activity and genotype have been shown to correlate with risk ofmyelotoxicity.
This has subsequently led to suggestions to introduce TPMT genotyping and or
TPMT activity assessments in patients before they start on such immunosuppressive
therapy (Jackson et al. 1997; Sebbag et al. 2000; Stolk et al. 1998). This is in the
hope that this may reduce the need for regular blood count monitoring and prevent
patients with genetically low levels of TPMT from potential life-threatening bone
marrow suppression. However, there has been conflicting reports on the relevance of
TPMT monitoring and bone marrow suppression (Kader et al. 2000; Naughton et al.
1999). It has been know for some time that bone marrow suppression can occur as a
sporadic phenomena much later into AZA (Higashida et al. 1997) therapy and
therefore the impact of introducing TPMT monitoring remains unknown, especially
from a cost-benefit aspect (Tavadia et al. 2000). While some groups strongly
advocate TPMT assessment prior to AZA therapy (Jackson et al. 1997; Lennard,
1998), others have shown that bone marrow suppression occurs at a higher frequency
in the presence of normal TPMT levels than originally thought (Kader et al. 2000;
Naughton et al. 1999) raised concerns that regular blood count monitoring should
continue in these patients.
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This data reveals a strong correlation between WCC/neutrophil count at 4 months and
the nadirWCC/neutrophil count later on into AZA therapy. In this cohort, this data
would support the idea that if bone marrow suppression is to occur, it will occur
relatively early in therapy (as indicated by WCC/neutrophil count at 4 months). This
would parallel that experience of our patients with low levels of TPMT taking AZA
therapy.
Subsequent analysis of this data showed that MCV while on therapy with AZA or the
change in MCV between pre-AZA values and while on stable AZA dosage did not
correlate with either outcome as far as prevention of relapse was concerned or red cell
TPMT activity. (Joy et al 2002)
In conclusion, WCC/neutrophil count at 4 months into AZA therapy appears to be a
good predictor of future bone marrow suppression. It should be borne in mind that
myelosuppression can occur at any time during AZA therapy and therefore, diligent
blood count monitoring remains essential to the safety ofpatients taking such
immunosuppressive therapy.
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Chapter 9. Relevance of TPMT activity in IBP patients
treated with low dose Azathioprine
9.1 Introduction
TPMT is a cytosolic enzyme that catalyses the S-methylation of aromatic and
heterocyclical sulphydryl compounds including 6-MP and AZA. Metabolism of 6-MP
is competitive between TPMT and two other enzymes (xanthine oxidase and
hypoxanthine guanine phosphoribosyltransferase). TPMT converts 6-MP into an
inactive form 6-methymercaptopurine while hypoxanthine guanine
phosphoribosyltransferase converts 6-MP into its active form - 6-thioguanine (Kelley
etal. 1967).
AZA is generally prescribed in a dose of 2mg/kg, though some authorities especially
in the US, recommend higher doses of 2.5-3.0 mg/kg body weight. In the UK, it is not
uncommon to prescribe doses lower than 2 mg/kg body weight, but the relationship of
the various dosing regimens on effectiveness ofmaintenance with reference to TPMT
activity has not been investigated.
Initial investigations into the clinical use and interpretation of intracellular
measurements of TPMT activity were in children with acute lymphoblastic leukaemia.
It has been known for some time that children with higher TPMT activities relapse
more frequently than those with lower activity of this enzyme (Bostrom and Erdmann
1993; Lilleyman and Lennard, 1994). Induction of TPMT activity after
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commencement ofAZA/6-MP remains controversial, with conflicting reports in the
literature(Keuzenkamp-Jansen et al. 1996; Weyer et al. 2001; Chocair et al. 1992).
In addition, TPMT measurement during AZA therapy may be a more clinically
relevant parameter than TPMT activity prior to commencement ofAZA.
Momentum into investigating the implications of TPMT activity in IBD patients has
steadily grown. In particular it is recognized that patients with low TPMT activity are
more susceptible in developing bone marrow suppression side effects (Dubinsky et al.
2000; Lennard, 1998; Stolk et al. 1998). The impact of TPMT activity on the clinical
course of IBD patients treated with low dose AZA has not been studied to date.
In this study we aimed to retrospectively evaluate the clinical course of IBD patients
currently taking AZA and relate this to their respective TPMT activity.
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9.2 Materials and Methods
The hypothesis was that there is no difference in remission maintenance in IBD
patients treated with AZA when comparing low TPMT activity (<20nmol/hour/ml)
versus normal TPMT activity (>20nmol/hour/ml).
9.2.1 Patients
We recruited a cohort of 113 IBD patients (52UC:61CD, 57 female:56 male, median
age = 45 years, range 18-71 years) who were taking AZA, had discontinued AZA
because of side effects or who had never taken AZA. We compared these patients
with a group of 17 healthy controls (8 female:9 male, median age = 39 years, range
26-62 years). Median duration of follow up was 4.7 years (range 0.6-9.9 years).
TPMT activity was determined from blood samples by a radiochemical assay detailed
below. Relapse rates per year of follow up (number of relapses divided by years of
treatment) and time to first relapse were analysed and compared with their respective
TPMT activity and their current AZA dose per kilogram body weight. TPMT activity
was classified as low ifactivity was below 20 nmol/h/ml RBC. All cases were
examined by one investigator (SC).
Other information that was collected included the lowest neutrophil count ever
recorded during therapy, concomitant drug therapy, anatomical disease distribution,
AZA dose and patients body weight at induction of therapy. Relapse was defined by
necessity for surgery, endoscopic criteria or clinical recurrence (as assessed by an
experienced clinician based on clinical features and inflammatory parameters - ESR,
CRP, white cell count and platelets). Surgery for purely mechanical obstruction,
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without abnormal inflammatory parameters was not considered a relapse of active
disease. Endoscopic findings complemented clinical features and blood parameters,
but were not used solely to determine relapse.
9.2.2 Blood Samples
Blood was collected by venepuncture into 2.7ml EDTA vacutainer tubes. Red blood
cells (RBC) were washed twice with pH 7.4 phosphate buffer solution (PBS) and then
centrifuged at 3000 rpm for 10 minutes.). Haematocrit of a suspension of 0.5mls
RBC suspended in 0.5 mis PBS were then measured. Finally, the suspension was
haemolysed with 2.8mls of ice-cold distilled water and 0.7mls aliquots were pipetted
into 1.5ml epindorff tubes ready for the assay.
9.2.3 TPMT assay
TPMT activity was measured in haemolysed red blood cells utilising the following
reaction
14C-S-adenosyl methionine S-adenosyl homocysteine
+ -> via TPMT +
6-mercaptopurine 14C-methyI-mercaptopurine
Haemolysed red cells were spun at 13000 rpm for 10 minutes in a microfuge
centrifuge at 4°C. For each sample, lOOpl red cell lysate were then added to 15ml
plastic tubes for blank and the test estimation (both in duplicate). Twenty-five
microlitres ofpH 7.5 potassium phosphate buffer was added to each tube, then 5ul of
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6-MP was added to the test and 5pl of dimethylsuphoxide (DMSO) added to the other
2. The reaction was started by adding 25pl of reagent mixture (containing l4C-S-
adenosyl methionine, S-adenosyl methionine and dithiothreitol solution) and
incubating at 37°C in a shaking water bath for 1 hour. The reaction was stopped by the
addition of 500pl of 0.5M borate buffer pHlO.O. The methyl-mercaptopurine was
extracted into an isoamyl alcohol/toluene mixture and centrifuged at 2700rpm for 10
minutes at room temperature. One point five millilitres of the organic phase was then
added to 1 Omls scintillant (OpticSafe, Pharmacia) and radioactivity counted for each
of the vials for 10 minutes in a (3-scintillation counter. The activity of TPMT in the
RBC samples was calculated from the concentration of 14C-methyl mercaptopurine in
the test sample (corrected for the blank sample) and the activity expressed as
nmol/hour/ml RBC.
9.2.4 Statistical analysis
Relapse rates per year of follow up were compared in patients with their TPMT
activity by non-parametric Mann-Whitney test (MWT) and p values of <0.05 were
regarded as significant. Times to first relapse were also compared by Kaplan-Meier
curves using log rank analysis and Chi square testing. Comparisons between multiple
groups were performed using ANOVA analysis, p <0.05 was considered significant.




One hundred and thirty blood samples were analysed from 113 IBD patients and 17
healthy controls. The IBD patients were categorized as 'intolerant', 'maintenance
azathioprine' or as 'azathioprine naive' (see table 9.1). The 'intolerant' group were
patients who had previously received AZA, but had subsequently discontinued
treatment because of side effects (pancreatitis, bone marrow suppression, abdominal
pain, nausea, dermatological manifestations). The 'maintenance azathioprine' group
were patients who were currently taking and stable on AZA therapy. The
'azathioprine naive' group were IBD patients who had never received AZA treatment.
Figure 9.1 illustrates TPMT activity in these groups; analysis comparing the control
group against the other 3 groups was not significant by MWT and shown in the figure.
The 'intolerant' category was then further analysed. Side effects were individually
grouped as neutropenia (neutrophil count <2.5 x 106- mean TPMT 19nmol/hr/ml),
pancreatitis (as defined by clinical symptoms and a raised amylase- mean TPMT 24
nmol/hr/ml), hepatitis (raised alanine transaminase twice above baseline measurement
- mean TPMT 28nmol/hr/ml), dermatological (skin rashes that resolved once AZA
was stopped - mean TPMT 27 nmol/hr/ml) and other (a variety of side effects
including non-specific abdominal pain, nausea, vomiting, taste disturbance and
headaches - mean TPMT 27 nmol/hr/ml). This is shown in figure 9.2.
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The mean TPMT activity in the neutropenic patient group was significantly lower
than the mean TPMT activity ofpatients who had other side effects (ANOVA, p
<0.05).
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To investigate the impact ofTPMT activity upon relapse rates in IBD patients we
examined 2 groups. Both groups were taking AZA at a dose of less than 2mg/kg for a
minimum of 1 year. The groups were subdivided by their respective relapse rates as
either 'non-relapsers' (n=20) or 'relapsers'(n=14) (i.e. more than zero relapse per year
of follow up). These groups were well matched for AZA dose (1.5mg/kg vs. 1.45
mg/kg), duration of follow up (3.0 years vs. 2.6 years) and age (36 years vs. 35 years).
The mean TPMT activity within the 'non-relapser' group was 19.8 nmol/hr/ml versus
27.6 nmol/hr/ml for the 'relapser' group. This was statistically significant (Mann-
Whitney Test, p<0.005). These results are summarised in table 9.2. To further analyse
this a Kaplan-Meier survival curve was constructed based on time to first relapse in
the low-dose AZA treated patients (<2.0 mg/kg body weight, n=34, 19CD:15UC) for
TPMT activity of<20 nmol/hour/ml and >20 nmol/hour/ml (Figure 9.3). Log rank
analysis was statistically significant (x2=4.0, p<0.05). Further survival curves were
constructed for CD only (Figure 9.4) and UC only patients (Figure 9.5), and log rank
analysis was significant in both groups (for CD, x2=3.2, p=0.04 and for UC, y?=2.9,
p=0.05).
Finally the 'maintenance azathioprine' group was divided into low TPMT activity
(using the lower limit of our control group - <20nmol/hr/ml) or normal TPMT
activity (>20nmol/hr/ml) and constructed further survival curves based on time to first
relapse for all IBD patients. There were a total of 63 patients taking AZA (33
female:30 male, 33CD:30 UC, median age 44 years). Mean follow up in this group
was 3.0 years with a median AZA dose of 1.75 mg/kg (range 1.4-2.4 mg/kg). This is
shown in Figure 9.6. Log rank analysis did not show statistical significance (x2=0.2,
p=NS) despite a trend of shorter time to relapse in patients with TPMT activity
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>20nmol/hr/ml. Further analyses were performed on CD only (Figure 9.7) and UC
groups only (Figure 9.8) - Log rank analysis did not show statistical significance in





























Low TPMT activity appeared to be predictive of a favourable response in patients
treated with lower doses ofAZA (< 2mg/kg). None of the patients in this cohort had
extremely low TPMT activity (<5nmol/hr/ml) suggesting that none were homozygote
recessive for the TPMT gene (Weyer et al 2001). As shown by other studies, there is
an inverse relationship between red cell TPMT activity and 6-TG levels in acute
lymphoblastic leukaemia - corresponding to a reduce risk of relapse but a higher
probability of neutropenia(Bostrom and Erdmann 1993; Lilleyman and Lennard,
1994). This relation with neutropenia was also confirmed in this study. TPMT activity
correlated well with lowest neutrophil count within the first 4 months ofAZA therapy
(figure 9.9) in this group (r=0.41, p=0.0001). It should be noted that patients who
became neutropenic within the first 4 months maintained this degree of neutropenia
throughout AZA therapy. In this study there was no difference in time to first relapse
in all IBD patients on AZA with low (<20 nmol/hr/ml) or normal (>20 nmol/hr/ml)
TPMT activity (figure 9.6), further confirming that neutropenia is not required for
disease remission maintenance. Over the past two decades, it has become clear that
while AZA remains an essential second line agent in the treatment of steroid resistant
or refractory IBD, its relatively narrow therapeutic index means that patients may not
fully benefit from a 'standard dose' ofAZA (Weinshilboum and Sladek, 1980).
TPMT activity is determined by a polymorphic gene in a co-dominant fashion
leading to a trimodal distribution of phenotypes (Lennard et al. 1987) and there also
evidence of ethnic variation of TPMT activity (Kumagai et al. 2001; McLeod et al.
1994; McLeod et al. 1999). Genotype TPMTL/TPMTL gives rise to low TPMT
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activity and accounts for only 1% of the western population (McLeod et al. 1994;
Weinshilboum and Sladek, 1980) - these patients are particularly susceptible to
serious bone marrow suppression side effects (Dubinsky et al. 2000). Although our
cohort did not have any patients with a phenotype like this, it may be possible that
these homozygote recessive patients could be safely treated with AZA - but at very
low doses (<0.5mg/kg). Conversely, genotype TPMTH/TPMTH (approximately 9% of
the western population (McLeod et al. 1994; Weinshilboum and Sladek, 1980)) leads
to high TPMT activity and hence these may benefit from higher doses (>2mg/kg) of
AZA that are not currently routinely prescribed in the UK. The majority of the
population (90%) are heterozygotes TPMTH/TPMTL giving a wide spectrum of
TPMT activity (McLeod et al. 1994; Weinshilboum and Sladek, 1980). It is this
majority ofpatients that would also further benefit by dose titration according to their
TPMT activity, as shown by this study. There have also been concerns in paediatric
patients treated with 6-MP that low levels of TPMT may have secondary carcinogenic
effects on bone marrow stem cells in leukaemia patients receiving chemotherapy
protocols including 6-MP (Thomsen et al. 1999). This clearly needs to be borne in
mind, especially when contemplating long term AZA therapy. However, it remains
unknown whether 'dose adjustment' for lower TPMT activity may have the benefit of
reducing such complications in the long term.
The principal finding of this study is that if a low dose regimen ofAZA i.e. <2mg/kg
body weight is used, knowledge of the TPMT phenotype is essential. If a low dose of
AZA is used in IBD patients with a high TPMT phenotype, the number of relapses
suffered is likely to be high and maintenance of remission imperfect. The higher doses
ofAZA generally recommended and used in the US probably saturates this
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phenotypic variation in TPMT activity, resulting in higher overall remission rates.
Though speculative, it is possible that the higher dose ofAZA is only necessary in
patients with higher TPMT activity. Our study results also provide an explanation for
the commonly observed phenomenon ofprolonged remissions on a low dose ofAZA
in a proportion ofUK IBD patients. In future it may be possible to take into account
the phenotypic variation of TPMT in deciding on the exact dosage of AZA to be used
in an individual patient.
This study used data from a large database of IBD patients who were well matched for
disease type and distribution, and there were comparable numbers ofpatients taking
5-aminosalicylate (5-ASA) compounds to those who were not (table 2). However, this
is a retrospective analysis of patients and therefore subject to bias. In addition,
patients TPMT activity was measured while they were on concurrent medication that
may have induced or inhibited red cell TPMT activity. However, this was addressed
by the fact that groups were well matched with regards to their concomitant
medication type. Induction of TPMT activity by AZA remains a controversial issue.
Studies reporting significant rises in TPMT activity after AZA have predominantly
been in renal transplant patients(Weyer et al. 2001; Chocair et al. 1992; Cho et al.
2000) and leukaemia patients(Lennard et al. 1987; Lennard et al. 1990). These
patients have been started on other concomitant medications that may also be
responsible for TPMT induction in their own right, an observation reported previously
with other commonly prescribed medications (Lennard, 1998). Furthermore, it has
recently been shown that uraemia in renal transplant is a significant inducer of TPMT
activity, making the role ofAZA in the induction of TPMT less clear (Weyer et al.
2001). Only one study to date has addressed the issue ofTPMT activity induction in
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healthy controls following administration of 6-MP, and they reported no induction of
TPMT activity (Keuzenkamp-Jansen et al. 1996). Finally, it is worthy to note that
since some have reported somewhat erratic levels of TPMT activity induction
following commencement ofAZA (McLeod et al. 1995), it could be argued that a
single TPMT activity measurement while stable on AZA therapy is more clinically
relevant. To date, there have been no studies addressing these issues in IBD patients.
Further analysis were also performed on patients taking 5-ASA medications, in view
of recent concerns over in-vitro 5-ASA enzyme inhibition (Lewis et al. 1997; Lowry
et al. 1999; Szumlanski and Weinshilboum, 1995). Mean TPMT activities in IBD
patients either taking 5-ASA versus those who were not were not statistically
significant (data not shown).
This is the first report addressing the issue of TPMT activity and disease relapse in
IBD patients to the author's knowledge, opening up a further avenue in enabling the
physician to individualize effective AZA therapy in these patients. We have shown
that in patients on a low dose ofAZA (<2mg/kg), the mean TPMT activity was
significantly lower in those in remission compared with those that relapsed during the
follow-up period. TPMT activity was significantly lower in patients who discontinued
AZA due to neutropenia compared to TPMT activity of patients who discontinued
AZA due to other side effects.
The limitations of a retrospective study and potential selection bias of patients are
acknowledged, and prospective studies to tailor AZA dosage to TPMT polymorphism
are required.
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Chapter 10. Final Discussion
AZA immunosuppression is probably mediated through its effects on lymphocytes,
although there appears to be preferential suppression of neutrophils when leucopenia
occurs(Korelitz et al. 1997). This suggests that the anti-inflammatory action ofAZA
is mediated through its effects on neutrophils. Indeed, it has been shown that
neutrophil migration into the lamina propria occurs during clinical relapse in IBD
(Teahon and Bjarnason 1993). Recent data also suggests that lymphocyte apoptosis
may also underlie the action ofAZA (Tiede et al 2002).
From the cohort of 173 patients studied, remission maintenance was not statistically
different in neutropenic versus non-neutropenic patients. Even when a stricter cut off
for neutropenia and analysis were performed (using neutrophil count <2x 109) there
was no significant differences in relapse rates. The lowest neutrophil count reflected
in general the pattern of neutrophil counts closely. Analysis of the lowest neutrophil
counts within the first 4 months of therapy correlated well with the nadir neutrophil
count (Pearson correlation coefficient r= 0.7, P<0.005), supporting that neutropenia is
not purely a sporadic phenomenon. Fraser et al (Fraser et al 2002) examined a larger
cohort of IBD patients (n=424) retrospectively. They found that a lower mean WCC
(mean WCC 5.86 x 109 in remission achieved group versus mean WCC 7.91x109 in
remission not achieved, p=0.0001) and lower mean neutrophil count (mean neutrophil
counts were 3.83xl09 in remission achieved group versus 5.85xl09 in remission not
achieved group, p=0.0001) were a predictive factor for achieving remission.
Remission induction with respect to neutrophil count was not analysed in our data.
Further comparison were made on remission maintenance according to the nadir
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WCC during treatment - patients with a WCC of<5.0xl09 were more likely to
maintain remission than those with higher nadir WCC, p=0.03. However, their data
did not examine the nadir neutrophil count as studied here. It is difficult to draw any
comparative conclusions with our data, especially when lymphopenia (a common
phenomenon) may have contributed to some degree to their overall WCC. Work by
Colonna et al (Collona and Korelitz 1994) also examined leucopenia in 98 CD
patients. They concluded that patients achieving leucopenia were more successful in
maintaining clinical remission. This study's main weakness is in the small patient
numbers, which limits the power of the study and the short duration of follow-up (18
months). They also did not examine neutrophil count.
Dose titration ofAZA to achieve neutropenia cannot be justified from our results. The
study involves a large number of patients (n=173) over a long follow-up period of up
to 21 years. Although the retrospective nature of the study is a weakness, the power of
this analysis is sufficient to detect a clinically relevant difference in remission
maintenance. It could be argued that the potential risks of neutropenia alone would
require at least this clinically relevant difference before neutropenia could be used as a
goal ofAZA treatment in IBD. Finally, a prospective trial looking into dose titration
and degree of neutropenia is probably of too high a patient risk to be practical to
perform.
There was a statistically significant correlation between WCC and neutrophil count at
4 months and the lowest respective WCC and neutrophil count ever obtained during
AZA therapy. TPMT activity and genotype have been shown to correlate with risk of
myelotoxicity. This has given hope that the introduction of TPMT genotyping and or
TPMT activity assessments in patients before they start on such immunosuppressive
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therapy(Jackson et al. 1997; Sebbag et al. 2000; Stolk et al. 1998) may reduce the
need for regular blood count monitoring. There have been conflicting reports on the
relevance of TPMT monitoring and bone marrow suppression (Kader et al. 2000;
Naughton et al. 1999), and it has been know for some time that bone marrow
suppression can occur as a sporadic phenomena much later into AZA (Higashida et al.
1997) therapy. In addition, bone marrow suppression appears to occur at a higher
frequency in the presence of normal TPMT levels than originally thought (Kader et al.
2000; Naughton et al. 1999) raising concerns that regular blood count monitoring
should continue in these patients. In this cohort, the data would support the idea that if
bone marrow suppression is to occur, it will occur relatively early in therapy (as
represented by nadir WCC/neutrophil count at 4 months). It would seem sensible that
as long as the potential for myelosuppression at any time during is borne in mind, the
nadir WCC/neutrophil count can be used as a cost effective predictor of patients who
are more likely to require either cautious dose escalation or early cessation ofAZA.
Remission maintenance (as defined as relapse rates per year of follow up) were not
statistically different between the AZA + 5ASA groups and the AZA alone group (in
UC or CD groups). The cumulative remission curves compare well with other studies
which have looked at remission maintenance with 5-ASA and AZA(Messori et al,
1994; Pearson et al. 1995; .d'Albasio et al, 1997; Gendre et al, 1993; Rijk et al.
1992; Bouhnik et al, 1996). From our study, it was not possible to elucidate the
impact of 5-ASA compounds on long-term malignancy risks in these patients because
of its retrospective nature. Although there are recent studies advocating the protective
role of 5-ASA drugs in the development of colorectal malignancy ( Davis et al. 1992;
Ekbom, 1995; Moody et al. 1996; Andrianopoulos et al. 1989; Eaden et al. 2000),
it still remains uncertain whether this is a direct effect of 5-ASA drugs or merely as a
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result ofprolonged disease remission. There was no obvious excess occurrence of
malignancy in our group ofpatients taking 5-ASA, although some have advocated the
use of folate supplementation to reduce the incidence of dysplasia and CRC in chronic
UC patients maintained on sulphasalazine (Lashner et al 1989).
Despite recent reports of a potentially important drug interaction between 5-ASA
compounds and TPMT raising concerns over increased susceptibility of neutropenia
(Lowry et al 1999, Lewis et al 1997). The results from our data do not support the
idea that this is clinically relevant based upon discontinuation rates in the AZA+5-
ASA group compared to AZA alone. This is further supported by work from Lowry et
al (Lowry et al 2001) who found that the WCC in patients taking AZA+5-ASA was
significantly lower than patients on AZA alone, albeit that the WCC remained within
normal limits.
It would therefore appear that 5-ASA compounds afford no additional benefit to AZA
as judged by remission maintenance. Although this is perhaps not unexpected in CD
patients, this may help rationalise drug treatment in UC patients taking AZA+5-ASA.
This study used data from a large database (n=172) that were particularly well
matched for disease type and distribution. In addition, comparable numbers of patients
were taking 5-ASA drugs as were not. Although it could be argued that patients taking
AZA alone had more aggressive disease and hence bypassed 5-ASA therapy, this is
not support from the standpoint of previous relapses and anatomical extent of disease.
To answer questions over the potential role ofmalignancy/dysplasia protection, the
role of the TPMT/5-ASA interaction and further characterise the exact place of 5-
ASA therapy a prospective, double blinded, placebo control trial now needs to be
performed. However the duration of follow-up (a minimum of 3 years) and large
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patient numbers (more than 200) that would be required to give some of these
answers. This could be done through a multicentre study.
In humans, the effect ofAZA on pregnancy and offspring has been predominantly
studied in organ transplant patients - usually taking a combination of other
immunosuppressants including steroids, CyA or tacrolimus. Nonetheless cytogenetic
analysis has detected chromosomal aberrations in these offspring, but long term
follow up has not revealed further problems in these infants (Willoughby et al. 1971).
In addition, there is no current evidence of fertility problems in patients taking AZA
(Thiersch 1962). Immunological abnormalities have also been reported in the
newborn's of these patients (Golby, 1970; Williamson and Karp, 1981), constituting
lymphopenia, thymic hypoplasia and bone marrow hypoplasia, but all of these have
subsequently resolved later in infancy. Animal studies using much higher doses of
AZA (20mg/kg!) have shown teratogenicity (Gross et al. 1977, Alstead et al 1990),
but it is difficult to extrapolate these experiences into humans, especially when AZA
handling has been shown to be different in these animals.
In this study, 2 offspring suffered congenital abnormalities. There were no skeletal
deformities recorded in any of the infants (as reported anecdotally by others
(Schwartz 1966)), and it would seem more plausible that these infants had sporadic
abnormalities considering their polygenic aetiology in the normal population.
Previous studies in groups of IBD patients taking AZA have also recorded healthy
offspring, although there have been cases ofviral infections - Hepatitis B and
Cytomegalovirus in the mother and subsequently the offspring (Saarikoski and
Seppala, 1972; Willoughby et al. 1971).
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This study has several weaknesses. Namely its small numbers and retrospective
nature, as well as a lack of detailed immunological information on the offspring -
something that could only be obtained in a prospective setting. While we should be
cautious whenever using AZA during pregnancy, a more pragmatic approach should
be sort after full discussion with mother and father. Currently there seems to be a
small risk of prematurity and or possibly congenital abnormalities, but this has to be
balanced by the effects of sub-optimal disease control (in the mother) and its effect on
potential offspring. The study highlights all the problems about studying such a small
niche ofpatients - especially when there are such differing clinical practices across
the world. In addition, it highlights the difficulty in performing a prospective
randomised study in pregnant women - the issue of equipoise. Equipoise - the state of
mind characterized by the legitimate uncertainty as to choice of treatment strategy due
to a balance of benefits versus risks. While equipoise would be achievable in the
treating physician, it is highly unlikely that the same could be achieved in the
protective mother-to-be. This latter problem makes any potential prospective study
unlikely to be able to recruit sufficient numbers of patients to give enough power to
answer the hypothesis that AZA therapy does not affect pregnancy outcome in IBD
patients. It should also be borne in mind that this represents the largest study into
AZA use in pregnant IBD patients in the last decade and compares well with the
outcomes found by Alstead et al in 1990 (Alstead et al 1990). What is needed for the
future is a multicentre study using a specifically set up national database, so that
further conclusions can be drawn about the use and safety ofAZA on offspring of
IBD patients.
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Even less attention has focussed upon the progeny of fathers who have received
similar AZA therapy. There have been several small papers describing experiences
pregnancies in the partners of male renal transplant patients - more than 90% of births
were overtly normal, with spontaneous abortion, neural tube defects and trisomy 21
making up the remainder of birth complications (Eslami et al. 1976; Papoff et al.
1977; Whetham et al. 1983). To date there have been no published studies in IBD
patients taking AZA.
In this cohort, there were 2 progeny who later developed complications - one autism
and the other a cerebral astrocytoma at the age of 10 years. These 2 conditions are
relatively common childhood illnesses and it would be difficult to argue that they
were attributed by AZA therapy. While the aetiology of autism is unknown, there
have been reports of associations with maternal hypothyroidism (Gillberg et al.
1992). Cerebral tumours are the most common childhood cancers and their incidence
in the UK is rising (McKinney et al. 1998). The design of this study did not allow for
a detailed evaluation of fertility issues, but there were no reports ofproblems with
partners conceiving from the questionnaire. Other studies of spermatogenesis in
humans have had conflicting results with both normal and low sperm quality being
reported (Evans et al. 1975, Salant et al. 1976). Other studies in patients with
rheumatoid arthritis (Currey et al. 1974) and systemic lupus erythematosis
(Masramon et al. 1980) revealed normal sperm counts in all of their cohorts. Again,
there is scope for further research in this area. A prospective study with sperm
analysis as well as more detailed progeny analysis is now required to look at the
effects ofAZA in IBD male patients prior to their partner's conception.
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CyA rescue therapy has previously been shown to be extremely useful in inducing
remission and saving patients with UC from surgery. Early response rates have been
reported to be between 60 to 80% (Lichtiger and Present 1990; van Gossum et al.
1996; Sandborn 1995). Our series also confirms this relatively high initial response
rate (11 patients, 69%). Our long-term success rate was also comparable to that found
by other studies (Sandborn 1995). Only 2 (22%) patients who were started on
concurrent AZA later required surgery, with the remaining 7 patients maintaining
clinical remission to date (and also exhibited a significant steroid sparing effect). This
further advocates the concurrent use of oral AZA in the setting of CyA, is much more
impressive than the colectomy rate previously published with CyA therapy without
subsequent oral AZA (Gurudu et al. 1999). Side effects are a significant cause of
morbidity in patients treated with CyA(Cohen RD et al. 1999). Again, our experience
was similar to that published previously. More importantly though is the fact that
none of these side effects were deemed severe enough by the patient or physician to
merit discontinuation which may have been aided by strict and regular CyA level
monitoring and dose adjustment in this group.
Finally, this study supports the value ofpredictive markers of surgery previously
reported by Travis et al (Travis et al 1996) - namely bowel frequency and CRP at day
3 (albeit that the latter did not reach statistical significance).
This CyA study contains only a small number of patients and was performed in a
retrospective manner. However, its importance is shown by the higher proportion of
patients taking AZA as a long-term maintenance following remission induction by IV
CyA. The fact that these patients were from a single centre and therefore subject to
uniform clinical practice strengthens the fact that discontinuation of CyA because of
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side effects was not encountered here. Clearly a larger prospective study is required to
place AZA as a useful adjunct to CyA rescue therapy. Randomisation between CyA +
oral AZA + oral steroid against CyA and oral steroid therapy with a significant follow
up time of 18 months would help to prove or refute its usefulness. So far this data
adds further evidence for CyA as a 3rd line drug therapy in patients where surgery is
undesirable.
My final chapter examines the interesting field of pharmacogenetics in AZA use.
Over the past two decades, it has become clear that AZA is an essential second line
agent in the treatment of steroid resistant or refractory IBD, its relatively narrow
therapeutic index means that patients may not fully benefit from a 'standard dose' of
AZA(Weinshilboum and Sladek, 1980). TPMT activity has been shown to be an
important predictor of myelotoxicity in patients taking AZA. Indeed my work on
TPMT confirmed a reproducible method by which TPMT activity can be determined
from a simple blood sample. My results confirmed work by others that a lower
activity of TPMT correlated well with the neutrophil count and low TPMT activity
was a predictor for discontinuation ofAZA due to neutropenia rather than other side
effects (Bostrom and Erdmann 1993; Lilleyman and Lennard, 1994). The
polymorphic gene that dictates TPMT activity is well documented. There is also
evidence of ethnic variation of TPMT activity (Kumagai et al. 2001; McLeod et al.
1994; McLeod et al. 1999), suggesting that the TPMT phenotype may be a more
clinically relevant parameter when optimising AZA therapy. This work confirms that
importance, since the majority of patients who are heterozygote TPMTH/TPMTL have
a wide range of TPMT activities (McLeod et al. 1994). The study confirms for the
first time that IBD patients on lower AZA doses (<2mg/kg) and lower TPMT activity
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levels maintain remission longer than patients with normal/high TPMT activity levels.
These results provide an explanation for a commonly observed phenomenon of
prolonged remissions in patients on relatively low doses ofAZA. In addition, this
opens further potentially exciting avenues for tailoring individuals AZA therapy - it
may be possible for example to safely treat patients who have very low TPMT activity
(i.e. TPMTl/TPMTl genotype) with ultra-low doses ofAZA and the converse may
also hold true.
This study used data from a large database of IBD patients who were well matched for
disease type and distribution, and there were comparable numbers of patients taking
5-ASA compounds to those who were not. However this is a retrospective analysis
and therefore subject to bias. In addition, patients TPMT activity was measured while
they were on concurrent medication, which may have induced or inhibited red cell
TPMT activity. The latter point is an important one. While this remains a
controversial issue, the majority of studies to date have reported somewhat erratic
levels of TPMT activity induction following commencement ofAZA (McLeod et al
1995). It can therefore be argued that a single measurement of TPMT while on AZA
is a more clinically relevant parameter by which to adjust drug doses etc. To help
answer this question more comprehensibly a prospective study is now needed,
measuring TPMT activity pre and post AZA as well as correlating 6-TG
antimetabolite levels with these measurements and matching patient groups for
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SUMMARY
Background: It is well-recognized that patients with low
thiopurine methyltransferase activity are more suscept¬
ible to the development of bone marrow suppression
side-effects.
Aim: To study the impact of thiopurine methyltransfer¬
ase activity on the clinical course of inflammatory bowel
disease patients treated with low-dose azathioprine
(< 2 mg/kg).
Methods: We measured the thiopurine methyltransfer¬
ase activity of blood samples from 113 inflammatory
bowel disease patients who were taking azathiopurine,
had discontinued azathioprine because of side-effects, or
had never taken azathioprine. The thiopurine methyl¬
transferase activity was compared with that of 17
healthy controls. Relapse rates and time to first relapse
were compared in inflammatory bowel disease patients
and stratified according to their thiopurine methyl¬
transferase activity.
Results: Patients who became neutropenic had a
significantly lower mean thiopurine methyltransferase
activity than that of patients who developed other
side-effects (analysis of variance, P < 0.05). Survival
curves were constructed (time to first relapse) for
patients treated with low-dose azathioprine for thio¬
purine methyltransferase activities of <20 and
> 20 nmol/mL red blood cells/h. There was a signi¬
ficantly lower number of relapses in inflammatory
bowel disease patients with lower thiopurine methyl¬
transferase levels (P < 0.05).
Conclusions: The mean thiopurine methyltransferase
activity was significantly lower in patients on a low
dose of azathioprine in remission compared with
those who relapsed. The thiopurine methyltransferase
activity was significantly lower in patients who
discontinued azathioprine due to neutropenia
than in those who discontinued due to other side-
effects.
INTRODUCTION
Thiopurine methyltransferase (TPMT) is a cytosolic
enzyme that catalyses the S-methylation of aromatic
and heterocyclic sulphydryl compounds, including
6-mercaptopurine and azathioprine. The metabolism
of 6-mercaptopurine is competitive between TPMT and
two other enzymes (xanthine oxidase and hypoxanthine
Correspondence to: Dr S. Ghosh, Gastrointestinal Unit, Department of
Medical Sciences, University of Edinburgh, Western General Hospital,
Crewe Road, Edinburgh, EH4 2XU, UK.
E-mail: sg@srv0.med.ed.ac.uk
guanine phosphoribosyltransferase). TPMT converts
6-mercaptopurine into an inactive form, 6-methylmer-
captopurine, while hypoxanthine guanine phosphori¬
bosyltransferase converts 6-mercaptopurine into an
active form, 6-thioguanine1 (Figure 1).
Azathioprine is generally prescribed in a dose of 2 mg/
kg, although some authorities, especially in the USA,
recommend higher doses of 2.5-3.0 mg/kg body
weight. In the UK, it is not uncommon to prescribe
doses lower than 2 mg/kg body weight, but the
relationship of the various dosing regimens to the
effectiveness of maintenance with reference to TPMT
activity has not been investigated.
© 2002 Blackwell Science Ltd 389
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Figure 1. Mechanism of azathioprine metabolism: AZA, aza-
thioprine; HPRT, hypoxanthine guanine phosphoribosyltransfer-
ase; 6-MMP, 6-methylmercaptopurine; 6-MP, 6-mercaptopurine;
6-TGN, 6-thioguanine; TPMT, thiopurine methyltransferase.
It is well recognized that patients with low TPMT
activity are more susceptible to the development of
bone marrow suppression side-effects.2, 3 Initial inves¬
tigations into the clinical use and interpretation of
intracellular measurements of TPMT activity were in
children with acute lymphoblastic leukaemia. It has
been known for some time that children with higher
TPMT activities relapse more frequently than those
with a lower activity of this enzyme.4, 5 The induction
of TPMT activity after commencement of azathioprine/
6-mercaptopurine remains controversial, with conflict¬
ing reports in the literature.6""8 Such induction is
variable and unpredictable. In addition. TPMT meas¬
urement during azathioprine therapy may be a more
clinically relevant parameter than TPMT activity prior
to the commencement of azathioprine in the assess¬
ment of efficacy.
The momentum to investigate the implications of
TPMT activity in inflammatory bowel disease patients
has steadily grown. In particular, it is recognized that
patients with low TPMT activity are more susceptible
to the development of bone marrow suppression side-
effects.2, 3'9 The impact of TPMT activity on the
clinical course of inflammatory bowel disease patients
treated with low-dose azathioprine has not been
studied to date.
In this study, we aimed to retrospectively evaluate the
clinical course of inflammatory bowel disease patients
currently taking azathioprine and relate this to the
respective TPMT activity.
We recruited a cohort of 113 inflammatory bowel
disease patients (52 ulcerative colitis, 61 Crohn's
disease; 57 female, 56 male; median age, 45 years;
range, 18-71 years) who were taking azathioprine,
had discontinued azathioprine because of side-effects or
who had never taken azathioprine. We compared these
patients with a group of 17 healthy controls (eight
female, nine male; median age, 39 years; range, 26-
62 years). The median duration of follow-up was
4.7 years (range, 0.6-9.9 years). TPMT activity was
determined from blood samples by a radiochemical
assay, as detailed below. Relapse rates per year of
follow-up (number of relapses divided by number of
years of treatment) and time to first relapse were
analysed and compared with the respective TPMT
activity and the current azathioprine dose per kilogram
body weight. The TPMT activity was classified as low if
it was below 20 nmol/mL red blood cells/h. All cases
were examined by one investigator (SC).
Other information collected included the lowest neu¬
trophil count ever recorded during therapy, concomit¬
ant drug therapy, anatomical disease distribution,
azathioprine dose and the patient's body weight at
induction of therapy. Relapse was defined by necessity
for surgery, endoscopic criteria or clinical recurrence (as
assessed by an experienced clinician based on clinical
features and inflammatory parameters — erythrocyte
sedimentation rate, C-reactive protein concentration,
white cell count and platelet count). Surgery for purely
mechanical obstruction, without abnormal inflamma¬
tory parameters, was not considered to be a relapse of
active disease. Endoscopic findings complemented clin¬
ical features and blood parameters, but were not used
solely to determine relapse.
Blood samples
Blood was collected by venepuncture into 2.7 mL
ethylenediaminetetra-acetic acid vacutainer tubes. Red
blood cells were washed twice with pH 7.4 phosphate
buffer solution and then centrifuged at 2000 g for
10 min. The haematocrit of a suspension of 0.5 mL red
blood cells in 0.5 mL phosphate buffer solution was
then measured. Finally, the suspension was haemolysed
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 389-398
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with 2.8 raL of ice cold distilled water and 0.7 mL
aliquots were pipetted into 1.5 mL Eppendorf tubes
ready for the assay.
TPMT assay
The TPMT activity was measured in haemolysed red
blood cells utilizing the following reaction:
14C-S-adenosyl methionine + 6-mercaptopurine —>
via TPMT —► S-adenosyl homocysteine
+ 14C-methylmercaptopurine
Haemolysed red cells were spun at 11 600 g for
10 min in a microfuge centrifuge at 4 °C. For each
sample, 100 yL red cell lysate was then added to
15 mL plastic tubes for blank and test estimation
(both in duplicate). Twenty-five microlitres of pH 7.5
potassium phosphate buffer was added to each tube;
this was followed by 5 yL 6-mercaptopurine for test
estimation and 5 yL dimethylsulphoxide for blank
estimation. The reaction was started by adding 25 yL
of reagent mixture (containing 14C-S-adenosyl methi¬
onine, S-adenosyl methionine and dithiothreitol solu¬
tion) and incubating at 37 °C in a shaking water
bath for 1 h. The reaction was stopped by the
addition of 500 ^L of 0.5 m borate buffer, pH 10.0.
The methylmercaptopurine was extracted into an
isoamyl alcohol/toluene mixture and centrifuged
at 1600 g for 10 min at room temperature: 1.5 mL
of the organic phase was then added to 10 mL
scintillant (OpticSafe, Pharmacia) and the radioactiv¬
ity was counted for each of the vials for 10 min in a
^-scintillation counter. The activity of TPMT in the
red blood cell samples was calculated from the con¬
centration of 14C-methylmercaptopurine in the test
sample (corrected for the blank sample), and the
activity was expressed as nmol/mL red blood cells/h.
Statistical analysis
Relapse rates per year of follow-up were compared with
the patients' TPMT activities by non-parametric Mann-
Whitney test, and P values of < 0.05 were regarded as
significant. Time to first relapse was also compared by
Kaplan-Meier curves using log rank analysis and chi-
squared testing. Comparisons between multiple groups
were performed using analysis of variance (anova);
P < 0.05 was considered to be significant. All statistical
analyses were performed using Minitab (release 13.20)
statistical software.
RESULTS
One hundred and thirty blood samples were analysed
from 113 inflammatory bowel disease patients and 17
healthy controls. The inflammatory bowel disease
patients were categorized as 'azathioprine intolerant',
'azathioprine maintenance' or 'azathioprine naive' (see
Table 1). The 'intolerant' group were patients who had
previously received azathioprine, but had subsequently
discontinued treatment because of side-effects (pancre¬
atitis, bone marrow suppression, abdominal pain,
nausea, dermatological manifestations). The 'mainten¬
ance' group were patients who were currently taking
and were stable on azathioprine therapy. The 'naive'
group were inflammatory bowel disease patients who
had never received azathioprine treatment. Figure 2
illustrates the TPMT activity in these groups; the
analysis comparing the control group against the other
three groups was not significant by Mann-Whitney test.
The 'intolerant' category was then further analysed.
Side-effects were individually grouped as neutropenia
(neutrophil count, <2.5 106; mean TPMT activity,
19 nmol/mL red blood cells/h), pancreatitis (as defined
by clinical symptoms and a raised amylase; mean
TPMT activity, 24 nmol/mL red blood cells/h), hepatitis
(raised alanine transaminase twice above baseline
measurement; mean TPMT activity, 28 nmol/mL red
blood cells/h), dermatological (skin rashes that resolved
once azathioprine was stopped; mean TPMT activity,
27 nmol/mL red blood cells/h) and others (a variety of
side-effects including non-specific abdominal pain,
nausea, vomiting, taste disturbance and headaches;
mean TPMT activity, 27 nmol/mL red blood cells/h).
This is shown in Figure 3. The mean TPMT activity in
the neutropenic patient group was significantly lower
than that of patients who had other side-effects (anova,
P < 0.05).
To investigate the impact of TPMT activity on relapse
rates in inflammatory bowel disease patients, we
examined two groups. Both groups had taken azathio¬
prine at a dose of less than 2 mg/kg for a minimum of
1 year. The groups were subdivided by their respective
relapse rates as either 'non-relapsers' (n = 20) or
'relapsers' (n =14) (i.e. more than zero relapse per
year of follow-up). These groups were well matched for
azathioprine dose (1.5 mg/kg vs. 1.45 mg/kg), duration
© 2002 Blackweil Science Ltd, Ailment Pharmacol Ther 16, 389-398
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of follow-up (3.0 years vs. 2.6 years) and age (36 years
vs. 35 years). The mean TPMT activity within the 'non-
relapser' group was 19.8 nmol/mL red blood cells/h vs.
27.6 nmol/mL red blood cells/h for the 'relapser' group.
This was statistically significant (Mann-Whitney test,
P < 0.005). These results are summarized in Table 2. To
further analyse this, a Kaplan-Meier survival curve was
constructed based on the time to first relapse in the low-
dose azathioprine-treated patients (< 2.0 mg/kg body
weight; n = 34; 19 Crohn's disease, 15 ulcerative colitis)
for TPMT activities of < 20 nmol/mL red blood cells/h
and > 20 nmol/mL red blood cells/h (Figure 4.). Log
rank analysis was statistically significant (y2 = 4.0,
P < 0.05). Further survival curves were constructed
for Crohn's disease only and ulcerative colitis only, and
log rank analysis was significant in both groups (for
Crohn's disease: y2 = 3.2, P = 0.04; for ulcerative
colitis: x2 = 2.9, P = 0.05).
Finally, the 'maintenance' group was divided into low
TPMT activity (using the lower limit of our control
group: <20 nmol/mL red blood cells/h) or normal
TPMT activity (> 20 nmol/mL red blood cells/h), and
further survival curves were constructed based on time
to first relapse for all inflammatory bowel disease
patients. There were a total of 63 patients taking
azathioprine (33 female, 30 male; 33 Crohn's disease,
30 ulcerative colitis; median age, 44 years). The mean
follow-up in this group was 3.0 years, with a median
azathioprine dose of 1.75 mg/kg (range, 1.4-2.4 mg/
kg). This is shown in Figure 5. Log rank analysis did not
show statistical significance (y2 = 0.2, P = N.S.) despite
a trend of a shorter time to relapse in patients with a
TPMT activity >20 nmol/mL red blood cells/h. Further
analyses were performed on Crohn's disease only and
ulcerative colitis only. Log rank analysis did not show
statistical significance in either group (Crohn's disease:
y2 = 0.22, P = N.S.; ulcerative colitis: y2 = 0.06,
P = N.S.).
DISCUSSION
Low TPMT activity appeared to be predictive of a
favourable response in patients treated with low doses
of azathioprine (< 2 mg/kg). None of the patients in this
cohort had extremely low TPMT activity (< 5 nmol/mL
red blood cells/h), suggesting that none were homozy-
gote recessive for the TPMT gene.' As shown by other
studies, there is an inverse relationship between red cell
TPMT activity and 6-thioguanine levels in acute
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 389-398
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Figure 2. Thiopurine methyltransferase
(TPMT) activity plotted against subgroups
of inflammatory bowel disease and controls
(azathioprine (AZA) intolerant, n = 24;
AZA maintenance, n = 63; AZA naive,
n = 26; controls, n = 17). Horizontal bars
represent mean TPMT level of activity.
None of the groups were statistically dif¬
ferent from the control group.
lymphoblastic leukaemia, corresponding to a reduced
risk of relapse but a higher probability of neutrope¬
nia.4, 3 This relation with neutropenia was also con¬
firmed in this study. The TPMT activity correlated well
with the lowest neutrophil count within the first
4 months of azathioprine therapy (Figure 6) in this
group (r = 0.41, P = 0.0001). It should be noted that
patients who became neutropenic within the first
4 months maintained this degree of neutropenia
throughout azathioprine therapy. In addition, neutrope¬
nia has previously been shown to be of no advantage in
keeping inflammatory bowel disease patients maintained
in remission.10 This is further confirmed in this study by
the lack of any difference in time to first relapse in all
inflammatory bowel disease patients on azathioprine
with low (<20 nmol/mL red blood cells/h) or normal
Figure 3. Thiopurine methyltransferase
(TPMT) activity in different side-effect cat¬
egories (neutropenia, n = 8; pancreatitis,
n = 4; hepatitis, n = 5; dermatological,
n = 2; other, n = 7). The horizontal bars
represent the mean TPMT activity. TPMT
values in the neutropenic group were sig¬
nificantly lower than those in the other
side-effect groups (anova, P < 0.05).
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(>20 nmol/mL red blood cells/h) TPMT activities
(Figure 5). Over the past two decades, it has become
clear that, while azathioprine remains an essential
second-line agent in the treatment of steroid-resistant
or steroid-refractory inflammatory bowel disease, its
relatively narrow therapeutic index means that patients
may not fully benefit from a 'standard dose' of azathiop¬
rine.11
TPMT activity is determined by a polymorphic gene in
a co-dominant fashion, leading to a trimodal distribu¬
tion of phenotypes,12 and there is also evidence of
ethnic variation in TPMT activity.13-15 Genotype
TPMTL/TPMTL gives rise to low TPMT activity and
accounts for only 1% of the Western popula¬
tion.11' 14 These patients are particularly susceptible to
serious bone marrow suppression side-effects.9





































CO <v) <N (N (N ^
Pu (J Q Cu i4 Q
C/5 00 s































































Figure 4. Survival curve. Time to first relapse in low-dose aza-
thioprine (AZA) patients according to their thiopurine methyl-
transferase (TPMT) activity: (a) all inflammatory bowel disease
(IBD) patients (n = 34, x2 = 4.0, P < 0.05); (b) all Crohn's dis¬
ease (CD) patients (n = 19, x2 = 3.2, P < 0.04); (c) all ulcerative
colitis (UC) patients (n = 15, x2 = 2.9, P < 0.05). (■), < 20;
(A), > 20 nmol/mL red blood cells/h.
Although our cohort did not contain any patients with
this phenotype, it may be possible to treat these
homozygote recessive patients safely with azathioprine,
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 389-398
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Figure 5. Survival curve comparison for all
azathioprine (AZA) patients with low thiopurine
methyltransferase (TPMT) activity vs. those with
normal TPMT activity: (a) all inflammatory
bowel disease (IBD) patients (n = 63, x2 = 0.2,
P = N.S.): (b) all Crohn's disease (CD) patients
(n = 33, x2 = 0.22, P = N.S.); (c) all ulcerative
colitis (UC) patients (n = 30, x2 = 0.06,










but at very low doses (<0.5 mg/kg). Conversely,
genotype TPMTH/TPMTH (approximately 9% of the
Western population11,14) leads to high TPMT activity,
and hence these patients may benefit from higher doses
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 389-398
(> 2 mg/kg) of azathioprine that are not currently
routinely prescribed in the UK. The majority of the
population (90%) are heterozygotes TPMTH/TPMTL
giving a wide spectrum of TPMT activity.11,14 It is this










40 Figure 6. Plot of thiopurine methyltrans-
ferase (TPMT) activity against lowest neu¬
trophil count per litre within first 4 months
of treatment, r = 0.41, P < 0.0001.
majority of patients who would also further benefit by
dose titration according to their TPMT activity, as
shown by this study. There have also been concerns
that low levels of TPMT activity may lead to secondary
carcinogenic effects on bone marrow stem cells in
leukaemic patients receiving chemotherapy protocols
including 6-mercaptopurine.16 This clearly needs to be
borne in mind, especially when contemplating long-
term azathioprine therapy. However, it remains
unknown whether 'dose adjustment' for lower TPMT
activity may have the benefit of reducing such compli¬
cations in the long term.
The principal finding of this study is that, if a low-dose
regimen of azathioprine, i.e. < 2 mg/kg body weight is
used, a knowledge of the TPMT phenotype is essential. If
a low dose of azathioprine is used in inflammatory
bowel disease patients with a high TPMT phenotype, the
number of relapses suffered is likely to be high and the
maintenance of remission imperfect. The higher doses of
azathioprine generally recommended and used in the
USA probably saturate this phenotypic variation in
TPMT activity, resulting in higher overall remission
rates. Although speculative, it is possible that a higher
dose of azathioprine is only necessary in patients with
higher TPMT activity. Our study results also provide an
explanation for the commonly observed phenomenon of
prolonged remissions on a low dose of azathioprine in a
proportion of UK inflammatory bowel disease patients.
In future, it may be possible to take into account the
phenotypic variation of TPMT when deciding on the
exact dosage of azathioprine to be used in an individual
patient.
This study used data from a large database of
inflammatory bowel disease patients who were well
matched for disease type and distribution, and there
were comparable numbers of patients taking 5-amino-
salicylate compounds to those who were not (Table 2).
However, this is a retrospective analysis of patients and
therefore subject to bias. In addition, patients' TPMT
activities were measured while they were on concur¬
rent medication, which may have induced or inhibited
red cell TPMT activity. However, this was addressed by
the fact that groups were well matched with regard to
their concomitant medication type. The induction of
TPMT activity by azathioprine remains a controversial
issue. Studies reporting significant rises in TPMT
activity after azathioprine have predominantly been
in renal transplant patients7'8'17 and leukaemia
patients.12, 18 These patients have been started on other
concomitant medications that may also be responsible
for TPMT induction in their own right, an observation
reported previously with other commonly prescribed
medications.2 Furthermore, it has recently been shown
that uraemia in renal transplant is a significant inducer
of TPMT activity, making the role of azathioprine in the
induction of TPMT less clear.7 TPMT induction is very
variable and pre-treatment TPMT does not predict
TPMT activity on azathioprine therapy. Only one study
to date has addressed the issue of TPMT activity
induction in healthy controls following the administra-
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tion of 6-mercaptopurine, and reported no induction of
TPMT activity.6 Finally, it is worth noting that, as some
workers have reported somewhat erratic levels of TPMT
activity induction following the commencement of
azathioprine,19 it could be argued that a single TPMT
activity measurement while stable on azathioprine
therapy is more clinically relevant. To date, there have
been no studies addressing these issues in inflamma¬
tory bowel disease patients. In our cohort, the distribu¬
tion of TPMT activity was not different in those taking
azathioprine compared with those currently not
taking azathioprine. Further analyses have also been
performed on patients taking 5-aminosalicylate medica¬
tions, in view of recent concerns over in vitro 5-amino¬
salicylate enzyme inhibition.20-22 The mean TPMT
activities in inflammatory bowel disease patients taking
5-aminosalicylate vs. those who were not were not
statistically significantly different (data not shown),
and this confirms the in vivo results published
recently.23
This is the first report addressing the issue of TPMT
activity and disease relapse in inflammatory bowel
disease patients to the authors' knowledge, opening up
a further avenue in enabling the physician to individu¬
alize effective azathioprine therapy in these patients. We
have shown that, in patients on a low dose of
azathioprine (< 2 mg/kg), the mean TPMT activity
was significantly lower in those in remission compared
with those who relapsed during the follow-up period.
The TPMT activity was significantly lower in patients
who discontinued azathioprine due to neutropenia
compared with those who discontinued azathioprine
due to other side-effects.
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Azathioprine in Inflammatory Bowel
Disease — Are We Using it Appropriately?
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Azathioprine (AZA) therapy is an invaluable second-line immunosuppressant, used in the treatment of
IBD. Optimal use of AZA and 6-mercaptopurine continues to be refined with our growing experience
of its use. However, questions remain unanswered regarding the use of these immunosuppressants
during pregnancy, the place of thiopurine methyltransferase enzyme-activity monitoring to reduce
potential side effects, concurrent use of 5-aminosalicylic acid drugs in the role of maintenance therapy,
and the potential future role of red-cell metabolite monitoring in optimizing AZA drug therapy. This
article reviews current publications to help shed more light on these issues.
Azathioprine (AZA) and 6-mercaptopurine (6-MP)
are purine analogs that interfere with nucleic acid
metabolism and cell proliferation, and thus have
immunosuppressive properties. AZA, the pro-drug
form, was produced in 1957, and was first used
predominantly for preventing rejection in renal
allografts [1]. Since then, AZA, and to a lesser
extent 6-MP, have been regarded as the treatment
choice for IBD patients who are steroid refractory
or dependent.
Despite several conflicting reports, large meta¬
analyses have largely confirmed both the safety and
efficacy of the drug in maintaining remission, and
answered several questions concerning dosage, and
time to onset of action. Despite this, the use of AZA
remains small, with a Swedish study revealing that AZA
accounts for as little as 2.2% of the annual drug
prescriptions for Crohn's disease patients, and 0.5% for
ulcerative colitis patients [2], In addition, there is
considerable heterogeneity between countries in the
prescribing patterns of immunosuppressants [3], For
example, AZA is prescribed more often in Europe than
North America, but the reverse is true for 6-MP.
There still remain many unanswered questions
regarding the optimal use of AZA in the clinical setting,
and the purpose of this article is to cover these topics
with evidence from currently published work.
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General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
Mechanism of action
AZA is the prodrug of 6-MP. AZA is rapidly converted to
6-MP by a non-enzymatic pathway that is dependent
on glutathione and other sulfydryl-containing proteins
and, subsequently, 6-MP is left available to the
circulation. AZA is about 55% 6-MP by weight and,
since over 75% of AZA is converted to 6-MP, 1 mg of
AZA is equivalent to 0.5 mg of 6-MP [4],
Bioavailability of these drugs is low (<20%) due to
the extensive catabolism by xanthine oxidase (XO)
found in enterocytes and hepatocytes (but not
hemopoietic tissue) [5], 6-MP can be taken down two
remaining pathways (Fig. 1) [6,7]. It can be:
• converted by thiopurine methyltransferase (TPMT)
to an inactive form, 6-methylmercaptopurine
(6-MMP)
• anabolized by hypoxanthine guanine phosphoribosyl
transferase (HPRT) to its active metabolites,
6-thioguanine nucleotides (6-TGs) and 6-MMP
ribonucleotides (6-MMPRs).
Thus, 6-MP's mode of action rests on the
incorporation of these thiopurine nucleotide
metabolites into cellular nucleic acids, thereby
inhibiting de novo purine synthesis [8], These
enzymatic pathways are distinct and competitive.
Toxicity
The main limiting factor in AZA use is the occurrence
of side effects. Between 10-15% of patients who are
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AZA: azathioprine; HPRT: hypoxanthine phosphoribosyltransferase;
6-MP: 6-mercaptopurine; 6-MMP: 6-methylmercaptopurine;
6-TGN: 6-thioguanine nucleotide; TPMT: thiopurine
methyltransferase; ©: inhibition of synthesis.
Table 1. Azathioprine- and 6-mercaptopurine-related
toxic reactions, and their percentage occurrence in
treated patients.
Toxic reaction % occurrence
Infection
Bone marrow suppression
Hepatitis (mild derangement of liver
function tests, intrahepatic cholestasis,
irreversible iiver injury)
Malignancy (non-Hodgkin's lymphoma,
skin cancer, hepatoma, colorectal cancer)
Pancreatitis
Other allergic type reactions (nausea,







started on AZA will have some form of toxic reaction
[9], Broadly speaking, there are two categories of toxic
reactions, namely allergic type (e.g. pancreatitis, fever,
rash, non-specific abdominal pain, or nausea) and
non-allergic type (e.g. leukopenia, thrombocytopenia,
infections, malignancies, and some cases of hepatitis)
(Table 1). Non-allergic-type reactions usually occur
after months or years and appear to be dose
dependent, while allergic-type reactions occur much
earlier, usually within weeks. Table 1 summarizes the
occurrence of toxic reactions to AZA and 6-MP.
Pharmacogenetics
TPMT
TPMT is a cytosolic enzyme. TPMT levels are
determined by a well-documented co-dominant
genetic polymorphism in Caucasian and Afro-American
Figure 2. Trimodal frequency distribution of red cell




















TPMT": high thiopurine methyltransferase; TPMT1: low TPMT.
TPMT"/TPMT": homozygous normal TPMT. TPMT"/TPMTL:
heterozygous intermediate TPMT. TPMT7TPMT1: homozygous
low TPMT.
Reprinted with permission from [74],
populations [10,11], Approximately 90% of the
population has normal expression of TPMT
(TPMTH/TPMTH), 9% have intermediate activity due to
heterozygosity at the TPMT locus (TPMTH/TPMTL),
while 1 % have a TPMT deficiency (TPMTL/TPMTL),
which is inherited as an autosomal recessive trait [11].
In such patients, there is excessive shunting of
by-products down other enzymatic pathways, leading
to excesses in 6-TGs, which exert cytotoxic and
immunosuppressive effects leading to bone-marrow
toxicity. Other adverse side effects, such as pancreatitis
and hepatitis, are thought to be idiosyncratic reactions,
unrelated to TPMT activity [12].
There has been considerable interest in TPMT levels
and the occurrence of AZA/6-MP toxicity. This was
first investigated in children with acute lymphoblastic
leukemia, treated with AZA, where it was recognized
that TPMT levels corresponded to a reduced risk of
relapse, but a higher risk of neutropenia [13,14]. In
addition, TPMT genotyping has been shown to
correlate well with TPMT enzymatic activity [15] and
follows a trimodal distribution (Fig. 2). TPMT activity
can be measured in red blood cells by a variety of
methods, including reverse-phase high-performance
liquid chromatography (HPLC) [16], and by radio-
incorporation assay [17,18]. To date, there have been
few studies looking at TPMT activity and its associated
toxicity in IBD patients. TPMT genotyping (shown to
reflect enzymatic activity) has been shown to correlate
well with myelotoxicity, but otherwise does not predict
hepatotoxicity or the occurrence of pancreatitis.
It should be remembered that while TPMT
measurements (genotypic and activity) clearly appear to
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have a useful role in identifying patients susceptible to
myelotoxicity, other environmental factors can play a role
in the development of drug toxicity such as parvovirus
B19 infection [19]. This means that blood-count
monitoring remains essential, since severe
myelosuppression can occur despite normal TPMT levels.
HPRT
HPRT deficiency occurs in those patients with raised
urate levels who are predisposed to gout. In its severest
form, the deficiency presents in childhood, with
associated neurologic defects, and is known as
Lesch-Nyhan syndrome. The gene that codes for HPRT
is cross-linked, and there are several described
mutations along this gene that cause a variable degree
of deficiency in HPRT levels. Such is its rarity, that
deficiency of HPRT is probably of little clinical
relevance with respect to AZA therapy in IBD patients.
However, these patients would be resistant to the
immunosuppressive effects of AZA therapy [20].
XO
It is well recognized that allopurinol (which inhibits
XO) interacts with AZA, and can precipitate toxicity.
XO catalyzes the conversion of 6-MP to thiouric acid
(inactive), hence, genetically low levels of XO leave
more 6-MP available for conversion into 6-TGs. XO
deficiency is an autosomal recessive disorder, occurring
in about 2% of the population, and is often discovered
incidentally by the presence of hypouricemia [21], Like
TPMT deficiency, this condition is associated with
hemotoxicity, but has received only modest interest
when compared with TPMT-associated toxicity.
AZA — evidence-based medicine?
There has been a paucity of good, randomized,
double-blinded studies into the use of AZA and 6-MP
in IBD. In addition, trials in Crohn's disease patients
have generally been better represented than similar
trials in ulcerative colitis patients. However, there has
been a more thorough analysis undertaken through
meta-analysis, leading to more positive support for the
efficacy of AZA and 6-MP in IBD patients. There have
never been any direct comparative studies between
AZA and 6-MP, but it is reasonably assumed that both
drugs have similar effects, after taking into account the
obvious dose differences mentioned earlier.
Crohn's disease
Active disease
There have been only four studies that have addressed
treatment exclusively in active disease [22-25], These
studies were quite heterogenous in respect to the
outcomes (steroid-sparing effect, development of
remission, etc.) and study design (crossover versus
non-crossover), but all compared placebo with AZA.
Rhodes et al. found no difference in the response of
patients to AZA compared with placebo, but the study
was flawed by the short duration of therapy (7 weeks)
[25]. All of the other studies found varying degrees of
favorable response (odds ratio [OR] 1.0-10.45)
[22-24,26-28], and also found a steroid-sparing effect.
A meta-analysis of the results, by Pearson et al. [29],
included multi-arm studies that looked at active disease
and steroid-sparing effect. The estimated overall
common odds ratio [OR] was 3.09 (95% CI
2.45-3.91) in favor of AZA or 6-MP therapy (Table 2).
Maintenance therapy
Two studies have looked exclusively at treatment with
AZA in quiescent disease [30,31], several other studies
have included maintenance therapy as part of a multi-
arm study [26-28]. Again, all of these exhibited
varying degrees of benefit (OR 1.20-4.48), and meta¬
analysis by Pearson et al. estimated a common OR of




The use of both AZA and 6-MP in active colitis is
limited due to the protracted time to maximal onset
(approximately 3 months). There is no evidence that
AZA plus steroids, versus steroids alone, increases
remission rates, but there is evidence of a steroid-
sparing effect in the AZA group within this time
frame [32,33].
Maintenance therapy
AZA therapy has been studied more extensively than
6-MP in ulcerative colitis. There is good evidence that
both AZA and 6-MP allow a steroid-dose reduction, a
conclusion found in several studies to date (AZA dose
1.5-2.5 mg/kg) [32-36]. It should be noted that there
is no clear evidence to show that AZA or 6-MP are of
benefit in the chronic active ulcerative colitis patient
who is steroid resistant. Jewell and Truelove studied
such patients for 12 months and found no clear benefit
[35], although uncontrolled data from others has
shown beneficial effects [37], Further evidence can be
drawn from withdrawal studies, which have shown
that AZA withdrawal during remission leads to
increased relapse rates [38], There are no controlled,
randomized trials that have looked exclusively at 6-MP
and maintenance therapy in ulcerative colitis.
Current issues
Optimal antimetabolite therapy is a minefield in
current practice. This is partly due to poorly designed
studies, but more importantly, a lack of specific studies
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Table 2. Odds ratio of response in randomized
controlled studies of azathioprine and
6-mercaptopurine for active Crohn's disease.
Study Odds ratio (95% CI)
Rhodes et al. [25] 1.00 (no CI, no responders)
Klein et al. [23] 1.00 (0.22^t.54)
Candy (Part 1) et al. [26] 1.55 (0.52-4.59)
Summers etal. (National Cooperative 1.57 (0.75-3.29)
Crohn's Disease Study [Part I, Phase 1])
[27]
Ewe et al. [22] 4.57 (1.36-15.27)
Present et ai. [24] 10.45 (4.14-26.38)
Willoughby et al. (Group 1) [28] 23.17 (2.57-99.9)
Common odds ratio 3.09(2.45-3.91)
CI: confidence interval.
Reprinted with permission from [29].
looking at unanswered issues. Since there has been
more extensive research into AZA and other medical
conditions, the conclusions drawn from this have been
extrapolated for use in IBD therapy, but it should be
noted that, equally, some conclusions may not apply to
IBD patients.
Intravenous AZA use
In the light of the delayed onset of action of oral AZA,
there has been growing interest in the use of
intravenous AZA in the hope of decreasing the time of
therapeutic onset, and increasing the therapeutic
capability of AZA in acute ulcerative colitis. TPMT
activity status is a prerequisite to using AZA
intravenously, to stop potentially fatal side effects. The
first published experience in IBD was by Sandborn et
al. in 1995, where Crohn's disease patients were
loaded with 1800 mg of AZA over 36 h [39]. The
authors concluded that there was a reduced time-to-
response in these patients. Subsequently, Casson et al.
presented three patients with acute fulminant colitis
(one with ulcerative colitis, one with indeterminate
colitis, and one with Crohn's disease) who were treated
with low-dose intravenous AZA (3 mg/kg/daily) for
5-7 days [40], All three patients achieved remission on
this treatment. There have been two more
publications, the first, by Sandborn et al. in 1999, was
a placebo-controlled trial of an intravenous loading
dose of AZA (40 mg/kg/36 h) in 51 patients versus 45
placebo-treated 'control' patients — both patient
groups having steroid-resistant Crohn's disease [41],
There was no decrease in time-to-response in the AZA-
treated patients, despite achieving higher 6-TGN
concentrations at 0.2 weeks and 1 week. Thereafter,
6-TG concentrations in both groups were the same,
hinting that oral AZA therapy achieves similar 6-TG
levels to intravenous AZA. Finally, Mahadevan et al.
Table 3. Odds ratio of response in randomized
controlled studies of azathioprine for quiescent
Crohn's disease.
Study Odds ratio (95% CI)
National Cooperative Crohn's Disease 1.20 (0.60-2.41)
Study, (Part II) [27]
National Cooperative Crohn's Disease 1.73 (0.37-8.05)
Study, (Part I, Phase 2) [27]
O'Donohogue et al. [30] 2.95 (0.97-9.00)
Rosenberg et al.[31] 3.16(0.57-17.62)
Willoughby et al. (Group 2) [28] 4.48 (0.41-49.43)
Candy et al. (Part 2) [26] 7.12 (2.11-23.99)
Common Odds Ratio 2.27(1.76-2.93)
CI: confidence interval.
Reprinted with permission from [29],
looked at acute ulcerative colitis in nine patients [42].
Three groups, of three patients each, were treated with
20 mg/kg/36 h, 40 mg/kg/36 h, or 40 mg/kg as three
separate 8-h infusions over 3 days. Forty-six percent of
these patients avoided colectomy, and a response was
seen within 4 weeks, with therapeutic 6-TG
concentrations being achieved by 12 weeks. They
concluded that intravenous AZA appeared to be safe
and of clinical benefit in steroid refractory ulcerative
colitis patients.
AZA dose
Current practice involves the use of a low dose of
AZA/6-MP for the first 6-8 weeks, with subsequent
dose adjustment to approximately 2 mg/kg (or even
higher, if tolerated by the patient). There is evidence
that doses of 1.5-2.5 mg/kg are effective in IBD; this
has been found in both single studies and meta¬
analyses [32,33,36], Doses <1.5 mg/kg probably have
little clinical efficacy, and there is strong evidence that a
dose of 1 mg/kg is ineffective in Crohn's disease. There
are no studies that have directly compared different
doses of either AZA or 6-MP to look at either relapse
rates or the degree of steroid-sparing effect. In addition,
there have been no trials looking at doses of >3 mg/kg.
Concurrent 5-aminosalicylic acid use
The concomitant use of 5-aminosalicylic acid (5-ASA)
with AZA may a have potential advantage in reducing
the long-term colorectal malignancy risk associated with
IBD. On the other hand, there is rising concern over the
possible interaction of 5-ASA compounds, and their
breakdown products, with TPMT [43]. In vitro studies
have suggested that 4-ASA, 5-ASA, and sulphasalazine
all inhibit TPMT activity to differing degrees [44-46],
There is only one study to date that has addressed the
question as to whether concomitant 5-ASA therapy is
required in patients maintained in remission with
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AZA [47], This retrospective study looked at 169 IBD
patients maintained on AZA (with and without
concurrent 5-ASA), with a median follow-up duration
of 3.5 years. Relapse rates and side effect frequency in
the two groups were also examined and no differences
were found. Until there are further prospective studies
addressing this issue, it would seem sensible to add in
AZA/6-MP therapy with concurrent 5-ASA treatment,
where indicated, and to be aware of a potential drug
interaction. In addition, there is no current evidence
that 5-ASA therapy should be stopped if a patient is
stable on AZA/6-MP, or that the addition of 5-ASA is
beneficial in patients established on AZA/6-MP.
Neutropenia
It is a matter of debate whether neutropenia is a
prerequisite for optimal AZA therapy. In current clinical
practice, AZA dose is not titrated against neutropenia,
unless dangerous levels of neutropenia are seen.
There has been interest in the role of AZA- or 6-MP-
induced leukopenia in accomplishing disease remission
[48]. In addition, there have been anecdotal reports of
prolonged remission in patients who have sustained
pancytopenia during AZA therapy [49], It has been
proposed thai the preferential suppression of
neutrophils during leukopenia affects remission
induction with AZA/6-MR A large, retrospective study
by Campbell and Ghosh [50] examined relapse rates
per year of follow-up in a cohort of 173 IBD patients,
as well as time-to-first-relapse in patients whose lowest
neutrophil counts were classified as neutropenic
(<2.5x109) versus those with non-neutropenic counts
(>2.5x109). There were no differences in relapse rates
between the two groups and, at present, this would
suggest that neutrophil count should not be used as an
endpoint to dose titration of AZA or 6-MP.
Mean corpuscular volume
It has long been recognized that AZA/6-MP causes
blood-count abnormalities, such as raised leukopenia,
thrombocytopenia, and raised mean corpuscular
volume (MCV). The latter parameter is not a sign of
toxicity. The mechanism by which MCV increases is
thought to be related to interference of cell
proliferation in blood precursors committed to
erythropoiesis [51]. The rise in MCV following
administration of AZA/6-MP is not necessarily
inevitable, and the level that the MCV rises does not
correlate with drug dosage [52].
MCV changes (8MCV) have been studied
extensively in renal transplant patients, but currently
no studies have been published in IBD patients. More
recently, 8MCV during therapy have been shown to be
a reasonable indirect estimation of 6-TG levels.
However, a prospective study should be undertaken
before this parameter is utilized in clinical practice [53].
Levels of 6-TG measured directly have been shown to
correlate well with the actual bioavailability of oral
AZA/6-MP, and, hence, with the ability to retain
disease remission during therapy.
6-TG monitoring
There has been increasing interest in the use of
monitoring 6-MP metabolite levels as a more accurate
method of assuring drug response. Erythrocyte 6-TG
levels represent an indirect measure of bone marrow
uptake and hence the degree of immunosuppression.
Red cell 6-TG levels can be measured by a modification
of a reversed-phase HPLC method, initially used to
measure TPMT levels [16]. 6-TG levels have been
shown to exhibit a significant inverse correlation with
the Harvey Bradshaw index (HBI) activity index in
Crohn's disease [54]. Thus, the measurement of 6-TG
levels is useful in assessing both drug compliance and
responsiveness to treatment, while preventing under-
and over-dosing.
Pregnancy and fertility issues
Clinicians are not under any obligation to report the
outcome of the administration of drugs during
pregnancy to a central monitoring authority. Therefore,
data concerning both pregnancy and fertility in patients
taking AZA is confined to the voluntary reports
submitted for publication, and those cases reported to
the pharmaceutical company. Initially, published
literature focused on renal transplant patients,
subsequently, smaller and less-detailed reports have
been published on this, and other medical conditions,
such as rheumatoid arthritis, systemic lupus
erythematosus, autoimmune hepatitis, and IBD
[55-58]. There is no doubt that AZA crosses the
placenta and is expressed in the breast milk of mothers
taking AZA. However, the concentrations in the
placental tissue are small (representing up to 14% of
the orally administered dose), and thus it appears
unlikely that such metabolite concentrations will have a
clinically significant effect on the fetus [59],
Cytogenetic analysis has detected chromosomal
aberrations in the offspring of mothers with Crohn's
disease, but long-term follow-up has not revealed
further problems in these infants [28]. Immunologic
abnormalities (e.g. lymphopenia, thymic hypoplasia,
and bone marrow hypoplasia) have also been reported
in the newborn offspring of these female patients
[60,61], but all of these have subsequently resolved
later in infancy. Unfortunately, there is a lack of reports
of detailed immunologic assessments in these patients.
Overall, good control of the patient's IBD is much
more important for pregnancy and the well-being of
the fetus. It should be remembered that patients with
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Figure 3. Key points.
• On current evidence, AZA is safe during pregnancy.
• TPMT activity monitoring is useful in reducing the occurrence
of associated bone marrow toxicity.
• Concurrent use of 5-ASA drugs is probably unnecessary in
patients maintained in remission on AZA
• The degree of neutropenia associated with AZA therapy does
not relate to efficacy of maintaining remission in IBD patients.
• Optimal dosing of AZA should be achieved and, in future, the
measurement of 6-TG metabolites may help with
individualizing the optimal dosage of AZA.
ASA: aminosalicylic acid; AZA: azathioprine; TG: thioguanine;
TPMT: thiopurine methyltransferase.
Crohn's disease have higher rates of spontaneous
abortion and stillbirth, and that controlling disease
activity may reduce these risks [55],
Spermatogenesis has been studied in renal
transplant patients and shown to be similar to healthy
controls [62], other small reports in renal transplant
patients revealed decreased sperm counts, but the
counts remained within the normal range [63].
Neoplasia risk
It has been well recognized that the risk of various
malignant disorders is higher in transplant recipients
receiving immunosuppressive therapy than in the
general population. In particular, prospective studies
have shown an excess of non-Hodgkin's lymphoma
(NHL), squamous cell carcinoma, and hepatoma
[64-66]. In addition, rheumatoid arthritis patients
receiving AZA have been shown to exhibit excessive
frequencies of these malignancies beyond those
associated with rheumatoid disease [67], Probably the
largest IBD study was by Connell et al. in 1994, who
followed 755 IBD patients taking AZA (2 mg/kg), over
a 29-year period [68]. The group concluded that, while
colorectal carcinoma occurred in excess (something
observed in IBD patients anyway), there were no cases
of NHL. Another study by Present et al. looked at
396 IBD patients, treated with 6-MP for a mean period
of 5.4 years. They described 12 cases of malignancy,
one of which was NHL [9]. Finally, a large analysis of
782 IBD patients by Farrell et al. concluded that,
although there was an increased risk of NHL, the
overall risk was low [69]. Clearly, as long as patients
are informed of the potential and seemingly small risks
of AZA therapy, it seems sensible that AZA should be
used considering the morbidity associated with other
long-term medical therapies and risks from surgery.
Duration of therapy
There have now been several long-term studies looking
at both AZA and 6-MP use in Crohn's disease and
ulcerative colitis. Probably the most quoted paper is that
from Bouhnik et al. that first addressed this issue [70],
They looked at 157 patients over a 6-year period.
Relapse rates were examined in patients on AZA/6-MP
compared with those whose AZA/6-MP therapy was
discontinued. They concluded that beyond 4 years of
therapy, relapse rates were the same for both groups. It
should be noted that at this time point, the two groups
were small and, hence, may not have had the power to
detect a significant difference in relapse rates. A smaller
study involving 105 ulcerative colitis patients came to a
different conclusion [37]. Duration of follow-up was
approximately 5 years, but relapse in the withdrawal
group was very small (n=15) making conclusions
somewhat difficult to interpret. More recently, Kim et al.
looked at 6-MP therapy in 120 Crohn's disease patients
with a follow-up period of >8 years [71], Again, study
design was similar, but final conclusions found statistical
significance between 6-MP and the withdrawal group.
Their conclusions advocated the indefinite use of 6-MP
therapy, once remission was achieved. However, until
there is a placebo-controlled withdrawal trial, optimal
duration of therapy is unlikely to be known.
Clearly, there appears to be good evidence for
the use of AZA/6-MP therapy of up to 4-5 years
and, if the drug is well tolerated, longer therapy may
well be indicated.
AZA or 6-MP therapy?
Although the side-effect profiles of both AZA and
6-MP are very similar, there is evidence of differences
in the bioavailabilities of these two drugs, and between
those of branded AZA and generic AZA [72]. This has
further implications with regard to optimizing drug
treatment with 6-TG monitoring. In addition, there has
been a small series of patients who have been
re-challenged with 6-MP after being intolerant to AZA.
In a group of 11 patients, 54% were able to tolerate
6-MP [6], hinting that 6-MP may have benefits over
AZA for initial therapy [73], More studies are required
before any firm conclusions can be drawn.
Conclusion
In summary, antimetabolite therapy has proven itself
an extremely valuable and efficacious tool that now
forms an invaluable addition to the armament of the
gastroenterologist in helping treat steroid
refractory/dependent IBD. Although there may well be
a great number of small and poorly designed studies,
experience has given us an increased understanding,
and has helped to develop ever more optimal
immunosuppressive therapy for IBD patients (Fig. 3).
Its long-term safety is now generally well accepted,
and with appropriate monitoring and with more
studies, further information will help us refine
antimetabolite use for the future.
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Is neutropenia required for effective maintenance of
remission during azathioprine therapy in inflammatory bowel
disease?
Simon Campbell and Subrata Ghosh
Background Azathioprine is an effective treatment for
maintaining remission in inflammatory bowel disease
(IBD). It is a matter of debate as to whether neutropenia is
required during azathioprine therapy to achieve more
effective disease remission. We evaluated whether
neutropenia during azathioprine therapy reduced relapse
rates in IBD patients.
Patients and methods This retrospective study was
based on a total of 173 IBD (96 Crohn's disease (CD), 77
ulcerative colitis (UC)) patients who were stable on
azathioprine for a minimum of 6 months. Median duration
of follow-up was 4.0 years (range 0.6-21 years). The
lowest neutrophil counts during treatment for these
patients were recorded. Relapse rates per year of follow-
up were compared in non-ncutropcnic patients (neutrophil
count > 2.5 x 109, n = 129) and neutropenic patients
(neutrophil count s 2.5 x 109, n = 44) groups, and survival
curves for cumulative remission rates compared by log-
rank test.
Results Mean relapse rate per year of follow-up for the
non-neutropenic group was 0.19/year (SD = 0.37/year)
compared with the neutropenic group 0.28/year
(SD = 0.43/year) (P= NS). Analysis was performed on UC
and CD subgroups, and relapse rates were not significantly
different. The cumulative remission per cent determined by
Kaplan-Meier survival analysis showed no difference
between non-neutropenic and neutropenic groups by log-
rank analysis, for UC and CD as well as for all IBD patients.
Conclusion Neutropenia =£ 2.5 x 109 while on
azathioprine does not reduce the relapse rates of IBD
patients who were established on azathioprine therapy
compared with neutrophil counts > 2.5 x 109. Eur J
Gastroenterol Hepatol 13:1073-1076 © 2001 Lippincott
Williams & Wilkins
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Introduction
Azathioprine use in inflammatory bowel disease (IBD)
is now widely accepted as an invaluable second-line
immunosuppressive agent in the treatment of steroid-
refractory or steroid-dependent disease [1,2]. The opti¬
mal treatment regimen for azathioprine use continues
to be defined as our experience with its use in IBD
grows.
Azathioprine is usually introduced at a low dose and
titrated up to an arbitrary dose of approximately 2 mg/
kg, although higher doses are generally used in the
USA. The mean time to onset of effect of azathioprine
is about 3 months, and it is generally accepted that a
dose of 2-2.5 mg/kg is efficacious. Azathioprine is
broken down to 6-mercaptopurine and then to active 6-
thioguanine by the enzyme thiopurine methyltransfer-
ase (TPMT). TPMT is genetically determined, and is
inherited in a co-dominant fashion [3]. Genetically low
levels of TPMT have shown to correlate well with the
0954-691X © 2001 Lippincott Williams & Wilkins
occurrence of some azathioprine-induced side effects,
in particular the development of neutropenia [4],
Both macrocytosis and lymphopenia are well-recog¬
nized haematological effects of azathioprine therapy,
and their relevance to achieving or maintaining remis¬
sion remains uncertain [5,6], The dangers of leucopenia
and, perhaps more importantly, neutropenia have long
been recognized, necessitating regular blood count
monitoring of patients taking azathioprine.
More recently, there has been interest in the potential
therapeutic value of 'safe' levels of neutropenia and
leucopenia in achieving and maintaining remission
[5,7]. Anecdotal reports have suggested that these may
be now desirable end points to azathioprine therapy
[8]. However, this remains unproven, and in current
clinical practice azathioprine dose is not titrated against
neutropenia, unless dangerous levels of neutropenia are
seen.
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Patients and methods
A database was constructed containing information on
IBD patients maintained on azathioprine (n = 203;
ulcerative colitis (UC) = 94; Crohn's disease (CD) =
109; median age 39 years, range 15-82 years; 88 male,
115 female). For the purposes of this study, patients
were excluded if they were not maintained on
azathioprine for a minimum of 6 months, or if treatment
was stopped due to non-haematological side effects, or
if the disease remained active despite azathioprine
therapy. This left a total of 173 IBD patients (UC = 77,
CD = 96; median age 39 years, range 16-81 years; 76
male, 97 female) who had been maintained in remission
on azathioprine. Median duration of follow-up was 4.0
years (range 0.6-21 years). Other information that was
collected included the lowest neutrophil count recorded
during therapy, the lowest neutrophil count within the
first 4 months of therapy, anatomical disease distribu¬
tion, azathioprine dose, patient's weight at induction of
therapy, and smoking status. Relapse was defined as
necessity for surgery, or clinical recurrence (as assessed
by an experienced clinician based on clinical features
of diarrhoea, abdominal pain, general wellbeing, weight
loss and inflammatory parameters - haemoglobin, ery¬
throcyte sedimentation rate (ESR), C-Reactive Protein
(CRP), white cell count and platelets). Requirement for
surgery for purely mechanical obstruction, without
abnormal inflammatory parameters, was not considered
a relapse of active disease. Endoscopic findings comple¬
mented clinical features and blood parameters, but
were not used solely to determine relapse. Relapse
rates per year of follow-up were compared with the
lowest degree of neutropenia achieved during azathio¬
prine therapy. A neutrophil count of =£ 2.5 X 109 was
used to define neutropenic patients. All cases were
examined by one investigator (SG).
There were 44 patients who had been neutropenic
(mean neutrophil count 1.9 X 109, SD 0.34) while
taking azathioprine, with 129 patients not achieving
any neutropenia (mean neutrophil count 3.7 X 109, SD
0.9). Doses of azathioprine were similar in both groups
of patients (neutropenic: 1.8 mg/kg, SD 0.41; UC
1.9 mg/kg, SD 0.42; CD 1.75 mg/kg, SD 0.43; non-
neutropenic: 1.9 mg/kg, SD 0.47; UC 1.85 mg/kg, SD
0.48; CD 1.95 mg/kg, SD 0.45). Also comparable were
mean duration of follow-up, duration of therapy, disease
anatomy, concurrent use of steroids, and use of 5-
aminosalicylic acid (5-ASA) drugs. These results are
summarized in Table 1.
Statistical analysis was by non-parametric Mann-Whit-
ney test (MWT) for comparing the two groups. Relapse
rates were calculated using Kaplan-Meier survival
curves and compared using log-rank test analysis.
Results
A total of 173 IBD patients were stable on azathioprinc
for a minimum of 6 months. Median duration of
therapy was 4.0 years (range 0.6-21 years). Forty-four
patients (25%) became neutropenic (lowest neutrophil
count achieved during therapy 2.5 X 109) while tak¬
ing azathioprine, of which four patients stopped treat¬
ment due to severe life-threatening neutropenia (2 CD,
2 UC), and were included in the final analysis. The two
CD patients suffered from severe sepsis. One was from
a urinary tract infection (lowest neutrophil count
0.5 X 109), which resolved with intravenous antibiotics.
The other patient developed neutropenic sepsis neces¬
sitating the use of granulocyte colony stimulating factor
(GCSF, Filgrastim, Roche, Welwyn Garden City, UK)
(lowest neutrophil count 0.2 X 109), intensive care
admission for 10 days and haemodialysis, but made a
full recovery. One of the UC patients developed severe
pancytopenia and subsequent adult respiratory distress
syndrome (ARDS; lowest neutrophil count 0.8 X 109),
necessitating intensive care treatment for 5 days, but
made a full recovery. The other UC patient developed
no complications (lowest neutrophil count 0.8 X 109),
and the blood count returned to normal within 1 week
of stopping azathioprine.
For the UC patients (M = 22, F = 56), the neutropenia
group (mean azathioprine dose 1.90 mg/kg, SD 0.42;
M = 11, F = 17) had a mean relapse rate of 0.30/year
follow-up (SD = 0.48) compared with 0.18/year follow-
up for the non-neutropenic group (mean azathioprine
dose 1.85 mg/kg, SD 0.48; M=ll, F = 39; P=0.63
table 1 Patient characteristics
Mean AZA Mean AZA Mean lowest
CD disease UC disease treatment Mean age Sex dose neutrophil
Group n CD:UC distribution distribution (years) (years) (M:F) (mg/kg) count
Non-neutropenic 129 79:50 Tl = 15 Pan colitis = 13 4.8 38 49:80 1.9 3.2
(> 2.5 X 109) Colitis = 50 Left-sided = 20
lleocolonic = 14 Proctitis = 17
Neutropenic 44 16:28 Tl = 3 Pan colitis = 7 5.0 41 17:27 1.8 1.9
(< 2.5 X 109) Colitis = 10 Left-sided = 14
lleocolonic = 3 Proctitis = 7
AZA, azathioprine; CD, Crohn's disease; UC, ulcerative colitis.
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MWT). For CD patients (M = 44, F = 51), the neutro¬
penic patients (mean azathioprine dose 1.75 mg/kg, SD
0.43; M = 6, F = 10) had a mean relapse rate of 0.20/
year follow-up (SD = 0.32) compared with 0.23/year
follow-up (SD = 0.44) in the non-neutropenic group
(mean azathioprine dose 1.95 mg/kg, SD 0.45; M = 38,
F = 41; /> = 0.41 MWT). Figure 1 shows cumulative
remission percentages in UC and CD using Kaplan-
Meier survival curves. There is no statistical difference
between neutropenic and non-neutropenic groups (chi-
squared 0.76 for UC, 0.33 for CD; P = NS). These
results are summarized in Table 2.
For all IBD patients (M = 66, F = 107), mean relapse
rates in the neutropenic group (mean azathioprine dose
1.80 mg/kg, SD 0.41; M = 17, F = 27) were 0.28/year
follow-up (SD = 0.43) compared with 0.19/year follow-
up (SD = 0.37) for the non-neutropenic group (mean
azathioprine dose 1.90 mg/kg, SD 0.47; M = 49, F =
80). This was not statistically significant (/) = 0.37,
Mann-Whitney test). Figure 2 shows cumulative survi¬
val curves for IBD patients with no statistical difference
between neutropenic and non-neutropenic groups by
log-rank analysis (chi-squared 1.49; P = NS).
In addition, univariate and multivariate analyses were
performed in smoking and non-smoking groups. These
were not statistically significant in any group.
Discussion
From this cohort of 173 patients, remission mainte¬
nance is not statistically different in neutropenic versus
non-neutropenic patients. If anything, the survival
curves suggest that time to first relapse is shorter for
patients who achieved neutropenia (neutrophil count
=£ 2.5 X 109). Further analysis was performed using
*£ 2 X 109 as the cut-off for the neutropenic groups
(data not shown); again, no significant differences in
relapse rates were found. In addition, we analysed the
lowest neutrophil counts within the first 4 months of
therapy (data not shown). This correlated well with the
nadir neutrophil count (Pearson correlation coefficient
r=0.7; P < 0.005), again supporting the theory that
neutropenia is not purely a sporadic phenomenon. In
view of the fact that neutropenia is not a sporadic
phenomenon, in our study we have used not the mean
of neutrophil counts, but the lowest neutrophil count.
The lowest neutrophil count reflected, in general, the
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Kaplan-Meier survival curves for (a) ulcerative colitis patients and (b) Crohn's disease patients.











UC (non-neutropenic) 50 0.18 0-1.0 0.23 P= 0.41 1.85
UC (neutropenic) 28 0.30 0-2.0 0.48 1.90
CD (non-neutropenic) 79 0.23 0-2.6 0.44 P = 0.48 1.95
CD (neutropenic) 16 0.20 0-1.0 0.32 1.75
IBD (non-neutropenic) 129 0.19 0-2.6 0.37 P= 0.37 1.90
IBD (neutropenic) 44 0.28 0-2.0 0.43 1.80
AZA, azathioprine; MWT, Mann-Whitney Test; SD, standard deviation.
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Kaplan-Meier survival curve for inflammatory bowel disease patients.
Azathioprine immunosuppression is probably mediated
through its effects on lymphocytes, although there
appears to be preferential suppression of neutrophils
when leucopenia occurs [7]. This suggests that azathio-
prine's anti-inflammatory actions are mediated through
its effects on neutrophils. Indeed, it has been shown
that neutrophil migration into the lamina propria occurs
during clinical relapse in IBD [9]. An anecdotal report
has described prolonged remission in excess of 4 years
following induced pancytopenia [8], This report com¬
pares well with our own experience, where three of the
four patients that developed severe neutropenia have
remained in remission for up to 21 months following
that episode. More interestingly, the three patients
achieving remission all developed sepsis necessitating
hospital admission for treatment.
occur at any time during treatment, and thus is
relatively unpredictable, a randomized study would
prove extremely difficult to perform.
In conclusion, it appears that azathioprine dose titration
to achieve neutropenia is not necessary for optimal
therapy in IBD patients. Neutropenia =s 2.5 X 109
while on azathioprine does not reduce the relapse rates
of IBD patients who were established on azathioprine
therapy compared with neutrophil counts > 2.5 X 109.
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Probably the best documented study looking at the role
of leucopenia is by Colonna and Korelitz [5], who
studied 98 CD patients retrospectively. They con¬
cluded that patients achieving leucopenia were more
successful in reducing their CCFA-IOIBD (Crohn's
and Colitis Foundation of America/International Orga¬
nization of Inflammatory Bowel Disease) index, and in
maintaining or inducing clinical remission. In addition,
these patients were more able to reduce their corticos¬
teroid dose. However, this study had a relatively short
period of follow-up (about 18 months), and did not look
specifically at neutropenia.
Our study involves a large number of patients over a
long period of follow-up of up to 21 years. Despite this
being a retrospective analysis, hence subject to type-II
errors, this study has an 80% power to detect a 30%
difference between the two groups. Thus it could be
argued that a smaller difference between the two
groups may not have clear implications considering the
potential risks of neutropenia. Since neutropenia can
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Effective maintenance of inflammatory bowel disease
remission by azathioprine does not require concurrent
5-aminosalicylate therapy
Simon Campbell and Subrata Ghosh
Objectives To assess the effect of 5-aminosalicylate
treatment in conjunction with azathioprine on remission
maintenance in inflammatory bowel disease patients.
Method This retrospective study was based on a total of
186 inflammatory bowel disease patients (104 with
Crohn's disease; 82 with ulcerative colitis), who were
stable on azathioprine for a minimum of 6 months. The
median duration of follow-up was 4.3 years (range 0.6-
15.5 years). Relapse rates per year of follow-up were
compared in an azathioprine + 5-aminosalicylate group
(n = 103) and an azathioprine alone group (n = 83);
survival curves for cumulative remission rates were
compared by log-rank test. Discontinuation of azathioprine
in both groups was also recorded, as was the incidence of
malignancy.
Results In ulcerative colitis patients (n = 82), mean relapse
rates for the azathioprine + 5-aminosalicylate group were
0.21 /year compared with 0.19/year for the azathioprine
alone group (P= not significant). In Crohn's disease
patients (n = 104), mean relapse rates for the
azathioprine + 5-aminosalicylate group were 0.27/year
compared with 0.3/year for the azathioprine alone group
(P= not significant). The cumulative remission percentage
(determined from time to first relapse) was used in
Kaplan-Meier survival analysis and showed no difference
between the azathioprine + 5-aminosalicylate group and
the azathioprine alone group by log-rank analysis, for
ulcerative colitis and Crohn's disease as well as for all
inflammatory bowel disease patients. Concurrent use of 5-
aminosalicylates was no more frequent in patients who
discontinued azathioprine due to adverse events. The only
malignancy recorded was Waldenstrom's
macroglobulinaemia after 7 years of azathioprine therapy.
Conclusion Concurrent use of 5-aminosalicylate drugs did
not reduce the relapse rates of inflammatory bowel
disease patients who were established on azathioprine
therapy. The use of 5-aminosalicylate drugs did not lead to
any increase in discontinuation of azathioprine due to
adverse events. Eur J GastroenterolHepatol 13:1297-
1301 ©2001 Lippincott Williams & Wilkins
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Introduction
Azathioprine (AZA) therapy is an extremely valuable
second-line therapy in inflammatory bowel disease
(IBD) patients who are refractory to or dependent on
steroid therapy. The optimal drug therapy in patients
on AZA still remains unclear, with a considerable
percentage of patients remaining on a 5-aminosalicylate
(ASA) derivative as well as AZA. Some may also require
low-dose corticosteroid therapy.
The concomitant use of 5-ASA with AZA has a
potential advantage in reducing the long-term colo¬
rectal malignancy risk associated with IBD. On the
other hand, there is rising concern over the possible
interaction of 5-ASA compounds and their breakdown
products with thiopurine methyltransferase (TPMT) -
the enzyme used in the handling of both AZA and 6-
0954-691X © 2001 Lippincott Williams & Wilkins
mercaptopurine. In-vitro studies have suggested that
4-ASA, 5-ASA and sulphasalazine all inhibit TPMT
activity to differing degrees, but as yet no studies
have looked at the clinical impact and side-effect
profiles in patients who take AZA and concurrent 5-
ASA drugs.
It is not known whether concomitant 5-ASA therapy is
required in patients who remain in remission with
AZA. It is possible that 5-ASA therapy may be of
additional benefit in maintaining remission in ulcerative
colitis patients, but it is unlikely to have such a role in
Crohn's disease. In a retrospective study, we compared
the relapse rates and AZA discontinuation rates in
ulcerative colitis and Crohn's disease patients who
remained in remission on AZA alone with those in
patients maintained on AZA and a 5-ASA drug.
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Patients and methods
From our database of IBD patients maintained on AZA
(» = 220; ulcerative colitis = 94, Crohn's disease = 126;
median age 39 years, range 15-82 years; 105 men, 115
women), we retrospectively examined relapse rates per
year of follow-up (i.e. total number of relapses divided
by duration of follow-up). All case notes were examined
by one investigator (SC). Relapse was defined as a
requirement for surgery or documented symptoms con¬
sistent with a relapse necessitating rescue medication
such as corticosteroid therapy. Thirty-four patients
(15%) had stopped AZA due to side effects (dangerous
blood dyscrasias, pancreatitis, nausea, abdominal pain,
skin rashes or myalgia), 17 patients developed side
effects late into AZA therapy before discontinuation,
and the remaining 17 patients encountered side effects
within the first 6 months of treatment and were never
stabilized on AZA - this latter group were excluded
from further analysis. This left a total of 186 patients
(82 with ulcerative colitis: 44 men, 38 women; median
age 43 years, range 15-81 years; 104 with Crohn's
disease: 45 men, 59 women; median age 41 years, range
17-82 years) who were stable on therapy for a mini¬
mum of 6 months and in remission. The median dura¬
tion of follow-up was 4.3 years (range 0.6-15.5 years).
In addition, we examined information on 34 patients
who had to discontinue AZA due to adverse side
effects, and assessed whether the patients were on a 5-
ASA drug at the time of discontinuation.
Fifty-five patients with ulcerative colitis and 48 patients
with Crohn's disease, who were taking AZA for a
minimum of 6 months, were also on a concomitant 5-
ASA drug (mean AZA dose for ulcerative colitis pa¬
tients = 1.75 mg/kg, range 0.8-3.5 mg/kg; mean AZA
dose for Crohn's disease patients = 1.70 mg/kg, range
0.8-2.7 mg/kg). Twenty-seven patients with ulcerative
colitis and 56 with Crohn's disease were taking AZA
alone (mean AZA dose for ulcerative colitis pa¬
tients = 1.85 mg/kg, range 1.0-2.7 mg/kg; mean AZA
dose for Crohn's disease patients = 1.8 mg/kg, range
0.6-3.0 mg/kg). The median 5-ASA doses were 2.4 g/
day (range 0.8-3.2 g/day; n = 71) of mesalazine (Asacol,
GlaxoSmithKline Beecham Pharmaceuticals, Welwyn
Garden City, Herts, UK; and Pentasa, Ferring Pharma¬
ceuticals Ltd, Feltham, Middlesex, UK) and 1.5 g/day
(range 1-4 g/day; n = 28) of sulfasalazine. Two patients
were taking 7.5 g/day balsalazide and two patients
1.75 g/day olsalazine. The mean dose of AZA, duration
of therapy, frequency of low-dose corticosteroid use,
mean neutrophil counts, disease anatomy and fre¬
quency of surgery were comparable in the two groups.
These results are summarized in Table 1.
Statistical analysis was by Student's /-test for comparing
continuous variables between the two groups (AZA
alone and AZA + 5-ASA) in ulcerative colitis and
Crohn's disease patients separately. Categorical data
were compared using the chi-squared test with Yates'
correction. Kaplan-Meier survival curves were con¬
structed using the time to first relapse and compared
between the two groups using the log-rank test.
Results
A total of 186 IBD patients were stable on AZA for a
minimum of 6 months. The mean duration of therapy
was 4.3 years (standard deviation = 3.0). Of these pa¬
tients, 103 (55%) were taking concurrent 5-ASA drugs.
Analysis was performed for ulcerative colitis and
Crohn's disease patients separately. In the ulcerative
colitis patients (n = 82), the AZA + 5-ASA group (n =
55) had a mean relapse rate of 0.21/year of follow-up
(standard deviation = 0.31/ compared with the AZA
alone group (n = 27), who had a mean relapse rate of
0.19/year of follow-up (standard deviation = 0.28;
P = 0.69; Student's /-test). In the Crohn's disease pa¬
tients (» = 104), the relapse rate of the AZA + 5-ASA
group (n = 48) was 0.27/year of follow-up (standard
deviation = 1.0) while the relapse rate of the AZA alone
Table 1 Patient characteristics (disease distribution, steroid use, azathioprine therapy duration and neutrophil counts)
Mean Number of
duration of Mean AZA patients Number of
azathioprine Male to dose taking low- patients Mean
(AZA) therapy Mean age female (mg/kg) dose having neutrophil
Group n Disease distribution (years) (years) ratio (range) corticosteroid surgery count
AZA+5-aminosalicylate (ASA) 55 Pan colitis = 19 4.7 45 30:25 1.75 11 2 3.8
(ulcerative colitis) Left sided = 18
Proctitis = 18
(0.8-3.5)
AZA+5-ASA (Crohn's disease) 48 Terminal ileum = 8
Colitis = 31
lleocolonic = 9
4.0 40 15:33 1.70
(0.8-2.7)
10 4 4.3
AZA alone (ulcerative colitis) 27 Pan colitis = 11
Left sided = 8
Proctitis = 8
4.3 43 14:13 1.85
(1.0-2.7)
4 2 4.7
AZA alone (Crohn's disease) 56 Terminal ileum = 15
Colitis = 26
lleocolonic = 15
4.6 38 30:26 1.80
(0.6-3.0)
14 5 4.9
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(emission percentage based upon time to first relapse for
rative colitis patients, (b) Remission percentage based upon time
st relapse for Crohn's disease patients.
group (# = 56) was 0.30/year of follow-up (standard
deviation = 0.8; /> = 0.97; Student's /-test). Figure la
shows the remission percentage based upon the time to
first relapse for ulcerative colitis patients; Figure lb
shows the same analysis in Crohn's disease patients.
There was no statistical difference between patients on
AZA alone and those on AZA 4- 5-ASA in either disease
by log-rank test (x2= 0.06 for ulcerative colitis patients
and 0.01 for Crohn's disease patients; P — not signifi¬
cant). These results are summarized in Table 2.
In those patients who had to discontinue AZA therapy
due to side effects (# = 34), there was no increase in
frequency of 5-ASA therapy (# = 15; number discontin¬
ued in AZA alone group vs. number discontinued in
AZA -F 5-ASA group: "/} = 0.4; P = not significant). In
addition, the 17 patients who discontinued AZA before
stabilization (i.e. before 6 months) showed no signifi¬
cant differences in side effect types or mean dose of
AZA from those patients who discontinued AZA after
6 months (n = 17). This is summarized in Table 3.
Finally, there were no cases of malignancy in this
group, although one patient with Crohn's disease devel¬
oped Waldenstrom's macroglobulinaemia after 7 years
of AZA and mesalazine therapy, and two patients with
ulcerative colitis developed low-grade dysplasia, one
after 5.8 years of treatment with AZA and sulfasalazine
and the other after 3 years of treatment with AZA and
mesalazine.
Discussion
Relapse rates per year of follow-up were not statistically
different between the AZA + 5-ASA group and the
AZA alone group (in either ulcerative colitis or Crohn's
disease patients) and our cumulative remission curves
compare well with other studies which have looked at
remission maintenance with 5-ASA and AZA [1-6], It
would therefore appear that 5-ASA compounds afford
no additional clinical benefit on relapse rates in patients
suffering from either ulcerative colitis or Crohn's dis¬
ease. This study used data from a large database of
IBD patients who were well matched for disease type
and distribution, use of low-dose corticosteroids and
frequency of surgery; there were comparable numbers
of patients taking, and not taking, 5-ASA compounds
(Table 1).
Flowever, this is a retrospective analysis of two groups
of patients and may be selectively biased. It could be
suggested that patients taking AZA alone had a more
aggressive disease, which was treated at an early stage
with AZA rather than using 5-ASAs. However, patients
who were taking 5-ASA in addition to AZA did not
have a more aggressive disease course in terms of
Table 2 Mean relapse rates for patients taking azathioprine (AZA) -f- 5-aminosalicylate (ASA),
and for patients taking AZA alone
Mean relapse Student's f-test
rate/year Range (relapse Standard (AZA+5-ASA Mean AZA
Group analysis n follow-up rate) deviation vs. AZA alone) dose (mg/kg)
Ulcerative colitis
(AZA + 5-ASA) 55 0.21 0-1.3 0.31 P = 0.69 1.75
Ulcerative colitis
(AZA alone) 27 0.19 0-0.9 0.28 1.85
Crohn's disease
(AZA + 5-ASA) 48 0.27 0-7.5 1.0 P= 0.97 1.7
Crohn's disease
(AZA alone) 56 0.30 0-5 0.8 1.8



































previous relapses, anatomical extent of disease or their
requirement for surgery than those taking AZA alone.
It was not possible to elucidate the impact of 5-ASA
compounds on long-term malignancy risks in these
patients because of the retrospective nature of the
study. Although there are recent studies advocating the
protective role of 5-ASA drugs in the development of
colorectal malignancy [7-11], it still remains uncertain
whether this is a direct effect of the 5-ASA drugs or
merely the result of prolonged disease remission. Inter¬
estingly, there have been reports of the potential role
of folate supplementation in patients taking sulfasala¬
zine (a competitive inhibitor of folate absorption) to
reduce the incidence of dysplasia and cancer in chronic
ulcerative colitis [12]. The role of 5-ASAs, especially
sulfasalazine, in the prevention of colorectal malignancy
is controversial and currently lacks firm evidence. It is
worthy of note that one case of dysplasia reported here
was in a patient taking sulfasalazine; there was no
obvious excess occurrence of malignancy in our group
of patients taking this drug.
There has been growing interest over the last few years
in the possible interaction between 5-ASA compounds
and the enzyme TPMT. It has been reported that
TPMT is potently inhibited by derivatives of benzoic
acid [13]. Indeed, there is convincing evidence that it is
the 3-, 4-, and 5-ASA components, rather than other
carrier molecules involved in the drug interaction, that
inhibit TPMT [14]. In-vitro analysis has highlighted
significant interactions with TPMT and balsalazide
[15], olsalazine [15] and sulfasalazine [16], and it is
likely that mesalazine has a similar effect, though there
is a lack of data on this drug. In our study, the majority
of patients were taking mesalazine, with smaller num¬
bers taking sulfasalazine, balsalazide and olsalazine, and
it would appear that there is no evidence of any clinical
risk from this potential drug interaction. Clearly, cau¬
tion should be exercised whenever 5-ASA drugs are
being used in conjunction with AZA or 6-mercaptopur-
ine, especially if more potent inhibitors such as olsala¬
zine and balsalazide are being used. The importance of
TPMT inhibition by these drugs will be especially
important in the minority of patients (up to 10%) who
have genetically low levels of TPMT.
In summary, it is now important to follow up this study
with a prospective double-blinded and placebo-con¬
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